```
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 2.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00290; IG_MHC; 1.
KW   Hypothetical protein.
SQ   SEQUENCE   233 AA;  24867 MW;  367411BFD6F4DF92 CRC64;

  Query Match             25.9%;  Score 170;  DB 4;  Length 233;
  Best Local Similarity   40.2%;  Pred. No. 6.1e-11;
  Matches   39;  Conservative   17;  Mismatches   25;  Indels   16;  Gaps    4;

Qy         22 LAQLDALLVFPGQVAQLSCT---LSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHH 78
              | |   :: | ||| |:::|:   |  |:          ||||: | ||  ::|    :|:
Db         23 LTQPPSVSVSPGQTARITCSGDALPKQY-------AYWYQQKPGQAPVLVIY----KDNE 71

Qy         79 RPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
              ||: ||:||| :  :     |||| || ||:|||||
Db         72 RPSGIPERFSGS--SSGTTVTLTISGVQAEDEADYYC 106


RESULT 15
Q7Z2U7
ID   Q7Z2U7      PRELIMINARY;      PRT;   234 AA.
AC   Q7Z2U7;
DT   01-OCT-2003 (TrEMBLrel. 25, Created)
DT   01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22388257; PubMed=12477932;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA   Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA   Jones S.J., Marra M.A.;
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [2]
RP   SEQUENCE FROM N.A.
RA   Strausberg R.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; BC054883; AAH54883.1; -.
KW   Hypothetical protein.
SQ   SEQUENCE   234 AA;  25015 MW;  9A5723ABC393A06F CRC64;

  Query Match             25.9%;  Score 170;  DB 4;  Length 234;
  Best Local Similarity   36.3%;  Pred. No. 6.1e-11;
  Matches   41;  Conservative   22;  Mismatches   36;  Indels   14;  Gaps    4;

Qy          9 LLMGTFL----SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSA 64
              ||:|       ||:  || |  :: | ||: |:::|        |    | ||||:   |
Db          6 LLLGLLSHCTDSVASYVLTQPPSVSVAPGKTARITCGAD----NIGAKSVHWYQQKTDQA 61

Qy         65 PRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSV 117
                 |  :::    :|: ||: ||:||| :   : |   |:|| |:| |:|||:| |
Db         62 PVLVVH----DDNDRPSGIPERFSGS--NSGNTATLSISRVEPGDEADYFCQV 108


Search completed: September  7, 2004, 20:53:02
Job time : 126 secs
```

```
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Brain;
RA   Strausberg R.;
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; BC028090; AAH28090.1; -.
DR   PIR; S12441; S12441.
DR   InterPro; IPR003599; Ig.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003597; Ig_c1.
DR   InterPro; IPR003006; Ig_MHC.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 2.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00407; IGc1; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00290; IG_MHC; 1.
KW   Hypothetical protein.
SQ   SEQUENCE   234 AA;  24792 MW;  CC848CAEBA4A9D63 CRC64;

  Query Match             27.1%;  Score 178;  DB 4;  Length 234;
  Best Local Similarity   38.9%;  Pred. No. 7.6e-12;
  Matches   44;  Conservative   18;  Mismatches   37;  Indels   14;  Gaps    4;

Qy          9 LLMGTFL----SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSA 64
              ||:|       ||:  || |  :: | ||| |:::|  :     |    | ||||: | |
Db          6 LLLGLLSHCTGSVTSYVLTQPPSVSVAPGQTARITCGGN----NIGSKSVHWYQQKPGQA 61

Qy         65 PRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSV 117
              |  ::|    :|  ||: ||:||| :   : |   |||| |   |:|||| :
Db         62 PVLVVY----DDSDRPSGIPERFSGS--NSGNTATLTISRVDAGDEADYYCQL 108


RESULT 12
Q99M11
ID   Q99M11      PRELIMINARY;      PRT;   235 AA.
AC   Q99M11;
DT   01-JUN-2001 (TrEMBLrel. 17, Created)
DT   01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein.
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Strausberg R.;
RL   Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; BC002129; AAH02129.1; -.
DR   HSSP; P01703; 7FAB.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003006; Ig_MHC.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 2.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00290; IG_MHC; 1.
KW   Hypothetical protein.
SQ   SEQUENCE   235 AA;  25403 MW;  39807BFE6782A3FB CRC64;

  Query Match             26.5%;  Score 174;  DB 11;  Length 235;
  Best Local Similarity   40.0%;  Pred. No. 2.2e-11;
  Matches   40;  Conservative   16;  Mismatches   38;  Indels    6;  Gaps    2;

Qy         16 SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEE 75
              | :| || |  ::    |  |:| | |  :  | |  |:|||  | :|  ::|
Db         17 SCAQLVLTQPSSVSTSLGSTAKLPCKASTGN--IGDSYVNWYQQYMGRSPTNMIY----G 70

Qy         76 DHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
              |  ||: : |||| : | : |:  |||  || :|:|||||
Db         71 DDLRPSGVSDRFSGSIDSSSNSAFLTIQNVQADDEADYYC 110


RESULT 13
Q9NSD6
ID   Q9NSD6      PRELIMINARY;      PRT;   107 AA.
AC   Q9NSD6;
DT   01-OCT-2000 (TrEMBLrel. 15, Created)
DT   01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein (Fragment).
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Lymphocytes;
RA   Hohmann A.;
RT   "Autoimmunity.";
RL   Submitted (JUL-1995) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; L43092; AAA69746.2; -.
DR   HSSP; P01709; 2MCG.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
FT   NON_TER       1       1
FT   NON_TER     107     107
SQ   SEQUENCE   107 AA;  11306 MW;  A2B04B37187A5F00 CRC64;

  Query Match             26.0%;  Score 171;  DB 4;  Length 107;
  Best Local Similarity   40.0%;  Pred. No. 1.8e-11;
  Matches   38;  Conservative   18;  Mismatches   29;  Indels   10;  Gaps    3;

Qy         22 LAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRPA 81
              | |    : |  ||  :::|     |  ::| |  |||||: | ||  ::| :    ::||:
Db          2 LTQDPVVSVALGQTVRITC----QGDSLRSYYASWYQQKPGQAPVLVIYGK----NNRPS 53

Qy         82 DIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCS 116
              ||||||  :   : |   |||:  | ||:|||||:
Db         54 GIPDRFSGS--SSGNTASLTITGAQAEDEADYYCN 86


RESULT 14
Q8TBC9
ID   Q8TBC9      PRELIMINARY;      PRT;   233 AA.
AC   Q8TBC9;
DT   01-JUN-2002 (TrEMBLrel. 21, Created)
DT   01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=B-cell;
RA   Strausberg R.;
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; BC022823; AAH22823.1; -.
DR   PIR; S12442; S12442.
DR   PIR; S30526; S30526.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003006; Ig_MHC.
```

```
Qy          16 SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEE 75
               | :|:|||| ::  ||| :||| | ::   | | |||| |:||: |:|
Db          17 SWAQSVLAQPPSVSGAPGQTVTISCTGSSTNIG-AGYAVHWYQQFPGAAPKVLIY----G 71

Qy          76 DHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
               :::||: :||||| :|  :  :  | |: :| ||:|||||
Db          72 NYNRPSGVPDRFSGSK--SGTSASLAITGLQAEDEADYYC 109


RESULT 8
Q8WTU6
ID   Q8WTU6      PRELIMINARY;      PRT;   237 AA.
AC   Q8WTU6;
DT   01-MAR-2002 (TrEMBLrel. 20, Created)
DT   01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Tonsil;
RA   Strausberg R.;
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; BC022098; AAH22098.1; -.
DR   PIR; S12441; S12441.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003006; Ig_MHC.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 2.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00290; IG_MHC; 1.
KW   Hypothetical protein.
SQ   SEQUENCE   237 AA;  24884 MW;  E6CF371E753968E8 CRC64;

  Query Match             28.5%;  Score 187;  DB 4;  Length 237;
  Best Local Similarity   41.1%;  Pred. No. 7.5e-13;
  Matches   44;  Conservative   20;  Mismatches   35;  Indels    8;  Gaps    4;

Qy          16 SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEE 75
               | :|:|| |  ::   |||   :||| |  ::    | | |||| |:||: |:|  |
Db          17 SWAQSVLTQPPSVSGAPGQRVTISCTGSSSNIG-AGYDVHWYQQLPGTAPKLLIYGNS-- 73

Qy          76 DHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYGFS 122
                :||: :||||| :|  :  :  | |: :| ||:|||||   | :|
Db          74 --NRPSGVPDRFSGSK--SGTSASLAITGLQAEDEADYYCQ-SYDYS 115


RESULT 9
Q8WUK4
ID   Q8WUK4      PRELIMINARY;      PRT;   237 AA.
AC   Q8WUK4;
DT   01-MAR-2002 (TrEMBLrel. 20, Created)
DT   01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Tonsil;
RA   Strausberg R.;
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; BC020233; AAH20233.1; -.
DR   PIR; S12441; S12441.
DR   PIR; S12627; S12627.
DR   PIR; S29258; S29258.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003006; Ig_MHC.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 2.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00290; IG_MHC; 1.
KW   Hypothetical protein.
SQ   SEQUENCE   237 AA;  24897 MW;  73C7D70B8039D186 CRC64;

  Query Match             28.1%;  Score 184.5;  DB 4;  Length 237;
  Best Local Similarity   42.0%;  Pred. No. 1.4e-12;
  Matches   42;  Conservative   19;  Mismatches   32;  Indels    7;  Gaps    3;

Qy          16 SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEE 75
               | :|:|| |  ::   |||   :||| |  ::    | | |||| |:||: |:|  |
Db          17 SWAQSVLTQPPSVSGAPGQRVTISCTGSSSNIG-AGYDVHWYQQLPGTAPKLLIYGNS-- 73

Qy          76 DHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
                :||: :||||| :|  :  :  | |: :| ||:|||||
Db          74 --NRPSGVPDRFSGSK--SGTSASLAITGLQAEDEADYYC 109


RESULT 10
Q8WUK3
ID   Q8WUK3      PRELIMINARY;      PRT;   240 AA.
AC   Q8WUK3;
DT   01-MAR-2002 (TrEMBLrel. 20, Created)
DT   01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Tonsil;
RA   Strausberg R.;
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; BC020236; AAH20236.1; -.
DR   PIR; S16439; S16439.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003006; Ig_MHC.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 2.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00290; IG_MHC; 1.
KW   Hypothetical protein.
SQ   SEQUENCE   240 AA;  25977 MW;  921E47DDCA7259F0 CRC64;

  Query Match             27.7%;  Score 182;  DB 4;  Length 240;
  Best Local Similarity   33.9%;  Pred. No. 2.8e-12;
  Matches   43;  Conservative   24;  Mismatches   44;  Indels   16;  Gaps    4;

Qy           6 LSFLLMGTFLSV---SQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAG 62
               :|| |:    |  :  || |  :   | |   :|:|||| :|     | : ||||| |
Db           4 VSFYLLPFIFSTGLCALPVLTQPPSASAFLGASIKLTCTLSREH---SSYTIEWYQQRPG 60

Qy          63 SAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC------- 115
               :|:|::  :|:  |::   |||||  :   |     ||:| :| :|:|:|:|
Db          61 RSPQYIMKVKSDGSHNKGDGIPDRFMGSSSGADR--YLTLSNLQSDDEAEYHCGESHTID 118

Qy         116 -SVGYGF 121
                ||: |
Db         119 GQVGWVF 125


RESULT 11
Q8N355
ID   Q8N355      PRELIMINARY;      PRT;   234 AA.
AC   Q8N355;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
```

```
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Ileal mucosa;
RA   Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K.,
RA   Nakajima Y., Mizuno T., Morinaga M., Tanigami A., Fujiwara T., Ono T.,
RA   Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y., Ota T., Suzuki Y.,
RA   Obayashi M., Nishi T., Shibahara T., Tanaka T., Nakamura Y.,
RA   Isogai T., Sugano S.;
RT   "NEDO human cDNA sequencing project.";
RL   Submitted (AUG-2000) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AK026408; BAB15473.1; -.
DR   HSSP; P01607; 1REI.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   SMART; SM00406; IGv; 1.
KW   Hypothetical protein.
SQ   SEQUENCE   135 AA;  14780 MW;  652492DED930F401 CRC64;

  Query Match             30.3%;  Score 199;  DB 4;  Length 135;
  Best Local Similarity   45.3%;  Pred. No. 1.7e-14;
  Matches   34;  Conservative   17;  Mismatches   24;  Indels    0;  Gaps    0;

Qy         48 TIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQP 107
              :: |: : ||||: |: ||||||| |: :  : : :| ||| : | : || :| || :||
Db          7 SVGDFWIRWYQQKPGNPPRYLLYYHSDSNKGQGSGVPSRFSGSNDASANAGILRISGLQP 66

Qy        108 EDDADYYCSVGYGFS 122
              ||:|||||  :  |
Db         67 EDEADYYCGTWHSNS 81


RESULT 5
Q96JD2
ID   Q96JD2      PRELIMINARY;      PRT;   112 AA.
AC   Q96JD2;
DT   01-DEC-2001 (TrEMBLrel. 19, Created)
DT   01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Amyloid lambda 6 light chain variable region NEG (Fragment).
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Bone marrow;
RA   Perfetti V., Casarini S., Colli Vignarelli M., Merlini G.;
RT   "Amyloid lambda 6 light chain variable region NEG.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF267873; AAK58585.1; -.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
FT   NON_TER       1      1
FT   NON_TER     112    112
SQ   SEQUENCE   112 AA;  11908 MW;  080B4B37E2360B06 CRC64;

  Query Match             29.5%;  Score 194;  DB 4;  Length 112;
  Best Local Similarity   43.2%;  Pred. No. 4.9e-14;
  Matches   41;  Conservative   16;  Mismatches   32;  Indels    6;  Gaps    2;

Qy         21 VLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRP 80
              :| |  ::   ||:   :||| |     |    | ||||| |||  ::|   |:: ||
Db          3 MLTQPHSVSGSPGKTITISCTGSSGR--IASNSVQWYQQRPGSAPNIVMY----ENNQRP 56

Qy         81 ADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
              : :||||| : | : |:  |||| :  ||:|||||
Db         57 SGVPDRFSGSIDSSSNSASLTISGLMTEDEADYYC 91


RESULT 6
Q96JD0
ID   Q96JD0      PRELIMINARY;      PRT;   116 AA.
AC   Q96JD0;
DT   01-DEC-2001 (TrEMBLrel. 19, Created)
DT   01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Amyloid lambda 6 light chain variable region SAR (Fragment).
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Bone marrow;
RA   Perfetti V., Casarini S., Colli Vignarelli M., Merlini G.;
RT   "Amyloid lambda 6 light chain variable region SAR.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF267875; AAK58587.1; -.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
FT   NON_TER       1      1
FT   NON_TER     116    116
SQ   SEQUENCE   116 AA;  12294 MW;  F7B0E9F49FAE369E CRC64;

  Query Match             29.1%;  Score 191.5;  DB 4;  Length 116;
  Best Local Similarity   41.7%;  Pred. No. 9.7e-14;
  Matches   43;  Conservative   19;  Mismatches   30;  Indels   11;  Gaps    4;

Qy         21 VLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRP 80
              :| |  ::   ||:   :||| |   :   :| | ||| | ||||  ::|   ||: ||
Db          3 MLTQPHSVSESPGKTVTISCTGSSGSIA-TNY-VQWYQLRPGSAPTTVIY----EDNQRP 56

Qy         81 ADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC-----SVG 118
              : :||||| : | : |:  |||| :: ||:|||||     |:|
Db         57 SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSIG 99


RESULT 7
Q96E61
ID   Q96E61      PRELIMINARY;      PRT;   236 AA.
AC   Q96E61;
DT   01-DEC-2001 (TrEMBLrel. 19, Created)
DT   01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Brain;
RA   Strausberg R.;
RL   Submitted (AUG-2001) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; BC012876; AAH12876.1; -.
DR   PIR; S12440; S12440.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003006; Ig_MHC.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 2.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00290; IG_MHC; 1.
KW   Hypothetical protein.
SQ   SEQUENCE   236 AA;  24712 MW;  7EC9FB3622FED957 CRC64;

  Query Match             29.0%;  Score 190.5;  DB 4;  Length 236;
  Best Local Similarity   42.0%;  Pred. No. 3e-13;
  Matches   42;  Conservative   21;  Mismatches   30;  Indels    7;  Gaps    3;
```

```
RA   Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA   Suzuki H., Toyo-oka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA   Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA   Hayashizaki Y.;
RT   "Functional annotation of a full-length mouse cDNA collection.";
RL   Nature 409:685-690(2001).
DR   EMBL; D13208; BAA02495.1; -.
DR   EMBL; AK008794; BAB25899.1; -.
DR   PIR; S35302; S35302.
DR   HSSP; P01709; 2MCG.
DR   MGD; MGI:98938; Vpreb3.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
FT   CHAIN        20    123       8HS20 PROTEIN.
SQ   SEQUENCE   123 AA;  13400 MW;  2A1AD371D1CEE98F CRC64;

  Query Match             65.4%;  Score 430;  DB 11;  Length 123;
  Best Local Similarity   66.1%;  Pred. No. 1.2e-40;
  Matches   82;  Conservative   14;  Mismatches   26;  Indels    2;  Gaps    2;

Qy          1 MAC-RCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQ 59
              ||| |  ||  ||:|||::| |  | | ||  ||||| | ||||:: || |  | |||||||
Db          1 MACPGCLPLLLIGTFVAVFQPTLTQPDAFSVFPGQDAHLSCTINSQHATAGDIGVSWYQQ 60

Qy         60 RAGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGY 119
              : |||| :|||| :||:|:||||||||||  | |||||:|||||| |||||||:||: :
Db         61 QPGSAP-HLLYYYAEEEHYRPADIPDRFSATVDAAHNACILTISPVLPEDDADYFCSIAH 119

Qy        120 GFSP 123
               | |
Db        120 TFEP 123


RESULT 2
Q7Z2U3
ID   Q7Z2U3       PRELIMINARY;      PRT;   230 AA.
AC   Q7Z2U3;
DT   01-OCT-2003 (TrEMBLrel. 25, Created)
DT   01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22388257; PubMed=12477932;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA   Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA   Jones S.J., Marra M.A.;
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [2]
RP   SEQUENCE FROM N.A.
RA   Strausberg R.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; BC054893; AAH54893.1; -.
KW   Hypothetical protein.
SQ   SEQUENCE   230 AA;  24853 MW;  8BE60CC824BB886E CRC64;

  Query Match             35.8%;  Score 235.5;  DB 4;  Length 230;
  Best Local Similarity   45.5%;  Pred. No. 2.4e-18;
  Matches   46;  Conservative   21;  Mismatches   33;  Indels    1;  Gaps    1;

Qy         17 VSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEED 76
              :|| || |  :|   ||  | |:|||  :   : || : ||||::| :|:||| :||: |
Db          8 LSQAVLTQPSSLSASPGASASLTCTLR-RGFYVYDYRIYWYQQKSGRSPQYLLRHRSDSD 66

Qy         77 HHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSV 117
                 : :|| ||| :|| : || :| || :: ||:|||||
Db         67 KQQGSGVPSRFSGSKDASANAGILVISGLRSEDEADYYCMV 107


RESULT 3
Q96JD1
ID   Q96JD1       PRELIMINARY;      PRT;   112 AA.
AC   Q96JD1;
DT   01-DEC-2001 (TrEMBLrel. 19, Created)
DT   01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Amyloid lambda 6 light chain variable region PIP (Fragment).
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Bone marrow;
RA   Perfetti V., Casarini S., Colli Vignarelli M., Merlini G.;
RT   "Amyloid lambda 6 light chain variable region PIP.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF267874; AAK58586.1; -.
DR   PIR; A30323; A30323.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
FT   NON_TER      1      1
FT   NON_TER    112    112
SQ   SEQUENCE   112 AA;  12047 MW;  0D3885AC23567B9F CRC64;

  Query Match             30.3%;  Score 199;  DB 4;  Length 112;
  Best Local Similarity   44.2%;  Pred. No. 1.3e-14;
  Matches   42;  Conservative   17;  Mismatches   30;  Indels    6;  Gaps    2;

Qy         21 VLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRP 80
              :| |  ::   ||:   :||| |    :|    | ||||| |||| ::|    ||: ||
Db          3 MLTQPHSVSESPGKTITISCTRSSG--SIASNYVQWYQQRPGSAPTTVIY----EDNQRP 56

Qy         81 ADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
              : :||||| : | : |:  |||| :: ||:|||||
Db         57 SGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC 91


RESULT 4
Q9H5Z4
ID   Q9H5Z4       PRELIMINARY;      PRT;   135 AA.
AC   Q9H5Z4;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein FLJ22755.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
```

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: September 7, 2004, 20:45:09 ; Search time 123 Seconds
(without alignments)
315.518 Million cell updates/sec

Title: US-09-981-876-200
Perfect score: 657
Sequence: 1 MACRCLSFLLMGTFLSVSQT.....PVQPEDDADYYCSVGYGFSP 123

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SPTREMBL_25:*
1: sp_archea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_rvirus:*
16: sp_bacteriap:*
17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	430	65.4	123	11	Q61243	Q61243 mus musculu
2	235.5	35.8	230	4	Q7Z2U3	Q7z2u3 homo sapien
3	199	30.3	112	4	Q96JD1	Q96jd1 homo sapien
4	199	30.3	135	4	Q9H5Z4	Q9h5z4 homo sapien
5	194	29.5	112	4	Q96JD2	Q96jd2 homo sapien
6	191.5	29.1	116	4	Q96JD0	Q96jd0 homo sapien
7	190.5	29.0	236	4	Q96E61	Q96e61 homo sapien
8	187	28.5	237	4	Q8WTU6	Q8wtu6 homo sapien
9	184.5	28.1	237	4	Q8WUK4	Q8wuk4 homo sapien
10	182	27.7	240	4	Q8WUK3	Q8wuk3 homo sapien
11	178	27.1	234	4	Q8N355	Q8n355 homo sapien
12	174	26.5	235	11	Q99M11	Q99m11 mus musculu
13	171	26.0	107	4	Q9NSD6	Q9nsd6 homo sapien
14	170	25.9	233	4	Q8TBC9	Q8tbc9 homo sapien
15	170	25.9	234	4	Q7Z2U7	Q7z2u7 homo sapien
16	169.5	25.8	236	4	Q8NEJ1	Q8nej1 homo sapien
17	168	25.6	108	4	Q96SB0	Q96sb0 homo sapien
18	167.5	25.5	109	4	Q9UL86	Q9ul86 homo sapien
19	166	25.3	100	6	O77624	O77624 bos taurus
20	166	25.3	110	4	Q8TE63	Q8te63 homo sapien
21	164	25.0	233	4	Q96I69	Q96i69 homo sapien
22	164	25.0	233	4	Q8N5F4	Q8n5f4 homo sapien
23	159.5	24.3	109	4	Q9UL78	Q9ul78 homo sapien
24	158.5	24.1	105	4	Q8WVJ6	Q8wvj6 homo sapien
25	156	23.7	81	4	Q7Z2E8	Q7z2e8 homo sapien
26	154.5	23.5	132	4	Q8TBD0	Q8tbd0 homo sapien
27	154	23.4	107	4	Q9UL82	Q9ul82 homo sapien
28	151	23.0	101	4	Q8IZD8	Q8izd8 homo sapien
29	147	22.4	248	13	Q7SYU1	Q7syu1 xenopus lae
30	145.5	22.1	131	11	Q811C3	Q811c3 mus musculu
31	140.5	21.4	108	4	Q9UL83	Q9ul83 homo sapien
32	136.5	20.8	484	11	Q8VEA0	Q8vea0 mus musculu
33	136	20.7	129	11	Q8VDE2	Q8vde2 mus musculu
34	135.5	20.6	109	4	Q9UL85	Q9ul85 homo sapien
35	135.5	20.6	113	11	Q8CGS1	Q8cgs1 mus musculu
36	134	20.4	97	4	O43234	O43234 homo sapien
37	134	20.4	107	11	Q9ERZ9	Q9erz9 mus musculu
38	134	20.4	235	11	Q91W12	Q91w12 mus musculu
39	134	20.4	237	13	Q7SZ36	Q7sz36 xenopus lae
40	133.5	20.3	93	4	Q9UL76	Q9ul76 homo sapien
41	131.5	20.0	111	11	Q811U6	Q811u6 mus musculu
42	131	19.9	235	11	Q7TMK0	Q7tmk0 mus musculu
43	131	19.9	239	4	Q8NEK0	Q8nek0 homo sapien
44	130.5	19.9	99	11	Q9JL74	Q9jl74 mus musculu
45	130.5	19.9	108	4	Q9UL79	Q9ul79 homo sapien

ALIGNMENTS

RESULT 1
Q61243
ID Q61243 PRELIMINARY; PRT; 123 AA.
AC Q61243;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE 8HS20 protein precursor (Pre-B lymphocyte gene 3).
GN VPREB3.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BALB/C;
RX MEDLINE=93259124; PubMed=8491176;
RA Shirasawa T., Ohnishi K., Hagiwara S., Shigemoto K., Takebe Y.,
RA Rajewsky K., Takemori T.;
RT "A novel gene product associated with mu chains in immature B cells.";
RL EMBO J. 12:1827-1834(1993).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Stomach;
RX MEDLINE=21085660; PubMed=11217851;
RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,

```
DR   PIR; A01993; LVHU2.
DR   HSSP; P80748; 2LOI.
DR   GO; GO:0005576; C:extracellular; NAS.
DR   GO; GO:0003823; F:antigen binding; NAS.
DR   GO; GO:0006955; P:immune response; NAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin V region; Signal.
FT   SIGNAL        1     20
FT   CHAIN        21    117       IG LAMBDA CHAIN V REGION 4A.
FT   DOMAIN       21     42       FRAMEWORK-1.
FT   DOMAIN       43     55       COMPLEMENTARITY-DETERMINING-1.
FT   DOMAIN       56     71       FRAMEWORK-2.
FT   DOMAIN       72     78       COMPLEMENTARITY-DETERMINING-2.
FT   DOMAIN       79    110       FRAMEWORK-3.
FT   DOMAIN      111    117       COMPLEMENTARITY-DETERMINING-3.
FT   DISULFID     42    110       BY SIMILARITY.
FT   NON_TER     117    117
SQ   SEQUENCE   117 AA;  12380 MW;  C587B0047CC1CD62 CRC64;

  Query Match             27.5%;  Score 180.5;  DB 1;  Length 117;
  Best Local Similarity   42.9%;  Pred. No. 1.9e-12;
  Matches   45;  Conservative   13;  Mismatches   40;  Indels    7;  Gaps    3;

Qy         16 SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEE 75
              | ||||: |  :| | ||    |:|  |   ||   |  :|:||: | ||| |:|  | :
Db         18 SNSQTVVTQEPSLTVSPGGTVTLTCASSTGAVT-SGYYPNWFQQKPGQAPRALIYSTSNK 76

Qy         76 DHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
                 ||    ||| :          ||:| |||||:|:||| : ||
Db         77 HSWTPA----RFSGSL--LGGKAALTLSGVQPEDEAEYYCLLYYG 115


Search completed: September  7, 2004, 20:50:55
Job time : 28 secs
```

```
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin V region; Signal.
FT   SIGNAL        1     19
FT   CHAIN        20    130       IG LAMBDA CHAIN V-I REGION BL2.
FT   DOMAIN       20    115       V SEGMENT.
FT   DOMAIN      116    130       J SEGMENT.
FT   DISULFID     41    108       BY SIMILARITY.
FT   NON_TER     130    130
SQ   SEQUENCE   130 AA;  13564 MW;  FA44BB17D3A55EBF CRC64;

  Query Match             27.9%;  Score 183.5;  DB 1;  Length 130;
  Best Local Similarity   40.5%;  Pred. No. 1e-12;
  Matches   47;  Conservative   22;  Mismatches   38;  Indels    9;  Gaps    5;

Qy          1 MACR-CLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQ 59
              |  |   |  ||:    | :|:|| |  ::   |||   :||: |  ::   || ||||||
Db          1 MTCSPLLLTLLIHCTGSWAQSVLTQPPSVSAAPGQKVTISCSGSSSNIG-NDY-VSWYQQ 58

Qy         60 RAGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
                |:||: |:|    ::: ||: |||||| :|  :  :  | |: :|  |:|||||
Db         59 VPGTAPKLLIY----DNNKRPSGIPDRFSGSK--SGTSATLGITGLQTGDEADYYC 108


RESULT 13
LV1D_HUMAN
ID   LV1D_HUMAN     STANDARD;      PRT;   111 AA.
AC   P01702;
DT   21-JUL-1986 (Rel. 01, Created)
DT   21-JUL-1986 (Rel. 01, Last sequence update)
DT   10-OCT-2003 (Rel. 42, Last annotation update)
DE   Ig lambda chain V-I region NIG-64.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=83186114; PubMed=6404900;
RA   Kametani F., Takayasu T., Suzuki S., Shinoda T., Okuyama T.,
RA   Shimizu A.;
RT   "Comparative studies on the structure of the light chains of human
RT   immunoglobulins. IV. Assignment of a subsubgroup.";
RL   J. Biochem. 93:421-429(1983).
CC   -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR   PIR; A01965; L1HUNG.
DR   HSSP; P01703; 7FAB.
DR   GO; GO:0005576; C:extracellular; NAS.
DR   GO; GO:0003823; F:antigen binding; NAS.
DR   GO; GO:0006955; P:immune response; NAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin V region; Pyrrolidone carboxylic acid.
FT   DOMAIN        1    105       IG-LIKE.
FT   MOD_RES       1      1       PYRROLIDONE CARBOXYLIC ACID.
FT   DISULFID     22     89       BY SIMILARITY.
FT   NON_TER     111    111
SQ   SEQUENCE   111 AA;  11454 MW;  A21C6121C18A61E0 CRC64;

  Query Match             27.5%;  Score 180.5;  DB 1;  Length 111;
  Best Local Similarity   41.1%;  Pred. No. 1.7e-12;
  Matches   44;  Conservative   19;  Mismatches   29;  Indels   15;  Gaps    4;

Qy         19 QTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHH 78
              |:|| |  ::   |||   :||: |  :  | |  |||||  |:||: |:|    :::
Db          1 QSVLTQPPSVSAAPGQEVTISCSGSSSN--IGDNFVSWYQQLPGTAPKLLIY----DNNK 54

Qy         79 RPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC-------SVG 118
              ||: |||||| :|  :  :  | |: :|  |:|||||       |||
Db         55 RPSGIPDRFSGSK--SGTSATLGITGLQTGDEADYYCGTWDSSLSVG 99


RESULT 14
LV2K_HUMAN
ID   LV2K_HUMAN     STANDARD;      PRT;   112 AA.
AC   P04209;
DT   20-MAR-1987 (Rel. 04, Created)
DT   20-MAR-1987 (Rel. 04, Last sequence update)
DT   10-OCT-2003 (Rel. 42, Last annotation update)
DE   Ig lambda chain V-II region NIG-84.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=85204383; PubMed=3922791;
RA   Tonoike H., Kametani F., Hoshi A., Shinoda T., Isobe T.;
RT   "Amino acid sequence of an amyloidogenic Bence Jones protein in
RT   myeloma-associated systemic amyloidosis.";
RL   FEBS Lett. 185:139-141(1985).
CC   -!- MISCELLANEOUS: THIS IS A BENCE-JONES PROTEIN ISOLATED FROM AN
CC       INDIVIDUAL WITH MYELOMA-ASSOCIATED SYSTEMIC AMYLOIDOSIS.
CC   -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR   PIR; A01971; L2HUNG.
DR   HSSP; P01709; 2MCG.
DR   GO; GO:0005576; C:extracellular; NAS.
DR   GO; GO:0003823; F:antigen binding; NAS.
DR   GO; GO:0006955; P:immune response; NAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin V region; Amyloid; Bence-Jones protein.
FT   DOMAIN        1    102       IG-LIKE.
FT   DISULFID     22     90       BY SIMILARITY.
FT   NON_TER     112    112
SQ   SEQUENCE   112 AA;  11581 MW;  988FEF363AE1E4F3 CRC64;

  Query Match             27.5%;  Score 180.5;  DB 1;  Length 112;
  Best Local Similarity   43.9%;  Pred. No. 1.8e-12;
  Matches   43;  Conservative   16;  Mismatches   32;  Indels    7;  Gaps    3;

Qy         19 QTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHH 78
              |: | |  ::   |||   :||| :   |  |: ||||||  | ||: |:|    : :
Db          1 QSALTQPASVSGSPGQSITISCTGTTSDVGGYDF-VSWYQQHPGKAPKLLIY----DVNS 55

Qy         79 RPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCS 116
              ||: | :||| :|  : |   |||| :| ||:||||||
Db         56 RPSGISNRFSGSK--SGNTASLTISGLQAEDEADYYCS 91


RESULT 15
LV0A_HUMAN
ID   LV0A_HUMAN     STANDARD;      PRT;   117 AA.
AC   P04211;
DT   20-MAR-1987 (Rel. 04, Created)
DT   20-MAR-1987 (Rel. 04, Last sequence update)
DT   15-JUL-1999 (Rel. 38, Last annotation update)
DE   Ig lambda chain V region 4A precursor.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=85014122; PubMed=6091030;
RA   Anderson M.L.M., Szajnert M.F., Kaplan J.C., McColl L.,
RA   Young B.D.;
RT   "The isolation of a human Ig V lambda gene from a recombinant library
RT   of chromosome 22 and estimation of its copy number.";
RL   Nucleic Acids Res. 12:6647-6661(1984).
```

```
RESULT 10
LV6E_HUMAN
ID   LV6E_HUMAN     STANDARD;      PRT;   131 AA.
AC   P06319;
DT   01-JAN-1988 (Rel. 06, Created)
DT   01-JAN-1988 (Rel. 06, Last sequence update)
DT   15-JUL-1999 (Rel. 38, Last annotation update)
DE   Ig lambda chain V-VI region EB4 precursor.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=85215660; PubMed=3923440;
RA   Anderson M.L.M., Brown L., McKenzie E., Kellow J.E., Young B.D.;
RT   "Cloning and sequence analysis of an Ig lambda light chain mRNA
RT   expressed in the Burkitt's lymphoma cell line EB4.";
RL   Nucleic Acids Res. 13:2931-2941(1985).
DR   PIR; A01990; L6HUEB.
DR   HSSP; P01709; 2MCG.
DR   GO; GO:0005576; C:extracellular; NAS.
DR   GO; GO:0003823; F:antigen binding; NAS.
DR   GO; GO:0006955; P:immune response; NAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin V region; Signal.
FT   SIGNAL        1     19
FT   CHAIN        20    131       IG LAMBDA CHAIN V-VI REGION EB4.
FT   DOMAIN       20     41       FRAMEWORK-1.
FT   DOMAIN       42     54       COMPLEMENTARITY-DETERMINING-1.
FT   DOMAIN       55     69       FRAMEWORK-2.
FT   DOMAIN       70     76       COMPLEMENTARITY-DETERMINING-2.
FT   DOMAIN       77    110       FRAMEWORK-3.
FT   DOMAIN      111    118       COMPLEMENTARITY-DETERMINING-3.
FT   DOMAIN      119    131       FRAMEWORK-4.
FT   DISULFID     41    110       BY SIMILARITY.
FT   NON_TER     131    131
SQ   SEQUENCE   131 AA;  14147 MW;  02A9179C8C05C2CD CRC64;

  Query Match             28.2%;  Score 185;  DB 1;  Length 131;
  Best Local Similarity   42.1%;  Pred. No. 6.9e-13;
  Matches   40;  Conservative   16;  Mismatches   33;  Indels    6;  Gaps    2;

Qy         21 VLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRP 80
              :| |   ::   ||:  :|||      :|    | |||||  |||  ::|    ||: ||
Db         22 MLTQPHSVSESPGKTVTISCT--GNSGSIASNYVQWYQQRRVSAPTIVIY----EDNQRP 75

Qy         81 ADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
                :|||||  : |  : |:  ||||  ::  ||:|||||
Db         76 LGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC 110


RESULT 11
LV2G_HUMAN
ID   LV2G_HUMAN     STANDARD;      PRT;   111 AA.
AC   P01710;
DT   21-JUL-1986 (Rel. 01, Created)
DT   21-JUL-1986 (Rel. 01, Last sequence update)
DT   10-OCT-2003 (Rel. 42, Last annotation update)
DE   Ig lambda chain V-II region BO.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=71103825; PubMed=5532228;
RA   Wikler M., Putnam F.W.;
RT   "Amino acid sequence of human lambda chains. 3. Tryptic peptides,
RT   chymotryptic peptides, and sequence of protein Bo.";
RL   J. Biol. Chem. 245:4488-4507(1970).
CC   -!- MISCELLANEOUS: This is a Bence-Jones protein.
CC   -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR   PIR; A01976; L2HUBO.
DR   HSSP; P01709; 2MCG.
DR   GO; GO:0005576; C:extracellular; NAS.
DR   GO; GO:0003823; F:antigen binding; NAS.
DR   GO; GO:0006955; P:immune response; NAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin V region; Bence-Jones protein;
KW   Pyrrolidone carboxylic acid.
FT   DOMAIN        1    106       IG-LIKE.
FT   MOD_RES       1      1       PYRROLIDONE CARBOXYLIC ACID.
FT   DISULFID     22     90       BY SIMILARITY.
FT   NON_TER     111    111
SQ   SEQUENCE   111 AA;  11785 MW;  92F5A1BF72421BAC CRC64;

  Query Match             28.1%;  Score 184.5;  DB 1;  Length 111;
  Best Local Similarity   41.8%;  Pred. No. 6.5e-13;
  Matches   41;  Conservative   16;  Mismatches   34;  Indels    7;  Gaps    3;

Qy         19 QTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHH 78
              |: | |  :    |||   :||| :   |    | ||||||  | ||: :::    |
Db          1 QSALTQPPSASGSPGQSVTISCTGTSSDVGDNKY-VSWYQQHPGRAPKLVIF----EVSQ 55

Qy         79 RPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCS 116
              ||: :||||| :| :  |   ||:| :: ||:||||||
Db         56 RPSGVPDRFSGSKSD--NTASLTVSGLRAEDEADYYCS 91


RESULT 12
LV1G_HUMAN
ID   LV1G_HUMAN     STANDARD;      PRT;   130 AA.
AC   P06316;
DT   01-JAN-1988 (Rel. 06, Created)
DT   01-JAN-1988 (Rel. 06, Last sequence update)
DT   15-JUL-1999 (Rel. 38, Last annotation update)
DE   Ig lambda chain V-I region BL2 precursor.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=85062823; PubMed=6095199;
RA   Tsujimoto Y., Croce C.M.;
RT   "Molecular cloning of a human immunoglobulin lambda chain variable
RT   sequence.";
RL   Nucleic Acids Res. 12:8407-8414(1984).
CC   ----------------------------------------------------------------------
CC   This SWISS-PROT entry is copyright. It is produced through a collaboration
CC   between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC   the European Bioinformatics Institute. There are no restrictions on its
CC   use by non-profit institutions as long as its content is in no way
CC   modified and this statement is not removed. Usage by and for commercial
CC   entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC   or send an email to license@isb-sib.ch).
CC   ----------------------------------------------------------------------
DR   EMBL; X01147; CAA25598.1; -.
DR   PIR; A01966; L1HUBL.
DR   HSSP; P01703; 7FAB.
DR   GO; GO:0005576; C:extracellular; NAS.
DR   GO; GO:0003823; F:antigen binding; NAS.
DR   GO; GO:0006955; P:immune response; NAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
```

```
DR   GO; GO:0005576; C:extracellular; NAS.
DR   GO; GO:0003823; F:antigen binding; NAS.
DR   GO; GO:0006955; P:immune response; NAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin V region; Bence-Jones protein; 3D-structure;
KW   Pyrrolidone carboxylic acid.
FT   DOMAIN        1    108       IG-LIKE.
FT   MOD_RES       1      1       PYRROLIDONE CARBOXYLIC ACID.
FT   DISULFID     22     90       BY SIMILARITY.
FT   STRAND        5      5
FT   STRAND       10     12
FT   STRAND       18     23
FT   TURN         26     32
FT   STRAND       36     40
FT   TURN         42     43
FT   STRAND       50     51
FT   TURN         52     54
FT   STRAND       55     55
FT   TURN         62     63
FT   STRAND       66     68
FT   STRAND       72     77
FT   HELIX        82     84
FT   STRAND       86     93
FT   STRAND       99    101
FT   STRAND      105    109
FT   NON_TER     111    111
SQ   SEQUENCE   111 AA;  11558 MW;  7CC1D6E2FA3377BA CRC64;

  Query Match             28.4%;  Score 186.5;  DB 1;  Length 111;
  Best Local Similarity   43.9%;  Pred. No. 4e-13;
  Matches   43;  Conservative   16;  Mismatches   32;  Indels    7;  Gaps    3;

Qy         19 QTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHH 78
              |: | |  :    ||   :||| :   |   :| |||||| || ||: ::|    | :
Db          1 QSALTQPPSASGSLGQSVTISCTGTSSDVGGYNY-VSWYQQHAGKAPKVIIY----EVNK 55

Qy         79 RPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCS 116
              ||: :||||| :|  : |   ||:| :| ||:||||||
Db         56 RPSGVPDRFSGSK--SGNTASLTVSGLQAEDEADYYCS 91


RESULT 8
LV2L_HUMAN
ID   LV2L_HUMAN     STANDARD;      PRT;   111 AA.
AC   P80422;
DT   01-NOV-1995 (Rel. 32, Created)
DT   01-NOV-1995 (Rel. 32, Last sequence update)
DT   10-OCT-2003 (Rel. 42, Last annotation update)
DE   Ig gamma lambda chain V-II region DOT.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=95255298; PubMed=7737190;
RA   Stoppini M., Bellotti V., Negri A., Merlini G., Garver F., Ferri G.;
RT   "Characterization of the two unique human anti-flavin monoclonal
RT   immunoglobulins.";
RL   Eur. J. Biochem. 228:886-893(1995).
CC   -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR   HSSP; P01709; 2MCG.
DR   GO; GO:0005576; C:extracellular; NAS.
DR   GO; GO:0003823; F:antigen binding; NAS.
DR   GO; GO:0006955; P:immune response; NAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin V region.
FT   DOMAIN        1    106       IG-LIKE.
FT   DISULFID     22     90       BY SIMILARITY.
FT   NON_TER     111    111
SQ   SEQUENCE   111 AA;  11787 MW;  F358B1EA2CD7109A CRC64;

  Query Match             28.2%;  Score 185.5;  DB 1;  Length 111;
  Best Local Similarity   44.8%;  Pred. No. 5.1e-13;
  Matches   43;  Conservative   14;  Mismatches   32;  Indels    7;  Gaps    3;

Qy         20 TVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHR 79
              : | |  :|   |||   :|||  |  |   |  |||||  | ||| |:|    :|  |
Db          2 SALTQPRSLSGSPGQAVTISCTGLPS-VVDDDNFVSWYQQTPGRAPRLLIY----DDSLR 56

Qy         80 PADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
              |: :|:||| :| :   |  |||| :||:|:| |:|
Db         57 PSGVPNRFSGSKSDTKAA--LTISGLQPDDEATYFC 90


RESULT 9
LV6D_HUMAN
ID   LV6D_HUMAN     STANDARD;      PRT;   111 AA.
AC   P06318;
DT   01-JAN-1988 (Rel. 06, Created)
DT   01-JAN-1988 (Rel. 06, Last sequence update)
DT   15-JUL-1999 (Rel. 38, Last annotation update)
DE   Ig lambda chain V-VI region WLT.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=86122667; PubMed=4089539;
RA   Dwulet F.E., Strako K., Benson M.D.;
RT   "Amino acid sequence of a lambda VI primary (AL) amyloid protein
RT   (WLT).";
RL   Scand. J. Immunol. 22:653-660(1985).
DR   PIR; A01989; L6HULT.
DR   HSSP; P01709; 2MCG.
DR   GO; GO:0005576; C:extracellular; NAS.
DR   GO; GO:0003823; F:antigen binding; NAS.
DR   GO; GO:0006955; P:immune response; NAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin V region.
FT   DOMAIN        1     22       FRAMEWORK-1.
FT   DOMAIN       23     35       COMPLEMENTARITY-DETERMINING-1.
FT   DOMAIN       36     50       FRAMEWORK-2.
FT   DOMAIN       51     57       COMPLEMENTARITY-DETERMINING-2.
FT   DOMAIN       58     91       FRAMEWORK-3.
FT   DOMAIN       92    101       COMPLEMENTARITY-DETERMINING-3.
FT   DOMAIN      102    111       FRAMEWORK-4.
FT   DISULFID     22     91       BY SIMILARITY.
FT   NON_TER     111    111
SQ   SEQUENCE   111 AA;  11966 MW;  0C88B2FE37BCE24F CRC64;

  Query Match             28.2%;  Score 185;  DB 1;  Length 111;
  Best Local Similarity   45.2%;  Pred. No. 5.7e-13;
  Matches   38;  Conservative   16;  Mismatches   24;  Indels    6;  Gaps    2;

Qy         32 PGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRPADIPDRFSAAK 91
              | :   :||| |    :|    | ||||| ||||  ::|    |:: ||:::||||| :
Db         14 PEKTVTISCTGSSG--SIGSNYVQWYQQRPGSAPTNVIY----ENNQRPSEVPDRFSGSI 67

Qy         92 DEAHNACVLTISPVQPEDDADYYC 115
              | : |:  |||| :: ||:|||||
Db         68 DSSSNSASLTISGLKTEDEADYYC 91
```

```
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE.
RA   Solomon A., Kyle R.A., Frangione B.;
RT   "Light chain variable region subgroups of monoclonal immunoglobulins
RT   in amyloidosis AL.";
RL   (In) Glenner G.G., Osserman E.F., Benditt E.P., Calkins E.,
RL   Cohen A.S., Zucker-Franklin D. (eds.);
RL   Amyloidosis, pp.449-462, Plenum Press, New York (1986).
DR   PIR; A01988; L6HUST.
DR   PDB; 1CD0; 06-MAR-00.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin V region; 3D-structure.
FT   DOMAIN        1     22       FRAMEWORK-1.
FT   DOMAIN       23     35       COMPLEMENTARITY-DETERMINING-1.
FT   DOMAIN       36     50       FRAMEWORK-2.
FT   DOMAIN       51     57       COMPLEMENTARITY-DETERMINING-2.
FT   DOMAIN       58     91       FRAMEWORK-3.
FT   DOMAIN       92    100       COMPLEMENTARITY-DETERMINING-3.
FT   DOMAIN      101    111       FRAMEWORK-4.
FT   DISULFID     22     91       BY SIMILARITY.
FT   NON_TER     111    111
SQ   SEQUENCE   111 AA;  12247 MW;  0941DD547D983598 CRC64;

  Query Match             30.7%;  Score 202;  DB 1;  Length 111;
  Best Local Similarity   45.3%;  Pred. No. 8.5e-15;
  Matches   43;  Conservative   15;  Mismatches   31;  Indels    6;  Gaps    2;

Qy          21 VLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRP 80
               :| |  ::   ||:   :||| |    ||  | | ||||| | ||  :::    ||  ||
Db           3 MLTQPHSVSESPGKTVIISCTRSDG--TIAGYYVQWYQQRPGRAPTTVIF----EDTQRP 56

Qy          81 ADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
               : :|||| : | : |:  |||| :| ||:|||||
Db          57 SGVPDRFSGSIDRSSNSASLTISGLQTEDEADYYC 91


RESULT 6
LV6A_HUMAN
ID   LV6A_HUMAN     STANDARD;      PRT;   112 AA.
AC   P01721;
DT   21-JUL-1986 (Rel. 01, Created)
DT   21-JUL-1986 (Rel. 01, Last sequence update)
DT   10-OCT-2003 (Rel. 42, Last annotation update)
DE   Ig lambda chain V-VI region AR.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE (AMYLOID PROTEIN AR).
RX   MEDLINE=82091000; PubMed=6797401;
RA   Sletten K., Natvig J.B., Husby G., Juul J.;
RT   "The complete amino acid sequence of a prototype
RT   immunoglobulin-lambda light-chain-type amyloid-fibril protein AR.";
RL   Biochem. J. 195:561-572(1981).
CC   -!- MISCELLANEOUS: ABOUT HALF OF THE LAMBDA CHAIN C REGION IS MISSING
CC       FROM THIS PROTEIN.
CC   -!- MISCELLANEOUS: THIS PROTEIN WAS ISOLATED FROM THE SPLEEN OF A
CC       PATIENT WITH AMYLOIDOSIS.
CC   -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR   PIR; A01987; L6HUAR.
DR   HSSP; P01709; 2MCG.
DR   GO; GO:0005576; C:extracellular; NAS.
DR   GO; GO:0003823; F:antigen binding; NAS.
DR   GO; GO:0006955; P:immune response; NAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin V region; Amyloid.
FT   DOMAIN        1    107       IG-LIKE.
FT   NON_TER     112    112
SQ   SEQUENCE   112 AA;  11918 MW;  570BCD9A368EF1FE CRC64;

  Query Match             30.3%;  Score 199;  DB 1;  Length 112;
  Best Local Similarity   44.2%;  Pred. No. 1.8e-14;
  Matches   42;  Conservative   18;  Mismatches   29;  Indels    6;  Gaps    2;

Qy          21 VLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRP 80
               :| |  ::   ||:   ||| |    :| |  | ||||| |||| ::|    :|: ||
Db           3 MLTQPHSVSESPGKTVTFSCTGSGG--SIADSFVQWYQQRPGSAPTTVIY----DDNQRP 56

Qy          81 ADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
               : :|||| : |:: |:  |||| :: ||:|||||
Db          57 SGVPDRFSGSIDDSANSASLTISGLKTEDEADYYC 91


RESULT 7
LV2F_HUMAN
ID   LV2F_HUMAN     STANDARD;      PRT;   111 AA.
AC   P01709;
DT   21-JUL-1986 (Rel. 01, Created)
DT   21-JUL-1986 (Rel. 01, Last sequence update)
DT   10-OCT-2003 (Rel. 42, Last annotation update)
DE   Ig lambda chain V-II region MGC.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=75013804; PubMed=4415202;
RA   Fett J.W., Deutsch H.F.;
RT   "Primary structure of the Mcg lambda chain.";
RL   Biochemistry 13:4102-4114(1974).
RN   [2]
RP   LAMBDA CHAIN GENES.
RX   MEDLINE=76093781; PubMed=812801;
RA   Fett J.W., Deutsch H.F.;
RT   "A new lambda-chain gene.";
RL   Immunochemistry 12:643-652(1975).
RN   [3]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RA   Edmundson A.B., Ely K.R., Abola E.E., Schiffer M.,
RA   Panagiotopoulos N.;
RT   "Rotational allomerism and divergent evolution of domains in
RT   immunoglobulin light chains.";
RL   Biochemistry 14:3953-3961(1975).
RN   [4]
RP   X-RAY CRYSTALLOGRAPHY.
RX   MEDLINE=90133913; PubMed=2515285;
RA   Ely K.R., Herron J.N., Harker M., Edmundson A.B.;
RT   "Three-dimensional structure of a light chain dimer crystallized in
RT   water. Conformational flexibility of a molecule in two crystal
RT   forms.";
RL   J. Mol. Biol. 210:601-615(1989).
CC   -!- MISCELLANEOUS: This is a Bence-Jones protein.
CC   -!- MISCELLANEOUS: THE MCG-TYPE C REGION APPEARS TO BE CORRELATED WITH
CC       A VERY UNUSUAL V-REGION SUBSTITUTION, 103-THR ABOVE FOR GLY,
CC       SUGGESTING THAT THE V-C JOINING MECHANISM IS NOT ALWAYS RANDOM.
CC   -!- MISCELLANEOUS: THE C REGION OF THIS CHAIN HAS THE KERN+ AND MCG+
CC       MARKERS.
CC   -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR   PIR; A90381; L2HUMC.
DR   PDB; 2MCG; 15-JUL-92.
DR   PDB; 1A8J; 17-JUN-98.
DR   PDB; 1DCL; 15-MAY-97.
```

```
CC   or send an email to license@isb-sib.ch).
CC   ---------------------------------------------------------------------
DR   EMBL; X05556; CAA29071.1; -.
DR   EMBL; X05557; CAA29072.1; -.
DR   PIR; A28344; A28344.
DR   HSSP; P01607; 1REI.
DR   MGD; MGI:98936; Vpreb1.
DR   GO; GO:0005886; C:plasma membrane; IPI.
DR   GO; GO:0004872; F:receptor activity; IPI.
DR   GO; GO:0030097; P:hemopoiesis; IMP.
DR   GO; GO:0006955; P:immune response; IPI.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin domain; Signal.
FT   SIGNAL        1     19       POTENTIAL.
FT   CHAIN        20    142       IMMUNOGLOBULIN IOTA CHAIN.
FT   DOMAIN       20     41       FRAMEWORK-1.
FT   DOMAIN       42     56       COMPLEMENTARITY-DETERMINING-1.
FT   DOMAIN       57     70       FRAMEWORK-2.
FT   DOMAIN       71     81       COMPLEMENTARITY-DETERMINING-2.
FT   DOMAIN       82    115       FRAMEWORK-3.
FT   DISULFID     41    115       BY SIMILARITY.
SQ   SEQUENCE   142 AA;  16125 MW;  2E18BF963A0F448C CRC64;

  Query Match             34.9%;  Score 229.5;  DB 1;  Length 142;
  Best Local Similarity   53.5%;  Pred. No. 1.3e-17;
  Matches   46;  Conservative    9;  Mismatches   30;  Indels    1;  Gaps    1;

Qy         33 GQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRPADIPDRFSAAKD 92
              |   :||||||  |  |  | : ||||| |  ||:|| | |  | |:  ||| ||| :||
Db         34 GATIRLSCTLSNDH-NIGIYSIYWYQQRPGHPPRFLLRYFSHSDKHQGPDIPPRFSGSKD 92

Qy         93 EAHNACVLTISPVQPEDDADYYCSVG 118
                 |   |:|| :||||:| |||:||
Db         93 TTRNLGYLSISELQPEDEAVYYCAVG 118


RESULT 4
VPRE_HUMAN
ID   VPRE_HUMAN     STANDARD;      PRT;   145 AA.
AC   P12018;
DT   01-OCT-1989 (Rel. 12, Created)
DT   16-OCT-2001 (Rel. 40, Last sequence update)
DT   15-MAR-2004 (Rel. 43, Last annotation update)
DE   Immunoglobulin iota chain precursor (V(pre)B protein) (VpreB protein)
DE   (CD179a antigen).
GN   VPREB1 OR VPREB.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=95021318; PubMed=7935499;
RA   Guelpa-Fonlupt V., Bossy D., Alzari P., Fumoux F., Fougereau M.,
RA   Schiff C.;
RT   "The human pre-B cell receptor: structural constraints for a tentative
RT   model of the pseudo-light (psi L) chain.";
RL   Mol. Immunol. 31:1099-1108(1994).
RN   [2]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=97228902; PubMed=9074928;
RA   Kawasaki K., Minoshima S., Mine E., Shibuya K., Shintani A.,
RA   Schmeits J.L., Wang J., Shimizu N.;
RT   "One-megabase sequence analysis of the human immunoglobulin lambda
RT   gene locus.";
RL   Genome Res. 7:250-261(1997).
RN   [3]
RP   SEQUENCE OF 1-139 FROM N.A.
RX   MEDLINE=88196069; PubMed=3258819;
RA   Bauer S.R., Kudo A., Melchers F.;
RT   "Structure and pre-B lymphocyte restricted expression of the VpreB in
RT   humans and conservation of its structure in other mammalian
RT   species.";
RL   EMBO J. 7:111-116(1988).
CC   -!- FUNCTION: ASSOCIATES WITH THE IG-MU CHAIN TO FORM A MOLECULAR
CC       COMPLEX THAT IS EXPRESSED ON THE SURFACE OF PRE-B-CELLS. THIS
CC       COMPLEX PRESUMABLY REGULATES IG GENE REARRANGEMENTS IN THE EARLY
CC       STEPS OF B-CELL DIFFERENTIATION.
CC   -!- SUBUNIT: Associates non-covalently with IGLL1.
CC   -!- TISSUE SPECIFICITY: ONLY EXPRESSED BY PRE-B-CELLS.
CC   -!- SIMILARITY: Belongs to the immunoglobulin superfamily.
CC   -!- DATABASE: NAME=PROW; NOTE=PROW 1:59-63(2000);
CC       WWW="http://www.ncbi.nlm.nih.gov/prow/guide/574153212_g.htm".
CC   ---------------------------------------------------------------------
CC   This SWISS-PROT entry is copyright. It is produced through a collaboration
CC   between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC   the European Bioinformatics Institute. There are no restrictions on its
CC   use by non-profit institutions as long as its content is in no way
CC   modified and this statement is not removed. Usage by and for commercial
CC   entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC   or send an email to license@isb-sib.ch).
CC   ---------------------------------------------------------------------
DR   EMBL; D86992; BAA19987.1; -.
DR   EMBL; D88270; BAA20030.1; -.
DR   EMBL; S74019; AAB32118.1; -.
DR   EMBL; M34927; AAA61292.1; -.
DR   PIR; I57832; I57832.
DR   PIR; S00258; S00258.
DR   HSSP; P80748; 2LOI.
DR   Genew; HGNC:12709; VPREB1.
DR   MIM; 605141; -.
DR   GO; GO:0005576; C:extracellular; NAS.
DR   GO; GO:0003823; F:antigen binding; NAS.
DR   GO; GO:0006955; P:immune response; NAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Antigen; Signal; Immunoglobulin domain.
FT   SIGNAL        1     19       POTENTIAL.
FT   CHAIN        20    145       IMMUNOGLOBULIN IOTA CHAIN.
FT   DOMAIN       20     41       FRAMEWORK-1.
FT   DOMAIN       42     56       COMPLEMENTARITY-DETERMINING-1.
FT   DOMAIN       57     70       FRAMEWORK-2.
FT   DOMAIN       71     81       COMPLEMENTARITY-DETERMINING-2.
FT   DOMAIN       82    115       FRAMEWORK-3.
FT   DISULFID     41    115       BY SIMILARITY.
FT   CONFLICT     10     10       L -> H (IN REF. 3).
SQ   SEQUENCE   145 AA;  16605 MW;  197665B13AF64D46 CRC64;

  Query Match             32.8%;  Score 215.5;  DB 1;  Length 145;
  Best Local Similarity   47.0%;  Pred. No. 4.1e-16;
  Matches   47;  Conservative   13;  Mismatches   39;  Indels    1;  Gaps    1;

Qy         19 QTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHH 78
              | || |  |:    |   :|:|||   | |  | | ||||| |  ||:|| | |: |
Db         20 QPVLHQPPAMSSALGTTIRLTCTLRNDH-DIGVYSVYWYQQRPGHPPRFLLRYFSQSDKS 78

Qy         79 RPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVG 118
              :   :| ||| :|| | |   |:|| :||||:| |||::|
Db         79 QGPQVPPRFSGSKDVARNRGYLSISELQPEDEAMYYCAMG 118


RESULT 5
LV6C_HUMAN
ID   LV6C_HUMAN     STANDARD;      PRT;   111 AA.
AC   P06317;
DT   01-JAN-1988 (Rel. 06, Created)
DT   01-JAN-1988 (Rel. 06, Last sequence update)
DT   10-OCT-2003 (Rel. 42, Last annotation update)
DE   Ig lambda chain V-VI region SUT.
```

```
CC   This SWISS-PROT entry is copyright. It is produced through a collaboration
CC   between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC   the European Bioinformatics Institute. There are no restrictions on its
CC   use by non-profit institutions as long as its content is in no way
CC   modified and this statement is not removed. Usage by and for commercial
CC   entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC   or send an email to license@isb-sib.ch).
CC   ----------------------------------------------------------------------
DR   EMBL; AF163825; AAF09451.1; -.
DR   EMBL; AB050772; BAB83034.1; -.
DR   EMBL; BC020666; AAH20666.1; -.
DR   HSSP; P01709; 2MCG.
DR   Genew; HGNC:12710; VPREB3.
DR   MIM; 605017; -.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin domain; Signal.
FT   SIGNAL        1     20       POTENTIAL.
FT   CHAIN        21    123       PRE-B LYMPHOCYTE PROTEIN 3.
FT   DOMAIN       21    123       IG-LIKE.
FT   DISULFID     40    115       BY SIMILARITY.
SQ   SEQUENCE   123 AA;  13710 MW;  BF09AC5196059E85 CRC64;

  Query Match             100.0%;  Score 657;  DB 1;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 1.2e-63;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 2
VPR2_MOUSE
ID   VPR2_MOUSE     STANDARD;      PRT;   142 AA.
AC   P13373;
DT   01-JAN-1990 (Rel. 13, Created)
DT   01-JAN-1990 (Rel. 13, Last sequence update)
DT   15-MAR-2004 (Rel. 43, Last annotation update)
DE   Immunoglobulin omega chain precursor (VpreB2 protein).
GN   VPREB2.
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=C57BL/6 X DBA/2J;
RX   MEDLINE=88029315; PubMed=3117530;
RA   Kudo A., Melchers F.;
RT   "A second gene, VpreB in the lambda 5 locus of the mouse, which
RT   appears to be selectively expressed in pre-B lymphocytes.";
RL   EMBO J. 6:2267-2272(1987).
CC   -!- FUNCTION: ASSOCIATES WITH THE IG-MU CHAIN TO FORM A MOLECULAR
CC       COMPLEX THAT IS EXPRESSED ON THE SURFACE OF PRE-B-CELLS. THIS
CC       COMPLEX PRESUMABLY REGULATES IG GENE REARRANGEMENTS IN THE EARLY
CC       STEPS OF B-CELL DIFFERENTIATION.
CC   -!- TISSUE SPECIFICITY: ONLY EXPRESSED BY PRE-B-CELLS.
CC   -!- SIMILARITY: Belongs to the immunoglobulin superfamily.
CC   ----------------------------------------------------------------------
CC   This SWISS-PROT entry is copyright. It is produced through a collaboration
CC   between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC   the European Bioinformatics Institute. There are no restrictions on its
CC   use by non-profit institutions as long as its content is in no way
CC   modified and this statement is not removed. Usage by and for commercial
CC   entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC   or send an email to license@isb-sib.ch).
CC   ----------------------------------------------------------------------
DR   EMBL; X05563; CAA29077.1; -.
DR   PIR; B28344; B28344.
DR   HSSP; P01607; 1REI.
DR   MGD; MGI:98937; Vpreb2.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF00047; ig; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin domain; Signal.
FT   SIGNAL        1     19       POTENTIAL.
FT   CHAIN        20    142       IMMUNOGLOBULIN OMEGA CHAIN.
FT   DOMAIN       20     41       FRAMEWORK-1.
FT   DOMAIN       42     56       COMPLEMENTARITY-DETERMINING-1.
FT   DOMAIN       57     70       FRAMEWORK-2.
FT   DOMAIN       71     81       COMPLEMENTARITY-DETERMINING-2.
FT   DOMAIN       82    115       FRAMEWORK-3.
FT   DISULFID     41    115       BY SIMILARITY.
SQ   SEQUENCE   142 AA;  16052 MW;  7EA7128A4E63D920 CRC64;

  Query Match             35.5%;  Score 233.5;  DB 1;  Length 142;
  Best Local Similarity   54.7%;  Pred. No. 4.7e-18;
  Matches   47;  Conservative    9;  Mismatches   29;  Indels    1;  Gaps    1;

Qy         33 GQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRPADIPDRFSAAKD 92
              |   :||||| | | | : ||||| | ||:|| | |  | |: ||| ||| :||
Db         34 GATIRLSCTLSNDH-NIGIYSIYWYQQRPGHPPRFLLRYFSHSDKHQGPDIPPRFSGSKD 92

Qy         93 EAHNACVLTISPVQPEDDADYYCSVG 118
                | |   |:|| :||||:| |||:||
Db         93 TARNLGYLSISELQPEDEAVYYCAVG 118


RESULT 3
VPR1_MOUSE
ID   VPR1_MOUSE     STANDARD;      PRT;   142 AA.
AC   P13372;
DT   01-JAN-1990 (Rel. 13, Created)
DT   01-JAN-1990 (Rel. 13, Last sequence update)
DT   15-MAR-2004 (Rel. 43, Last annotation update)
DE   Immunoglobulin iota chain precursor (VPreB1 protein).
GN   VPREB1.
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=C57BL/6 X DBA/2J;
RX   MEDLINE=88029315; PubMed=3117530;
RA   Kudo A., Melchers F.;
RT   "A second gene, VpreB in the lambda 5 locus of the mouse, which
RT   appears to be selectively expressed in pre-B lymphocytes.";
RL   EMBO J. 6:2267-2272(1987).
CC   -!- FUNCTION: ASSOCIATES WITH THE IG-MU CHAIN TO FORM A MOLECULAR
CC       COMPLEX THAT IS EXPRESSED ON THE SURFACE OF PRE-B-CELLS. THIS
CC       COMPLEX PRESUMABLY REGULATES IG GENE REARRANGEMENTS IN THE EARLY
CC       STEPS OF B-CELL DIFFERENTIATION.
CC   -!- TISSUE SPECIFICITY: ONLY EXPRESSED BY PRE-B-CELLS.
CC   -!- SIMILARITY: Belongs to the immunoglobulin superfamily.
CC   ----------------------------------------------------------------------
CC   This SWISS-PROT entry is copyright. It is produced through a collaboration
CC   between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC   the European Bioinformatics Institute. There are no restrictions on its
CC   use by non-profit institutions as long as its content is in no way
CC   modified and this statement is not removed. Usage by and for commercial
CC   entities requires a license agreement (See http://www.isb-sib.ch/announce/
```

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: September 7, 2004, 20:38:02 ; Search time 23 Seconds
(without alignments)
278.462 Million cell updates/sec

Title: US-09-981-876-200
Perfect score: 657
Sequence: 1 MACRCLSFLLMGTFLSVSQT.....PVQPEDDADYYCSVGYGFSP 123

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SwissProt_42:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	657	100.0	123	1	VPR3_HUMAN	Q9uki3 homo sapien
2	233.5	35.5	142	1	VPR2_MOUSE	P13373 mus musculu
3	229.5	34.9	142	1	VPR1_MOUSE	P13372 mus musculu
4	215.5	32.8	145	1	VPRE_HUMAN	P12018 homo sapien
5	202	30.7	111	1	LV6C_HUMAN	P06317 homo sapien
6	199	30.3	112	1	LV6A_HUMAN	P01721 homo sapien
7	186.5	28.4	111	1	LV2F_HUMAN	P01709 homo sapien
8	185.5	28.2	111	1	LV2L_HUMAN	P80422 homo sapien
9	185	28.2	111	1	LV6D_HUMAN	P06318 homo sapien
10	185	28.2	131	1	LV6E_HUMAN	P06319 homo sapien
11	184.5	28.1	111	1	LV2G_HUMAN	P01710 homo sapien
12	183.5	27.9	130	1	LV1G_HUMAN	P06316 homo sapien
13	180.5	27.5	111	1	LV1D_HUMAN	P01702 homo sapien
14	180.5	27.5	112	1	LV2K_HUMAN	P04209 homo sapien
15	180.5	27.5	117	1	LV0A_HUMAN	P04211 homo sapien
16	179	27.2	111	1	LV2I_HUMAN	P01712 homo sapien
17	177.5	27.0	109	1	LV2E_HUMAN	P01708 homo sapien
18	175	26.6	108	1	LV3A_HUMAN	P01714 homo sapien
19	175	26.6	108	1	LV5A_HUMAN	P01719 homo sapien
20	173	26.3	109	1	LV1F_HUMAN	P04208 homo sapien
21	173	26.3	111	1	LV3B_HUMAN	P80748 homo sapien
22	172.5	26.3	110	1	LV2J_HUMAN	P01713 homo sapien
23	168.5	25.6	111	1	LV2B_HUMAN	P01705 homo sapien
24	167	25.4	106	1	LV4D_HUMAN	P01718 homo sapien
25	166	25.3	106	1	LV4B_HUMAN	P01716 homo sapien
26	166	25.3	111	1	LV1C_HUMAN	P01701 homo sapien
27	165	25.1	107	1	LV4C_HUMAN	P01717 homo sapien
28	164.5	25.0	112	1	LV1B_HUMAN	P01700 homo sapien
29	163.5	24.9	111	1	LV2H_HUMAN	P01711 homo sapien
30	163.5	24.9	112	1	LV1H_HUMAN	P06887 homo sapien
31	163	24.8	106	1	LV4A_HUMAN	P01715 homo sapien
32	162.5	24.7	109	1	KV3D_HUMAN	P01622 homo sapien
33	162.5	24.7	111	1	LV2A_HUMAN	P01704 homo sapien
34	162	24.7	109	1	LV1I_HUMAN	P06888 homo sapien
35	161.5	24.6	129	1	KV3L_HUMAN	P18135 homo sapien
36	160.5	24.4	108	1	KV3A_HUMAN	P01619 homo sapien
37	159.5	24.3	111	1	LV2C_HUMAN	P01706 homo sapien
38	158.5	24.1	111	1	LV2D_HUMAN	P01707 homo sapien
39	158	24.0	113	1	LV1_CHICK	P04210 gallus gall
40	157.5	24.0	109	1	KV3B_HUMAN	P01620 homo sapien
41	157.5	24.0	109	1	KV3G_HUMAN	P04206 homo sapien
42	155.5	23.7	129	1	KV3M_HUMAN	P18136 homo sapien
43	153	23.3	112	1	LV6B_HUMAN	P01722 homo sapien
44	151.5	23.1	115	1	KV3I_HUMAN	P04433 homo sapien
45	151	23.0	106	1	LV4E_HUMAN	P06889 homo sapien

ALIGNMENTS

RESULT 1
VPR3_HUMAN
ID VPR3_HUMAN STANDARD; PRT; 123 AA.
AC Q9UKI3;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Pre-B lymphocyte protein 3 precursor (VpreB3 protein) (N27C7-2).
GN VPREB3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20169186; PubMed=10702669;
RA Rosnet O., Mattei M.-G., Delattre O., Schiff C.;
RT "VPREB3: cDNA characterization and expression in human and chromosome
RT mapping in human and mouse.";
RL Cytogenet. Cell Genet. 87:205-208(1999).
RN [2]
RP SEQUENCE FROM N.A.
RA Shimizu N., Minosima S., Kawasaki K., Sasaki T., Hosono K.;
RT "Molecular cloning of N27C7-2 gene.";
RL Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC TISSUE=Testis;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -!- FUNCTION: ASSOCIATES WITH THE IG-MU CHAIN TO FORM A MOLECULAR
CC COMPLEX THAT IS EXPRESSED ON THE SURFACE OF PRE-B-CELLS.
CC -!- TISSUE SPECIFICITY: Expressed in B cell precursors. Expressed in
CC fetal liver, bone marrow, spleen and lymph node.
CC -!- SIMILARITY: Belongs to the immunoglobulin superfamily.
CC -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC ----------

```
C;Species: Homo sapiens (man)
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 21-Jan-2000
C;Accession: S60297; S16848
R;Kueppers, R.; Fischer, U.; Rajewsky, K.; Gause, A.
Immunol. Lett. 34, 57-62, 1992
A;Title: Immunoglobulin heavy and light chain gene sequences of a human CD5 positive imm
A;Reference number: S60295; MUID:93122853; PMID:1282498
A;Accession: S60297
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-136 <KU2>
A;Cross-references: EMBL:X62125; NID:g38334; PIDN:CAA44056.1; PID:g38335
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;34-111/Domain: immunoglobulin homology <IMM>

  Query Match             29.8%;  Score 196;  DB 2;  Length 136;
  Best Local Similarity   42.3%;  Pred. No. 1.3e-12;
  Matches   47;  Conservative   18;  Mismatches   38;  Indels    8;  Gaps    4;

Qy          6 LSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAP 65
              |: |  ||  | :|: | |  :    |||   :||| :   |   :| |||||   | ||
Db          8 LTLLTQGTG-SWAQSALTQPPSASGSPGQSVTISCTGTSSDVGAYNY-VSWYQHHPGKAP 65

Qy         66 RYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCS 116
              : ::|  ||    ||: :||||| :|  : |   ||:| :| ||:|||||:
Db         66 KLMMYEVSE----RPSGVPDRFSGSK--SGNTASLTVSGLQAEDEADYYCT 110


Search completed: September  7, 2004, 20:53:45
Job time : 39 secs
```

A;Reference number: A01988
A;Accession: A01988
A;Molecule type: protein
A;Residues: 1-111 <SOL>
C;Genetics:
A;Gene: GDB:IGLV@
A;Cross-references: GDB:119342; OMIM:147240
A;Map position: 22q11.2-22q11.2
C;Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kap
hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-22/Region: framework 1
F;15-93/Domain: immunoglobulin homology <IMM>
F;23-35/Region: complementarity-determining 1
F;36-50/Region: framework 2
F;51-57/Region: complementarity-determining 2
F;58-91/Region: framework 3
F;92-100/Region: complementarity-determining 3
F;101-111/Region: framework 4
F;22-91/Disulfide bonds: #status predicted

Query Match 30.7%; Score 202; DB 1; Length 111;
Best Local Similarity 45.3%; Pred. No. 2.5e-13;
Matches 43; Conservative 15; Mismatches 31; Indels 6; Gaps 2;

Qy 21 VLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRP 80
Db 3 MLTQPHSVSESPGKTVIISCTRSDG--TIAGYYVQWYQQRPGRAPTTVIF----EDTQRP 56

Qy 81 ADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
Db 57 SGVPDRFSGSIDRSSNSASLTISGLQTEDEADYYC 91

RESULT 12
A32529
Ig lambda chain precursor V region (clone pDH8) - rabbit (fragment)
C;Species: Oryctolagus cuniculus (domestic rabbit)
C;Date: 07-Jun-1990 #sequence_revision 23-Nov-1991 #text_change 16-Aug-1996
C;Accession: A32529
R;Hayzer, D.J.; Duvoisin, R.M.; Jaton, J.C.
Biochem. J. 245, 691-697, 1987
A;Title: cDNA clones encoding rabbit immunoglobulin lambda chains. Evidence for length v
A;Reference number: A90338; MUID:88024122; PMID:3117050
A;Accession: A32529
A;Molecule type: mRNA
A;Residues: 1-118 <HAY>
A;Cross-references: GB:M25617
A;Note: the authors translated the codon TTG for residue 37 as Phe
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin

Query Match 30.5%; Score 200.5; DB 2; Length 118;
Best Local Similarity 42.3%; Pred. No. 3.8e-13;
Matches 44; Conservative 14; Mismatches 41; Indels 5; Gaps 2;

Qy 16 SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEE 75
Db 3 SLSQPVLTQSPSAAAALGASAKLTCTLDSAHKTSL---VEWYQHQKGEAPRYLMWLRKDG 59

Qy 76 DHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGY 119
Db 60 SYTKGTGVPDRFSGSSSGADR--YLIISSVQADDEADYYCGVDY 101

RESULT 13
L6HUAR
Ig lambda chain V-VI region (AR) - human (tentative sequence)
C;Species: Homo sapiens (man)
C;Date: 02-Apr-1982 #sequence_revision 02-Apr-1982 #text_change 31-Mar-2000
C;Accession: A01987
R;Sletten, K.; Natvig, J.B.; Husby, G.; Juul, J.

Biochem. J. 195, 561-572, 1981
A;Title: The complete amino acid sequence of a prototype immunoglobulin-lambda light-cha
A;Reference number: A01987; MUID:82091000; PMID:6797401
A;Contents: amyloid protein AR
A;Accession: A01987
A;Molecule type: protein
A;Residues: 1-112 <SLE>
A;Note: about half of the lambda chain C region is missing from this protein
C;Comment: This protein was isolated from the spleen of a patient with amyloidosis.
C;Genetics:
A;Gene: GDB:IGLV@
A;Cross-references: GDB:119342; OMIM:147240
A;Map position: 22q11.2-22q11.2
C;Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kapp
hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: amyloid; heterotetramer; immunoglobulin
F;15-93/Domain: immunoglobulin homology <IMM>
F;22-91/Disulfide bonds: #status predicted

Query Match 30.3%; Score 199; DB 1; Length 112;
Best Local Similarity 44.2%; Pred. No. 5.1e-13;
Matches 42; Conservative 18; Mismatches 29; Indels 6; Gaps 2;

Qy 21 VLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRP 80
Db 3 MLTQPHSVSESPGKTVTFSCTGSGG--SIADSFVQWYQQRPGSAPTTVIY----DDNQRP 56

Qy 81 ADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
Db 57 SGVPDRFSGSIDDSANSASLTISGLKTEDEADYYC 91

RESULT 14
S04525
Ig lambda chain precursor V region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 04-Dec-1992 #sequence_revision 04-Dec-1992 #text_change 21-Jan-2000
C;Accession: S04525
R;Alexandre, D.; Chuchana, P.; Brockly, F.; Blancher, A.; Lefranc, G.; Lefranc, M.P.
Nucleic Acids Res. 17, 3975, 1989
A;Title: First genomic sequence of a human Ig variable lambda gene belonging to subgroup
A;Reference number: S04525; MUID:89282401; PMID:2499871
A;Accession: S04525
A;Molecule type: DNA
A;Residues: 1-117 <ALE>
A;Cross-references: EMBL:X14615; NID:g33397; PIDN:CAA32769.1; PID:g736246
C;Genetics:
A;Introns: 16/1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;34-110/Domain: immunoglobulin homology <IMM>

Query Match 30.0%; Score 197; DB 2; Length 117;
Best Local Similarity 40.3%; Pred. No. 8.6e-13;
Matches 50; Conservative 23; Mismatches 41; Indels 10; Gaps 5;

Qy 1 MACR-CLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQ 59
Db 1 MTCSPLLLTLLIHCTGSWAQSVLTQPPSVSAAPGQKVTISCSGSSS--DMGNYAVSWYQQ 58

Qy 60 RAGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGY 119
Db 59 LPGTAPKLLIY----ENNKRPSGIPDRFSGSK--SGTSATLGITGLWPEDEADYYC-LAW 111

Qy 120 GFSP 123
Db 112 DTSP 115

RESULT 15
S16848
Ig lambda chain V-II region precursor - human

```
Qy          79 RPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVG 118
               :   :| ||| :|| | |   |:|| :||||:| |||::|
Db          79 QGPQVPPRFSGSKDVARNRGYLSISELQPEDEAMYYCAMG 118


RESULT 7
S17399
Ig lambda chain precursor - rabbit (fragment)
C;Species: Oryctolagus cuniculus (domestic rabbit)
C;Date: 19-Feb-1994 #sequence_revision 10-Nov-1995 #text_change 21-Jan-2000
C;Accession: S17399
R;Hayzer, D.J.; Young-Cooper, G.O.; Mage, R.G.; Jaton, J.C.
Eur. J. Immunol. 20, 2707-2712, 1990
A;Title: cDNA clones encoding immunoglobulin lambda chains from rabbit expressing the ph
A;Reference number: S17399; MUID:91099420; PMID:2125274
A;Accession: S17399
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-232 <HAY>
A;Cross-references: EMBL:X57729; NID:g1593; PIDN:CAA40896.1; PID:g1594
A;Note: the authors translated the codon TTA for residue 92 as Trp and AGC for residue 1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;147-215/Domain: immunoglobulin homology <IMM>

  Query Match             32.5%;  Score 213.5;  DB 2;  Length 232;
  Best Local Similarity   41.7%;  Pred. No. 4e-14;
  Matches   48;  Conservative   18;  Mismatches   40;  Indels    9;  Gaps    3;

Qy           9 LLMGTFL----SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSA 64
               ||: | |    |:|| || |  ::    |  |:|:|||| | |   | : ||||: | |
Db           2 LLLLTLLQCTGSLSQPVLTQSPSVSAALGASARLTCTLSSAHKT---YTIDWYQQQQGEA 58

Qy          65 PRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGY 119
               ||||:: :|:  : :   :||||| :   |     | |  || :|:|||||   |
Db          59 PRYLMHIKSDGSYTKGTGVPDRFSGSSSGADR--YLIIPSVQADDEADYYCGADY 111


RESULT 8
PS0056
Ig lambda chain precursor V-III region - rabbit
C;Species: Oryctolagus cuniculus (domestic rabbit)
C;Date: 31-Mar-1990 #sequence_revision 31-Mar-1990 #text_change 23-Jul-1999
C;Accession: PS0056
R;Hayzer, D.J.; Jaton, J.C.
Gene 80, 185-191, 1989
A;Title: Cloning and sequencing of two functional rabbit germ-line immunoglobulin V lamb
A;Reference number: A91614; MUID:90006781; PMID:2507399
A;Accession: PS0056
A;Molecule type: DNA
A;Residues: 1-120 <HAY>
A;Cross-references: GB:M27841; NID:g341761; PIDN:AAA31364.1; PID:g552408
A;Note: the authors translated the codon TTG for residue 97 as Trp
C;Genetics:
A;Introns: 17/1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-20/Domain: signal sequence #status predicted <SIG>
F;21-120/Product: Ig lambda chain V-III region #status predicted <MAT>

  Query Match             32.0%;  Score 210.5;  DB 2;  Length 120;
  Best Local Similarity   41.9%;  Pred. No. 3.8e-14;
  Matches   49;  Conservative   16;  Mismatches   43;  Indels    9;  Gaps    3;

Qy           5 CLSFLLMGTFL----SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
               |   ||: | |    |:|| || |  :    |  |:|:|||| | |   | : ||||:
Db           3 CTPLLLLLTLLQSTGSLSQPVLTQSPSASAALGSSAKLTCTLSSAHKT---YYIEWYQQQ 59

Qy          61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSV 117
               | |||||:  :|:  : :   :||||| :   |     | || || :|:|||| | |
Db          60 QGEAPRYLMQLKSDGSYTKGTGVPDRFSGSSSGADR--YLIISSVQADDEADYICGV 114


RESULT 9
A28565
Ig lambda chain precursor V region (pDH7) - rabbit
C;Species: Oryctolagus cuniculus (domestic rabbit)
C;Date: 15-Dec-1988 #sequence_revision 15-Dec-1988 #text_change 18-Oct-1996
C;Accession: A28565
R;Hayzer, D.J.; Jaton, J.C.
J. Immunol. 138, 2316-2322, 1987
A;Title: Nucleotide sequence of a cDNA clone encoding a rabbit immunoglobulin-lambda ligh
A;Reference number: A92813; MUID:87167587; PMID:3104459
A;Accession: A28565
A;Molecule type: mRNA
A;Residues: 1-133 <HAY>
A;Note: the authors translated the codon TTA for residue 51 as Phe
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-20/Domain: signal sequence #status predicted <SIG>
F;21-133/Product: Ig lambda chain V region pDH7 #status predicted <MAT>

  Query Match             31.7%;  Score 208.5;  DB 2;  Length 133;
  Best Local Similarity   39.5%;  Pred. No. 6.9e-14;
  Matches   47;  Conservative   18;  Mismatches   45;  Indels    9;  Gaps    3;

Qy           5 CLSFLLMGTFL----SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
               |   ||: | |    |:|| || |  :    |  |:|:|||   | |:   ::||||:
Db           3 CTPLLLLLTLLQCTGSLSQPVLTQSPSASATLGASAKLTCTLDSAHKTLH---IAWYQQQ 59

Qy          61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGY 119
               | || ||:  :|:  : :   :||||| :   |     | || || :|:|||||   |
Db          60 QGEAPWYLMQLKSDGSYEKGTGVPDRFSGSSSGADR--YLIISSVQADDEADYYCGTDY 116


RESULT 10
S25755
Ig lambda chain - human
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 21-Jan-2000
C;Accession: S25755
R;Combriato, G.; Klobeck, H.G.
Eur. J. Immunol. 21, 1513-1522, 1991
A;Title: V(lambda) and J(lambda)-C(lambda) gene segments of the human immunoglobulin lamb
A;Reference number: S16439; MUID:91257162; PMID:1904362
A;Accession: S25755
A;Status: preliminary; translation not shown
A;Molecule type: mRNA
A;Residues: 1-243 <COM>
A;Cross-references: EMBL:X57820; NID:g33739; PIDN:CAA40957.1; PID:g33740
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;158-226/Domain: immunoglobulin homology <IMM>

  Query Match             31.6%;  Score 207.5;  DB 2;  Length 243;
  Best Local Similarity   40.2%;  Pred. No. 1.7e-13;
  Matches   43;  Conservative   21;  Mismatches   42;  Indels    1;  Gaps    1;

Qy          16 SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEE 75
               |:|| || |  :    |  :|:| ||    :: |: : ||||: |: |||||||  |:
Db          17 SLSQPVLTQPSSHSASSGASVRLTCMLS-SGFSVGDFWIRWYQQKPGNPPRYLLYYHSDS 75

Qy          76 DHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYGFS 122
               :  : : :| ||| : | : || :| || :| | :|||||   :  |
Db          76 NKGQGSGVPSRFSGSNDASANAGILRISGLQLEVEADYYCGTWHSNS 122


RESULT 11
L6HUST
Ig lambda chain V-VI region (SUT) - human
C;Species: Homo sapiens (man)
C;Date: 30-Jun-1987 #sequence_revision 30-Jun-1987 #text_change 02-Sep-1997
C;Accession: A01988
R;Solomon, A.; Kyle, R.A.; Frangione, B.
in Amyloidosis, Glenner, G.G., Osserman, E.F., Benditt, E.P., Calkins, E., Cohn, A.S., a
A;Title: Light chain variable region subgroups of monoclonal immunoglobulins in amyloido
```

```
A;Cross-references: GB:X05563; GB:Y00079; NID:g55415; PIDN:CAA29077.1; PID:g55416
A;Note: the authors translated the codon GAG for residue 110 as Gln
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;20-142/Product: VpreB protein #status predicted <MAT>

  Query Match             35.5%;  Score 233.5;  DB 2;  Length 142;
  Best Local Similarity   54.7%;  Pred. No. 2.2e-16;
  Matches   47;  Conservative    9;  Mismatches   29;  Indels    1;  Gaps    1;

Qy         33 GQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRPADIPDRFSAAKD 92
              |   :||||||  |  |  | : |||||  |  ||:|| | |  | |:  ||| ||| :||
Db         34 GATIRLSCTLSNDH-NIGIYSIYWYQQRPGHPPRFLLRYFSHSDKHQGPDIPPRFSGSKD 92

Qy         93 EAHNACVLTISPVQPEDDADYYCSVG 118
                | |   |:|| :||||:| |||:||
Db         93 TARNLGYLSISELQPEDEAVYYCAVG 118


RESULT 3
A28344
VpreB protein precursor - mouse
C;Species: Mus musculus (house mouse)
C;Date: 19-May-1989 #sequence_revision 19-May-1989 #text_change 21-Jul-2000
C;Accession: A28344
R;Kudo, A.; Melchers, F.
EMBO J. 6, 2267-2272, 1987
A;Title: A second gene, VpreB in the lambda-5 locus of the mouse, which appears to be se
A;Reference number: A91077; MUID:88029315; PMID:3117530
A;Accession: A28344
A;Molecule type: DNA
A;Residues: 1-142 <KUD>
A;Cross-references: GB:X05556; GB:Y00079; NID:g55409; PIDN:CAA29071.1; PID:g55410
A;Note: the authors translated the codon GAG for residue 110 as Gln
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;20-142/Product: VpreB1 protein #status predicted <MAT>

  Query Match             34.9%;  Score 229.5;  DB 2;  Length 142;
  Best Local Similarity   53.5%;  Pred. No. 5.6e-16;
  Matches   46;  Conservative    9;  Mismatches   30;  Indels    1;  Gaps    1;

Qy         33 GQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRPADIPDRFSAAKD 92
              |   :||||||  |  |  | : |||||  |  ||:|| | |  | |:  ||| ||| :||
Db         34 GATIRLSCTLSNDH-NIGIYSIYWYQQRPGHPPRFLLRYFSHSDKHQGPDIPPRFSGSKD 92

Qy         93 EAHNACVLTISPVQPEDDADYYCSVG 118
                |   |:|| :||||:| |||:||
Db         93 TTRNLGYLSISELQPEDEAVYYCAVG 118


RESULT 4
PS0055
Ig lambda chain precursor V-II region - rabbit
C;Species: Oryctolagus cuniculus (domestic rabbit)
C;Date: 31-Mar-1990 #sequence_revision 31-Mar-1990 #text_change 23-Jul-1999
C;Accession: PS0055
R;Hayzer, D.J.; Jaton, J.C.
Gene 80, 185-191, 1989
A;Title: Cloning and sequencing of two functional rabbit germ-line immunoglobulin V lamb
A;Reference number: A91614; MUID:90006781; PMID:2507399
A;Accession: PS0055
A;Molecule type: DNA
A;Residues: 1-120 <HAY>
A;Cross-references: GB:M27840; NID:g341760; PIDN:AAA31363.1; PID:g552407
A;Note: the authors translated the codon TTG for residue 97 as Trp
C;Genetics:
A;Introns: 17/1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-20/Domain: signal sequence #status predicted <SIG>
F;21-120/Product: Ig lambda chain V-II region #status predicted <MAT>

  Query Match             33.1%;  Score 217.5;  DB 2;  Length 120;
  Best Local Similarity   41.2%;  Pred. No. 7.6e-15;
  Matches   49;  Conservative   17;  Mismatches   44;  Indels    9;  Gaps    3;

Qy          5 CLSFLLMGTFL----SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              |   ||: | |     |:|| || |  ::    |  |:|:|||| | |   | : ||||:
Db          3 CTPLLLLLTLLQCTGSLSQPVLTQSPSVSAALGASAKLTCTLSSAHKT---YTIDWYQQQ 59

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGY 119
                 |||||:  :|:  : :   :|||||  :   |     | |  || :|:|||||   |
Db         60 QGEAPRYLMQLKSDGSYTKGTGVPDRFSGSSSGADR--YLIIPSVQADDEADYYCGADY 116


RESULT 5
S00258
VpreB protein - human
C;Species: Homo sapiens (man)
C;Date: 31-Dec-1988 #sequence_revision 31-Dec-1988 #text_change 05-Nov-1999
C;Accession: S00258
R;Bauer, S.R.; Kudo, A.; Melchers, F.
EMBO J. 7, 111-116, 1988
A;Title: Structure and pre-B lymphocyte restricted expression of the VpreB gene in humans
A;Reference number: S00258; MUID:88196069; PMID:3258819
A;Accession: S00258
A;Molecule type: DNA
A;Residues: 1-139 <BAU>
A;Cross-references: EMBL:M34927; NID:g340304; PIDN:AAA61292.1; PID:g340305
C;Genetics:
A;Gene: GDB:VPREB1
A;Cross-references: GDB:120493; OMIM:146770
A;Map position: 22q11.2-22q11.2
A;Introns: 16/1
C;Superfamily: immunoglobulin V region; immunoglobulin homology

  Query Match             32.8%;  Score 215.5;  DB 2;  Length 139;
  Best Local Similarity   47.0%;  Pred. No. 1.4e-14;
  Matches   47;  Conservative   13;  Mismatches   39;  Indels    1;  Gaps    1;

Qy         19 QTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHH 78
              | || |  |:    |   :|:|||  |  | | | | ||||| |  ||:|| | |: |
Db         20 QPVLHQPPAMSSALGTTIRLTCTLRNDH-DIGVYSVYWYQQRPGHPPRFLLRYFSQSDKS 78

Qy         79 RPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVG 118
              :   :| ||| :|| | |   |:|| :||||:| |||::|
Db         79 QGPQVPPRFSGSKDVARNRGYLSISELQPEDEAMYYCAMG 118


RESULT 6
I57832
VPre-B protein - human
C;Species: Homo sapiens (man)
C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 05-Nov-1999
C;Accession: I57832
R;Guelpa-Fonlupt, V.; Bossy, D.; Alzari, P.; Fumoux, F.; Fougereau, M.; Schiff, C.
Mol. Immunol. 31, 1099-1108, 1994
A;Title: The human pre-B cell receptor: structural constraints for a tentative model of t
A;Reference number: I57832; MUID:95021318; PMID:7935499
A;Accession: I57832
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-145 <RES>
A;Cross-references: GB:S74019; NID:g693810; PIDN:AAB32118.1; PID:g693811
C;Genetics:
A;Gene: Vpre-B
A;Introns: 16/1
C;Superfamily: immunoglobulin V region; immunoglobulin homology

  Query Match             32.8%;  Score 215.5;  DB 2;  Length 145;
  Best Local Similarity   47.0%;  Pred. No. 1.5e-14;
  Matches   47;  Conservative   13;  Mismatches   39;  Indels    1;  Gaps    1;

Qy         19 QTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHH 78
              | || |  |:    |   :|:|||  |  | | | | ||||| |  ||:|| | |: |
Db         20 QPVLHQPPAMSSALGTTIRLTCTLRNDH-DIGVYSVYWYQQRPGHPPRFLLRYFSQSDKS 78
```

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: September 7, 2004, 20:46:08 ; Search time 38 Seconds
(without alignments)
311.357 Million cell updates/sec

Title: US-09-981-876-200
Perfect score: 657
Sequence: 1 MACRCLSFLLMGTFLSVSQT.....PVQPEDDADYYCSVGYGFSP 123

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_78:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	430	65.4	123	2	S35302	B-cell protein 8HS
2	233.5	35.5	142	2	B28344	VpreB protein prec
3	229.5	34.9	142	2	A28344	VpreB protein prec
4	217.5	33.1	120	2	PS0055	Ig lambda chain pr
5	215.5	32.8	139	2	S00258	VpreB protein - hu
6	215.5	32.8	145	2	I57832	VPre-B protein - h
7	213.5	32.5	232	2	S17399	Ig lambda chain pr
8	210.5	32.0	120	2	PS0056	Ig lambda chain pr
9	208.5	31.7	133	2	A28565	Ig lambda chain pr
10	207.5	31.6	243	2	S25755	Ig lambda chain -
11	202	30.7	111	1	L6HUST	Ig lambda chain V-
12	200.5	30.5	118	2	A32529	Ig lambda chain pr
13	199	30.3	112	1	L6HUAR	Ig lambda chain V-
14	197	30.0	117	2	S04525	Ig lambda chain pr
15	196	29.8	136	2	S16848	Ig lambda chain V-
16	193.5	29.5	98	2	S36068	Ig lambda chain -
17	191.5	29.1	99	2	S36058	Ig lambda chain -
18	191.5	29.1	132	2	A55410	Ig light chain V r
19	191	29.1	235	2	S25758	Ig lambda chain -
20	190.5	29.0	216	2	S69130	Ig lambda chain (D
21	189.5	28.8	234	2	A39956	Ig lambda chain pr
22	186.5	28.4	99	2	S36057	Ig lambda chain -
23	186.5	28.4	111	1	L2HUMC	Ig lambda chain V-
24	185	28.2	111	1	L6HULT	Ig lambda chain V-
25	185	28.2	131	1	L6HUEB	Ig lambda chain pr
26	184.5	28.1	111	1	L2HUBO	Ig lambda chain V-
27	184.5	28.1	233	2	S25744	Ig lambda chain -
28	183.5	27.9	130	1	L1HUBL	Ig lambda chain pr
29	182.5	27.8	99	2	S36051	Ig lambda chain -
30	182.5	27.8	99	2	S36053	Ig lambda chain -
31	182.5	27.8	117	2	S23627	Ig lambda chain pr
32	182.5	27.8	233	2	S25752	Ig lambda chain -
33	182.5	27.8	235	2	S25750	Ig lambda chain -
34	181.5	27.6	111	2	S46397	Ig lambda chain V
35	181.5	27.6	112	2	S31515	Ig lambda chain V
36	181.5	27.6	117	2	S04526	Ig lambda chain pr
37	181.5	27.6	118	2	S12627	Ig lambda chain pr
38	181.5	27.6	234	2	S25757	Ig lambda chain -
39	180.5	27.5	107	2	B46516	Ig lambda chain V
40	180.5	27.5	111	1	L1HUNG	Ig lambda chain V-
41	180.5	27.5	112	1	L2HUNG	Ig lambda chain V-
42	180.5	27.5	117	1	LVHU2	Ig lambda chain pr
43	180.5	27.5	132	2	PL0114	Ig lambda chain pr
44	180.5	27.5	132	2	S04937	Ig lambda chain pr
45	180	27.4	108	2	S38498	Ig lambda chain -

ALIGNMENTS

RESULT 1
S35302
B-cell protein 8HS-20 precursor - mouse
C;Species: Mus musculus (house mouse)
C;Date: 31-Dec-1993 #sequence_revision 02-Jun-1994 #text_change 20-Jun-2000
C;Accession: S35302
R;Shirasawa, T.; Ohnishi, K.; Hagiwara, S.; Shigemoto, K.; Takebe, Y.; Rajewsky, K.; Take
EMBO J. 12, 1827-1834, 1993
A;Title: A novel gene product associated with mu chains in immature B cells.
A;Reference number: S35302; MUID:93259124; PMID:8491176
A;Accession: S35302
A;Molecule type: DNA
A;Residues: 1-123 <SHI>
A;Cross-references: EMBL:D13208; NID:g286064; PIDN:BAA02495.1; PID:g286065
C;Genetics:
A;Gene: 8HS-20
A;Introns: 18/1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: B-cell
F;1-19/Domain: signal sequence #status predicted <SIG>
F;20-123/Product: B-cell protein 8HS-20 #status predicted <MAT>

Query Match 65.4%; Score 430; DB 2; Length 123;
Best Local Similarity 66.1%; Pred. No. 2.9e-36;
Matches 82; Conservative 14; Mismatches 26; Indels 2; Gaps 2;

```
Qy          1 MAC-RCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQ 59
              |||  ||  ||:|||::|  |  | ||  ||||| | ||||:: || |  | |||||||
Db          1 MACPGCLPLLLIGTFVAVFQPTLTQPDAFSVFPGQDAHLSCTINSQHATAGDIGVSWYQQ 60

Qy         60 RAGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGY 119
              : |||| :|||| :||:|:|||||||||||  | |||||:|||||| ||||||||: : :
Db         61 QPGSAP-HLLYYYAEEEHYRPADIPDRFSATVDAAHNACILTISPVLPEDDADYFCSIAH 119

Qy        120 GFSP 123
               | |
Db        120 TFEP 123
```

RESULT 2
B28344
VpreB protein precursor - mouse
C;Species: Mus musculus (house mouse)
C;Date: 19-May-1989 #sequence_revision 19-May-1989 #text_change 05-Nov-1999
C;Accession: B28344
R;Kudo, A.; Melchers, F.
EMBO J. 6, 2267-2272, 1987
A;Title: A second gene, VpreB in the lambda-5 locus of the mouse, which appears to be se
A;Reference number: A91077; MUID:88029315; PMID:3117530
A;Accession: B28344
A;Molecule type: DNA
A;Residues: 1-142 <KUD>

```
  Best Local Similarity   41.8%;  Pred. No. 1.7e-12;
  Matches   41;  Conservative   21;  Mismatches   28;  Indels    8;  Gaps    4;

Qy         19 QTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHH 78
              |:|| |  ::   |||   :||: |  ::   :| ||||||  |:||: |:|     |:
Db          1 QSVLTQPPSVSAAPGQKVTISCSGSSSNIG-NNY-VSWYQQLPGTAPKLLIY----SDNQ 54

Qy         79 RPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCS 116
              ||: :||||| :|  :  :  | || :: ||:|||||:
Db         55 RPSGVPDRFSGSK--SGTSASLAISGLRSEDEADYYCA 90


RESULT 15
US-08-305-683A-4
; Sequence 4, Application US/08305683A
; Patent No. 5646041
;  GENERAL INFORMATION:
;    APPLICANT:  HARFELDT, Elisabeth
;    APPLICANT:  LAKE, Philip
;    APPLICANT:  NOTTAGE, Barbara
;    APPLICANT:  OSTBERG, Lars G.
;    TITLE OF INVENTION:  MONOCLONAL ANTIBODY TO HERPES SIMPLEX
;    TITLE OF INVENTION:  VIRUS AND CELL LINE PRODUCING THE SAME
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend Khourie and Crew
;      STREET:  379 Lytton Avenue
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  US
;      ZIP:  94301
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/305,683A
;      FILING DATE:  13-SEP-1994
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/759,279
;      FILING DATE:  13-SEP-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  11823-005230
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 326-2400
;      TELEFAX:  (415) 326-2422
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  131 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
US-08-305-683A-4

  Query Match             28.1%;  Score 184.5;  DB 1;  Length 131;
  Best Local Similarity   42.0%;  Pred. No. 2.9e-12;
  Matches   42;  Conservative   19;  Mismatches   32;  Indels    7;  Gaps    3;

Qy         16 SVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEE 75
              | :|:|| |  ::   |||   |||| |  ::    | | |||   |:||: |:|
Db         17 SWAQSVLTQPPSVSGAPGQGVTLSCTGSRSNIG-AGYDVHWYQHLPGTAPKLLIY----G 71

Qy         76 DHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
              |::||: :||||| :|  :  :   |: :| ||:|||||
Db         72 DNNRPSGVPDRFSGSK--SGTSASLAITGLQAEDEADYYC 109


Search completed: September  7, 2004, 20:54:24
Job time : 35 secs
```

```
;      APPLICATION NUMBER:  US/09/025,769B
;      FILING DATE:  18-FEB-1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 95 11 3021.0
;      FILING DATE:  18-AUG-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  James F. Haley, Jr., Esq.
;      REGISTRATION NUMBER:  27,794
;      REFERENCE/DOCKET NUMBER:  MORPHO/5
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212)596-9000
;      TELEFAX:  (212)596-9090
;  INFORMATION FOR SEQ ID NO:  55:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  107 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
US-09-025-769B-55

  Query Match             28.3%;  Score 186;  DB 4;  Length 107;
  Best Local Similarity   41.2%;  Pred. No. 1.6e-12;
  Matches   42;  Conservative   15;  Mismatches   35;  Indels   10;  Gaps    3;

Qy         22 LAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRPA 81
              |  |   ::  | |||  |::||:       : |   |||||: | ||  ::|    :|  ||:
Db          4 LTQPPSVSVAPGQTARISCSGD----ALGDKYASWYQQKPGQAPVLVIY----DDSDRPS 55

Qy         82 DIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYGFSP 123
                ||:||| :   : |   ||||  | ||:|||||   |   |
Db         56 GIPERFSGS--NSGNTATLTISGTQAEDEADYYCQQHYTTPP 95


RESULT 13
US-08-665-202-39
; Sequence 39, Application US/08665202
; Patent No. 5977322
;  GENERAL INFORMATION:
;    APPLICANT:  Marks, James D.
;    APPLICANT:  Schier, Robert
;    TITLE OF INVENTION:  No. 5977322el High Affinity Human Antibodies to
;    TITLE OF INVENTION:  Tumor Antigens
;    NUMBER OF SEQUENCES:  141
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/665,202
;      FILING DATE:  13-JUN-1996
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/000,238
;      FILING DATE:  14-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/000,250
;      FILING DATE:  15-JUN-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Hunter, Tom
;      REGISTRATION NUMBER:  38,498
;      REFERENCE/DOCKET NUMBER:  02307E-061410
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  39:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  112 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-665-202-39

  Query Match             28.3%;  Score 186;  DB 2;  Length 112;
  Best Local Similarity   41.8%;  Pred. No. 1.7e-12;
  Matches   41;  Conservative   21;  Mismatches   28;  Indels    8;  Gaps    4;

Qy         19 QTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHH 78
              |:|| |  ::   |||   :||: |  ::   :| ||||||  |:||: |:|     |:
Db          1 QSVLTQPPSVSAAPGQKVTISCSGSSSNIG-NNY-VSWYQQLPGTAPKLLIY----SDNQ 54

Qy         79 RPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCS 116
              ||: :||||| :|  :  :  | || :: ||:|||||:
Db         55 RPSGVPDRFSGSK--SGTSASLAISGLRSEDEADYYCA 90


RESULT 14
US-09-315-574-39
; Sequence 39, Application US/09315574
; Patent No. 6512097
;  GENERAL INFORMATION:
;    APPLICANT:  Marks, James D.
;    APPLICANT:  Schier, Robert
;    TITLE OF INVENTION:  No. 6512097el High Affinity Human Antibodies to
;    TITLE OF INVENTION:  Tumor Antigens
;    NUMBER OF SEQUENCES:  141
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Majestic, Parsons, Siebert & Hsue P.C.
;      STREET:  Four Embarcadero Center, Suite 1100
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111-4106
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/315,574
;      FILING DATE:  20-MAY-99
;      CLASSIFICATION:  530
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/000,238
;      FILING DATE:  14-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/000,250
;      FILING DATE:  15-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/665,202
;      FILING DATE:  13-JUN-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Hunter, Tom
;      REGISTRATION NUMBER:  38,498
;      REFERENCE/DOCKET NUMBER:  02307E-061411
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  39:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  112 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-09-315-574-39

  Query Match             28.3%;  Score 186;  DB 4;  Length 112;
```

```
RESULT 10
US-08-793-450-6
; Sequence 6, Application US/08793450
; Patent No. 6312690
;  GENERAL INFORMATION:
;    APPLICANT:  EDELMAN, LENA
;    APPLICANT:  MARGARITTE, CHRISTEL
;    APPLICANT:  KACZOREK, MICHEL
;    APPLICANT:  CHAABIHI, HASSAN
;    TITLE OF INVENTION:  MONOCLONAL RECOMBINANT ANTI-RHESUS D
;    TITLE OF INVENTION:
;    NUMBER OF SEQUENCES:  25
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT,
;      ADDRESSEE:  P.C.
;      STREET:  1755 SOUTH JEFFERSON DAVIS HIGHWAY, SUITE 400
;      CITY:  ARLINGTON
;      STATE:  VA
;      COUNTRY:  USA
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/793,450
;      FILING DATE:  03-MAR-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  FR 94/10566
;      FILING DATE:  02-SEP-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  OBLON, NORMAN F.
;      REGISTRATION NUMBER:  24,618
;      REFERENCE/DOCKET NUMBER:  660-118-0 PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703-413-3000
;      TELEFAX:  703-413-2220
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  238 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
US-08-793-450-6

  Query Match             28.4%;  Score 186.5;  DB 4;  Length 238;
  Best Local Similarity   37.8%;  Pred. No. 3.7e-12;
  Matches   45;  Conservative   21;  Mismatches   42;  Indels   11;  Gaps    4;

Qy          1 MACRCLSFLLMGTFLSV-SQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQ 59
              |    |:  |: |   | |   | |  |: |  ||  :::|     |  ::| |  |||||
Db          1 MGWSCIILFLVATATGVHSDIELTQDPAVSVALGQTVRITC----QGDSLRTYYASWYQQ 56

Qy         60 RAGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVG 118
              : | ||  ::| :    ::||: |||||| :   : |   |||:  | ||:|||:|: |
Db         57 KPGQAPVLVIYGK----NNRPSGIPDRFSGS--SSGNTASLTITGAQAEDEADYFCNSG 109


RESULT 11
US-09-025-769B-34
; Sequence 34, Application US/09025769B
; Patent No. 6300064
;  GENERAL INFORMATION:
;    APPLICANT:  Knappik, Achim
;    APPLICANT:  Pack, Peter
;    APPLICANT:  Ilag, Vic
;    APPLICANT:  Ge, Liming
;    APPLICANT:  Moroney, Simon
;    APPLICANT:  Plueckthun, Andreas
;    TITLE OF INVENTION:  Protein/(Poly)peptide libraries
;    NUMBER OF SEQUENCES:  373
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  James F. Haley, Jr., Esq. c/o Fish & Neave
;      STREET:  1251 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10021
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/025,769B
;      FILING DATE:  18-FEB-1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 95 11 3021.0
;      FILING DATE:  18-AUG-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  James F. Haley, Jr., Esq.
;      REGISTRATION NUMBER:  27,794
;      REFERENCE/DOCKET NUMBER:  MORPHO/5
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212)596-9000
;      TELEFAX:  (212)596-9090
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  107 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
US-09-025-769B-34

  Query Match             28.3%;  Score 186;  DB 4;  Length 107;
  Best Local Similarity   41.2%;  Pred. No. 1.6e-12;
  Matches   42;  Conservative   15;  Mismatches   35;  Indels   10;  Gaps    3;

Qy         22 LAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRPA 81
              | |  :: | ||| |::||:       : |   |||||: | ||  ::|    :| ||:
Db          4 LTQPPSVSVAPGQTARISCSGD----ALGDKYASWYQQKPGQAPVLVIY----DDSDRPS 55

Qy         82 DIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYGFSP 123
              ||:||| :   : |   ||||  | ||:|||||   |   |
Db         56 GIPERFSGS--NSGNTATLTISGTQAEDEADYYCQQHYTTPP 95


RESULT 12
US-09-025-769B-55
; Sequence 55, Application US/09025769B
; Patent No. 6300064
;  GENERAL INFORMATION:
;    APPLICANT:  Knappik, Achim
;    APPLICANT:  Pack, Peter
;    APPLICANT:  Ilag, Vic
;    APPLICANT:  Ge, Liming
;    APPLICANT:  Moroney, Simon
;    APPLICANT:  Plueckthun, Andreas
;    TITLE OF INVENTION:  Protein/(Poly)peptide libraries
;    NUMBER OF SEQUENCES:  373
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  James F. Haley, Jr., Esq. c/o Fish & Neave
;      STREET:  1251 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10021
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30 (EPO)
;    CURRENT APPLICATION DATA:
```

```
;       TELEPHONE:  7038164000
;       TELEFAX:  7038164100
;   INFORMATION FOR SEQ ID NO:  16:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  110 amino acids
;       TYPE:  amino acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  peptide
US-08-362-780-16

  Query Match             29.1%;  Score 191;  DB 2;  Length 110;
  Best Local Similarity   43.2%;  Pred. No. 4.8e-13;
  Matches   41;  Conservative   17;  Mismatches   31;  Indels    6;  Gaps    2;

Qy         21 VLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRP 80
              :| |  ::   ||:   :|||||  :  | :  | |||||  | ||  :::    :|  ||
Db          3 MLTQPHSVSESPGKTVIISCTLSSGN--IENNYVHWYQQRPGRAPTTVIF----DDDKRP 56

Qy         81 ADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
                :|||||  :  | : |:  |||| :| ||:|||||
Db         57 DGVPDRFSGSIDRSSNSASLTISGLQTEDEADYYC 91


RESULT 8
US-09-049-672A-10
; Sequence 10, Application US/09049672A
; Patent No. 6135941
;  GENERAL INFORMATION:
;    APPLICANT:  Hillman, Jennifer L.
;    APPLICANT:  Lal, Preeti
;    APPLICANT:  Tang, Y. Tom
;    APPLICANT:  Yue, Henry
;    APPLICANT:  Au-Young, Janice
;    APPLICANT:  Corley, Neil C.
;    APPLICANT:  Guegler, Karl J.
;    APPLICANT:  Baughn, Mariah R.
;    TITLE OF INVENTION:  HUMAN IMMUNE SYSTEM ASSOCIATED PROTEINS
;    NUMBER OF SEQUENCES:  28
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Incyte Pharmaceuticals, Inc.
;      STREET:  3174 Porter Drive
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/049,672A
;      FILING DATE:  HEREWITH
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Cerrone, Michael C
;      REGISTRATION NUMBER:  39,132
;      REFERENCE/DOCKET NUMBER:  PF-0497 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-855-0555
;      TELEFAX:  650-845-4166
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  10:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  235 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    IMMEDIATE SOURCE:
;      LIBRARY:  THYRNOT10
;      CLONE:  2872705
US-09-049-672A-10

  Query Match             28.5%;  Score 187;  DB 3;  Length 235;
  Best Local Similarity   42.3%;  Pred. No. 3.2e-12;
  Matches   47;  Conservative   20;  Mismatches   36;  Indels    8;  Gaps    4;

Qy          6 LSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAP 65
              |: |  ||  | :|: | |  ::   |||   :||| :   |   :| ||||||  |:||
Db          8 LTLLTQGTG-SWAQSALTQPASVSGSPGQSITISCTGTSSDVGGYNY-VSWYQQSPGTAP 65

Qy         66 RYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCS 116
              : ::|     |  :||: : :||| :|  : |   |||| :| ||:||||||
Db         66 KLMIY----EVSNRPSGVSNRFSGSK--SGNTASLTISGLQAEDEADYYCS 110


RESULT 9
US-10-039-785-49
; Sequence 49, Application US/10039785
; Patent No. 6538938
; GENERAL INFORMATION:
;  APPLICANT: Salcedo et al.
;  TITLE OF INVENTION: Antibodies that Immunospecifically Bind to TRAIL
;  TITLE OF INVENTION:  Receptors
;  FILE REFERENCE: PF550
;  CURRENT APPLICATION NUMBER: US/10/039,785
;  CURRENT FILING DATE:  2002-05-07
;  PRIOR APPLICATION NUMBER: 60/369,860
;  PRIOR FILING DATE: 2002-04-05
;  PRIOR APPLICATION NUMBER: 60/341,237
;  PRIOR FILING DATE: 2001-12-20
;  PRIOR APPLICATION NUMBER: 60/331,310
;  PRIOR FILING DATE: 2001-11-14
;  PRIOR APPLICATION NUMBER: 60/331,044
;  PRIOR FILING DATE: 2001-11-07
;  PRIOR APPLICATION NUMBER: 60/327,364
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/323,807
;  PRIOR FILING DATE: 2001-09-21
;  PRIOR APPLICATION NUMBER: 60/309,176
;  PRIOR FILING DATE: 2001-08-02
;  PRIOR APPLICATION NUMBER: 60/294,981
;  PRIOR FILING DATE: 2001-06-04
;  PRIOR APPLICATION NUMBER: 60/293,473
;  PRIOR FILING DATE: 2001-05-25
;  NUMBER OF SEQ ID NOS: 66
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 49
;   LENGTH: 245
;   TYPE: PRT
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: T1014G04 scFv
US-10-039-785-49

  Query Match             28.5%;  Score 187;  DB 4;  Length 245;
  Best Local Similarity   37.7%;  Pred. No. 3.4e-12;
  Matches   46;  Conservative   18;  Mismatches   34;  Indels   24;  Gaps    4;

Qy         12 GTFLSVS----------------QTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGV 54
              || ::||                | || |  :    |||   :||| :   |   :| |
Db        111 GTLVTVSSGGGGSGGGGSGGGGSAQPVLTQPPSASGSPGQSVTISCTGTSSDVGSYEY-V 169

Qy         55 SWYQQRAGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYY 114
              |||||  | ||| ::     | : ||: :|:||| :|  : |   ||:| :| :|:||||
Db        170 SWYQQHPGKAPRLMI----SEVNKRPSGVPNRFSGSK--SGNTASLTVSGLQADDEADYY 223

Qy        115 CS 116
              ||
Db        224 CS 225
```

```
;  CURRENT FILING DATE:  2002-05-07
;  PRIOR APPLICATION NUMBER: 60/369,860
;  PRIOR FILING DATE: 2002-04-05
;  PRIOR APPLICATION NUMBER: 60/341,237
;  PRIOR FILING DATE: 2001-12-20
;  PRIOR APPLICATION NUMBER: 60/331,310
;  PRIOR FILING DATE: 2001-11-14
;  PRIOR APPLICATION NUMBER: 60/331,044
;  PRIOR FILING DATE: 2001-11-07
;  PRIOR APPLICATION NUMBER: 60/327,364
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/323,807
;  PRIOR FILING DATE: 2001-09-21
;  PRIOR APPLICATION NUMBER: 60/309,176
;  PRIOR FILING DATE: 2001-08-02
;  PRIOR APPLICATION NUMBER: 60/294,981
;  PRIOR FILING DATE: 2001-06-04
;  PRIOR APPLICATION NUMBER: 60/293,473
;  PRIOR FILING DATE: 2001-05-25
;  NUMBER OF SEQ ID NOS: 66
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
;   LENGTH: 245
;   TYPE: PRT
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: T1014A04 scFv
US-10-039-785-42

  Query Match             29.4%;  Score 193;  DB 4;  Length 245;
  Best Local Similarity   38.5%;  Pred. No. 7.8e-13;
  Matches   47;  Conservative   19;  Mismatches   32;  Indels   24;  Gaps    4;

Qy          12 GTFLSVS----------------QTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGV 54
               || ::||                |:|| |  :    |||   :||| :   |   :| |
Db         111 GTMVTVSSGGGGSGGGGSGGGGSAQSVLTQPPSASGSPGQSVTISCTGTTSDVGGYNY-V 169

Qy          55 SWYQQRAGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYY 114
               |||||  | ||: ::|  ::    ||: :||||| :|  : |   ||:| :| ||:||||
Db         170 SWYQQHPGKAPKLMIYGVNQ----RPSGVPDRFSGSK--SGNTASLTVSGLQAEDEADYY 223

Qy          115 CS 116
                ||
Db          224 CS 225


RESULT 6
US-07-988-925-16
; Sequence 16, Application US/07988925
; Patent No. 5585097
;  GENERAL INFORMATION:
;    APPLICANT:  Bolt, Sarah L
;    APPLICANT:  Clark, Michael R
;    APPLICANT:  Gorman, Scott D
;    APPLICANT:  Routledge, Edward G
;    APPLICANT:  Waldmann, Herman
;    TITLE OF INVENTION:  antibody preparation
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Nixon and Vanderhye pc
;      STREET:  11th Floor, 1100 No. 5585097th Glebe Road
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22201
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/988,925
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  GB 9206422.9
;      FILING DATE:  24-MAR-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO PCT/GB92/01933
;      FILING DATE:  21-OCT-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Mitchard, Leonard C
;      REGISTRATION NUMBER:  29009
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  7038164000
;      TELEFAX:  7038164100
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  110 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-07-988-925-16

  Query Match             29.1%;  Score 191;  DB 1;  Length 110;
  Best Local Similarity   43.2%;  Pred. No. 4.8e-13;
  Matches   41;  Conservative   17;  Mismatches   31;  Indels    6;  Gaps    2;

Qy          21 VLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHHRP 80
               :| |  ::   ||:  :|||||  :  | :  | ||||| | ||  :::    :|  ||
Db           3 MLTQPHSVSESPGKTVIISCTLSSGN--IENNYVHWYQQRPGRAPTTVIF----DDDKRP 56

Qy          81 ADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC 115
                 :||||| : | : |:  |||| :| ||:|||||
Db          57 DGVPDRFSGSIDRSSNSASLTISGLQTEDEADYYC 91


RESULT 7
US-08-362-780-16
; Sequence 16, Application US/08362780
; Patent No. 5968509
;  GENERAL INFORMATION:
;    APPLICANT:  Gorman, Scott D
;    APPLICANT:  Routledge, Edward G
;    APPLICANT:  Waldmann, Herman
;    TITLE OF INVENTION:  Antibody Preparation
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Nixon and Vanderhye pc
;      STREET:  8th Floor, 1100 No. 5968509th Glebe Road
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22201
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/362,780
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/862,543
;      FILING DATE:  23-JUNE-1992
;      APPLICATION NUMBER:  GB 9021679.7
;      FILING DATE:  05-OCT-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO PCT/GB91/01726
;      FILING DATE:  04-OCT-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Mitchard, Leonard C
;      REGISTRATION NUMBER:  29009
;    TELECOMMUNICATION INFORMATION:
```

```
;  EARLIER APPLICATION NUMBER: 60/056,884
;  EARLIER FILING DATE: 1997-08-22
;  NUMBER OF SEQ ID NOS: 280
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 200
;   LENGTH: 123

  Query Match           100.0%;  Score 657;  DB 4;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 1.9e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 2
US-09-621-976-5367
; Sequence 5367, Application US/09621976
; Patent No. 6639063
; GENERAL INFORMATION:
;  APPLICANT: Dumas Milne Edwards, J.B.
;  APPLICANT:  Jobert, S.
;  APPLICANT:  Giordano, J.Y.
;  TITLE OF INVENTION: ESTs and Encoded Human Proteins.
;  FILE REFERENCE: GENSET.054PR2
;  CURRENT APPLICATION NUMBER: US/09/621,976
;  CURRENT FILING DATE:  2000-07-21
;  NUMBER OF SEQ ID NOS: 19335
;  SOFTWARE: Patent.pm
; SEQ ID NO 5367
;   LENGTH: 123
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SIGNAL
;   LOCATION: -20..-1
US-09-621-976-5367

  Query Match           100.0%;  Score 657;  DB 4;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 1.9e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 3
US-08-918-148-74
; Sequence 74, Application US/08918148A
; Patent No. 6342220
; GENERAL INFORMATION:
;  APPLICANT: Adams, Camellia
;  APPLICANT: W.
;  APPLICANT: Carter, Paul J.
;  APPLICANT: Fendly, Brian M.
;  APPLICANT: Gurney, Austin L.
;  TITLE OF INVENTION: Agonist Antibodies
;  FILE REFERENCE: P0979
;  CURRENT APPLICATION NUMBER: US/08/918,148A
;  CURRENT FILING DATE: 1997-08-25
;  NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 74
;   LENGTH: 249
;   TYPE: PRT
;   ORGANISM: artificial
US-08-918-148-74

  Query Match           30.7%;  Score 201.5;  DB 4;  Length 249;
  Best Local Similarity  47.5%;  Pred. No. 1e-13;
  Matches   47;  Conservative   16;  Mismatches   29;  Indels    7;  Gaps    3;

Qy         18 SQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDH 77
              ||:|| |  ::  |||  :||| :  |  :| |||||| | ||: |:|  |
Db        136 SQSVLTQPASVSGSPGQSITISCTGTSSGVGGYNY-VSWYQQHPGKAPKLLIYGNS---- 190

Qy         78 HRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCS 116
              :||: :||||||:|  : |   |||| :| ||:|||:||
Db        191 NRPSGVPDRFSASK--SGNTASLTISGLQAEDEADYFCS 227


RESULT 4
US-09-157-370-5
; Sequence 5, Application US/09157370A
; Patent No. 6262238
; GENERAL INFORMATION:
;  APPLICANT: STEIPE, Boris
;  APPLICANT: STEINBACHER, Stefan
;  TITLE OF INVENTION: PROCESS FOR MODIFYING THE STABILITY OF ANTIBODIES
;  FILE REFERENCE: P8341-8072
;  CURRENT APPLICATION NUMBER: US/09/157,370A
;  CURRENT FILING DATE: 1998-09-21
;  EARLIER APPLICATION NUMBER: 08/765,179
;  EARLIER FILING DATE: 1997-01-14
;  EARLIER APPLICATION NUMBER: PCT/EP95/02626
;  EARLIER FILING DATE: 1995-07-06
;  EARLIER APPLICATION NUMBER: DE/P44 25 115.7
;  EARLIER FILING DATE: 1994-07-15
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 109
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-157-370-5

  Query Match           29.4%;  Score 193;  DB 3;  Length 109;
  Best Local Similarity  41.7%;  Pred. No. 2.9e-13;
  Matches   45;  Conservative   18;  Mismatches   29;  Indels   16;  Gaps    4;

Qy         19 QTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQRAGSAPRYLLYYRSEEDHH 78
              |: | |  :: | |||   :||:     :      ||||||: | ||: ::|    :|:
Db          1 QSELTQPPSVSVSPGQTVTISCSGDSLGIGY----VSWYQQKPGQAPKLVIY----DDNK 52

Qy         79 RPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYC------SVGYG 120
              ||: |||||| :|  : |   |||| :| ||:|||||      || :|
Db         53 RPSGIPDRFSGSK--SGNTASLTISGLQAEDEADYYCQSWDSSSVVFG 98


RESULT 5
US-10-039-785-42
; Sequence 42, Application US/10039785
; Patent No. 6538938
; GENERAL INFORMATION:
;  APPLICANT: Salcedo et al.
;  TITLE OF INVENTION: Antibodies that Immunospecifically Bind to TRAIL
;  TITLE OF INVENTION:  Receptors
;  FILE REFERENCE: PF550
;  CURRENT APPLICATION NUMBER: US/10/039,785
```

; EARLIER APPLICATION NUMBER: 60/047,584
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,500
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,587
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,492
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,598
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,613
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,582
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,596
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,612
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,632
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,601
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,580
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,568
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,314
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,569
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,311
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,671
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,674
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,669
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,312
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,313
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,672
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,315
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/048,974
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/056,886
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,877
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,889
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,893
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,630
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,878
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,662
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,872
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,882
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,637
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,903
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,888
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,879
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,880
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,894
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,911
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,636
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,874
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,910
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,864
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,631
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,845
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,892
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/047,595
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/057,761
; EARLIER FILING DATE: 05-Sep-1997
; EARLIER APPLICATION NUMBER: 60/047,599
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,588
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,585
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,586
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,590
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,594
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,589
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,593
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,614
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,578
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,576
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/047,501
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,670
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/056,632
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,664
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,876
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,881
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,909
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,875
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,862
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,887
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,908
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/048,964
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/057,650
; EARLIER FILING DATE: 1997-09-05

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: September 7, 2004, 20:48:28 ; Search time 34 Seconds
(without alignments)
186.765 Million cell updates/sec

Title: US-09-981-876-200
Perfect score: 657
Sequence: 1 MACRCLSFLLMGTFLSVSQT.....PVQPEDDADYYCSVGYGFSP 123

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/2/iaa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	657	100.0	123	4	US-09-148-545-200	Sequence 200, App
2	657	100.0	123	4	US-09-621-976-5367	Sequence 5367, Ap
3	201.5	30.7	249	4	US-08-918-148-74	Sequence 74, Appl
4	193	29.4	109	3	US-09-157-370-5	Sequence 5, Appli
5	193	29.4	245	4	US-10-039-785-42	Sequence 42, Appl
6	191	29.1	110	1	US-07-988-925-16	Sequence 16, Appl
7	191	29.1	110	2	US-08-362-780-16	Sequence 16, Appl
8	187	28.5	235	3	US-09-049-672A-10	Sequence 10, Appl
9	187	28.5	245	4	US-10-039-785-49	Sequence 49, Appl
10	186.5	28.4	238	4	US-08-793-450-6	Sequence 6, Appli
11	186	28.3	107	4	US-09-025-769B-34	Sequence 34, Appl
12	186	28.3	107	4	US-09-025-769B-55	Sequence 55, Appl
13	186	28.3	112	2	US-08-665-202-39	Sequence 39, Appl
14	186	28.3	112	4	US-09-315-574-39	Sequence 39, Appl
15	184.5	28.1	131	1	US-08-305-683A-4	Sequence 4, Appli
16	183	27.9	109	4	US-09-025-769B-32	Sequence 32, Appl
17	183	27.9	109	4	US-09-025-769B-51	Sequence 51, Appl
18	183	27.9	111	2	US-08-652-816A-15	Sequence 15, Appl
19	183	27.9	245	4	US-10-039-785-48	Sequence 48, Appl
20	183	27.9	258	2	US-08-665-202-5	Sequence 5, Appli
21	183	27.9	258	4	US-09-315-574-5	Sequence 5, Appli
22	182	27.7	245	4	US-10-039-785-51	Sequence 51, Appl
23	182	27.7	245	4	US-10-039-785-52	Sequence 52, Appl
24	181.5	27.6	110	3	US-09-240-274-63	Sequence 63, Appl
25	181.5	27.6	111	2	US-08-958-201-14	Sequence 14, Appl
26	181.5	27.6	236	3	US-09-049-672A-7	Sequence 7, Appli
27	181	27.5	111	2	US-08-665-202-40	Sequence 40, Appl
28	181	27.5	111	4	US-09-315-574-40	Sequence 40, Appl
29	180.5	27.5	111	2	US-08-958-201-12	Sequence 12, Appl
30	180.5	27.5	244	4	US-08-918-148-79	Sequence 79, Appl
31	180	27.4	108	4	US-09-025-769B-20	Sequence 20, Appl
32	180	27.4	245	4	US-10-039-785-47	Sequence 47, Appl
33	179.5	27.3	310	4	US-09-079-029-11	Sequence 11, Appl
34	179	27.2	111	2	US-08-665-202-36	Sequence 36, Appl
35	179	27.2	111	4	US-09-315-574-36	Sequence 36, Appl
36	179	27.2	112	4	US-09-025-769B-18	Sequence 18, Appl
37	179	27.2	262	4	US-09-069-821-4	Sequence 4, Appli
38	179	27.2	282	4	US-09-420-592A-7	Sequence 7, Appli
39	178.5	27.2	249	4	US-10-039-785-53	Sequence 53, Appl
40	178.5	27.2	278	3	US-09-260-527-3	Sequence 3, Appli
41	178.5	27.2	280	3	US-09-260-527-1	Sequence 1, Appli
42	178	27.1	234	4	US-09-372-425A-4	Sequence 4, Appli
43	177.5	27.0	110	4	US-09-025-769B-33	Sequence 33, Appl
44	177.5	27.0	110	4	US-09-025-769B-53	Sequence 53, Appl
45	177.5	27.0	112	4	US-09-025-769B-19	Sequence 19, Appl

ALIGNMENTS

```
RESULT 1
US-09-148-545-200
; Sequence 200, Application US/09148545
; Patent No. 6590075
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: 70 Human Secreted Proteins
;  FILE REFERENCE: PZ001P1
;  CURRENT APPLICATION NUMBER: US/09/148,545
;  CURRENT FILING DATE: 1998-09-04
;  EARLIER APPLICATION NUMBER: PCT/US98/04482
;  EARLIER FILING DATE: 1998-03-06
;  EARLIER APPLICATION NUMBER: 60/040,162
;  EARLIER FILING DATE: 1997-03-07
;  EARLIER APPLICATION NUMBER: 60/040,333
;  EARLIER FILING DATE: 1997-03-07
;  EARLIER APPLICATION NUMBER: 60/038,621
;  EARLIER FILING DATE: 1997-03-07
;  EARLIER APPLICATION NUMBER: 60/040,161
;  EARLIER FILING DATE: 1997-03-07
;  EARLIER APPLICATION NUMBER: 60/040,626
;  EARLIER FILING DATE: 1997-03-07
;  EARLIER APPLICATION NUMBER: 60/040,334
;  EARLIER FILING DATE: 1997-03-07
;  EARLIER APPLICATION NUMBER: 60/040,336
;  EARLIER FILING DATE: 1997-03-07
;  EARLIER APPLICATION NUMBER: 60/040,163
;  EARLIER FILING DATE: 1997-03-07
;  EARLIER APPLICATION NUMBER: 60/047,615
;  EARLIER FILING DATE: 1997-05-23
;  EARLIER APPLICATION NUMBER: 60/047,600
;  EARLIER FILING DATE: 1997-05-23
;  EARLIER APPLICATION NUMBER: 60/047,597
;  EARLIER FILING DATE: 1997-05-23
;  EARLIER APPLICATION NUMBER: 60/047,502
;  EARLIER FILING DATE: 1997-05-23
;  EARLIER APPLICATION NUMBER: 60/047,633
;  EARLIER FILING DATE: 1997-05-23
;  EARLIER APPLICATION NUMBER: 60/047,583
;  EARLIER FILING DATE: 1997-05-23
;  EARLIER APPLICATION NUMBER: 60/047,617
;  EARLIER FILING DATE: 1997-05-23
;  EARLIER APPLICATION NUMBER: 60/047,618
;  EARLIER FILING DATE: 1997-05-23
;  EARLIER APPLICATION NUMBER: 60/047,503
;  EARLIER FILING DATE: 1997-05-23
;  EARLIER APPLICATION NUMBER: 60/047,592
;  EARLIER FILING DATE: 1997-05-23
;  EARLIER APPLICATION NUMBER: 60/047,581
;  EARLIER FILING DATE: 1997-05-23
```

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: September 8, 2004, 06:27:58 ; Search time 125 Seconds
(without alignments)
278.027 Million cell updates/sec

Title: US-09-981-876-200
Perfect score: 657
Sequence: 1 MACRCLSPLLMGTFLSVSQT.....PVQPEDDADYYCSVGYGFSP 123

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 206

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%
Maximum Match 100%
Listing first 1000 summaries

Database : A_Geneseq_29Jan04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	657	100.0	123	2	AAW75123	Aaw75123 Human sec
2	657	100.0	123	3	AAY66655	Aay66655 Membrane-
3	657	100.0	123	3	AAB24061	Aab24061 Human PRO
4	657	100.0	123	4	AAU12372	Aau12372 Human PRO
5	657	100.0	123	4	AAB65178	Aab65178 Human PRO
6	657	100.0	123	6	ABU57993	Abu57993 Human PRO
7	657	100.0	123	6	ABU59071	Abu59071 Novel hum
8	657	100.0	123	6	ABU82583	Abu82583 Human sec
9	657	100.0	123	6	ABO17816	Abo17816 Novel hum
10	657	100.0	123	6	ABU60502	Abu60502 Human sec
11	657	100.0	123	6	ABU13884	Abu13884 Human PRO
12	657	100.0	123	6	ABU81070	Abu81070 Human PRO
13	657	100.0	123	6	ABU72469	Abu72469 Novel hum
14	657	100.0	123	6	ABU66770	Abu66770 Human PRO
15	657	100.0	123	6	ABU59851	Abu59851 Novel sec
16	657	100.0	123	6	ABU59218	Abu59218 Human sec
17	657	100.0	123	6	ABO25915	Abo25915 Human PRO
18	657	100.0	123	6	ABO25041	Abo25041 Human sec
19	657	100.0	123	6	ABO01999	Abo01999 Novel hum
20	657	100.0	123	6	ABU58924	Abu58924 Human sec
21	657	100.0	123	6	ABU92302	Abu92302 Novel hum
22	657	100.0	123	6	ABU59367	Abu59367 Novel hum
23	657	100.0	123	6	ABU67046	Abu67046 Human sec
24	657	100.0	123	6	ABU92133	Abu92133 Novel hum
25	657	100.0	123	6	ABU10839	Abu10839 Human PRO
26	657	100.0	123	6	ABU81591	Abu81591 Novel hum
27	657	100.0	123	6	ABU88530	Abu88530 Human sec
28	657	100.0	123	6	ABO34044	Abo34044 Human PRO
29	657	100.0	123	6	ADA45921	Ada45921 Novel hum
30	657	100.0	123	6	ADA76352	Ada76352 Human PRO
31	657	100.0	123	6	ADA19002	Ada19002 Human PRO
32	657	100.0	123	6	ADA61625	Ada61625 Homo sapi
33	657	100.0	123	6	ADB19410	Adb19410 Novel hum
34	657	100.0	123	6	ADB27951	Adb27951 Human PRO
35	657	100.0	123	6	ADA86430	Ada86430 Novel hum
36	657	100.0	123	6	ADB15994	Adb15994 Human PRO
37	657	100.0	123	6	ADA37628	Ada37628 Human sec
38	657	100.0	123	6	ADA47780	Ada47780 Human PRO
39	657	100.0	123	6	ADA21314	Ada21314 Human sec
40	657	100.0	123	6	ADA10101	Ada10101 Human sec
41	657	100.0	123	6	ADA67575	Ada67575 Human PRO
42	657	100.0	123	6	ADB30582	Adb30582 Human PRO
43	657	100.0	123	6	ADA85878	Ada85878 Novel hum
44	657	100.0	123	6	ADA17645	Ada17645 Human PRO
45	657	100.0	123	6	ADA97090	Ada97090 Human PRO
46	657	100.0	123	6	ADA79394	Ada79394 Human PRO
47	657	100.0	123	6	ADA87533	Ada87533 Novel hum
48	657	100.0	123	6	ADB16735	Adb16735 Human PRO
49	657	100.0	123	6	ADA27753	Ada27753 Human sec
50	657	100.0	123	6	ADA91827	Ada91827 Novel hum
51	657	100.0	123	6	ADB14890	Adb14890 Human PRO
52	657	100.0	123	6	ADB18851	Adb18851 Novel hum
53	657	100.0	123	6	ADA94066	Ada94066 Human PRO
54	657	100.0	123	6	ADB19962	Adb19962 Novel hum
55	657	100.0	123	6	ADB13274	Adb13274 Human PRO
56	657	100.0	123	6	ABO43349	Abo43349 Novel hum
57	657	100.0	123	6	ADA94333	Ada94333 Human sec
58	657	100.0	123	6	ADA74528	Ada74528 Human PRO
59	657	100.0	123	6	ADB24761	Adb24761 Human PRO
60	657	100.0	123	6	ADA82285	Ada82285 Human PRO
61	657	100.0	123	6	ADA75248	Ada75248 Human PRO
62	657	100.0	123	6	ADA85326	Ada85326 Novel hum
63	657	100.0	123	6	ADA84774	Ada84774 Novel hum
64	657	100.0	123	6	ADB30030	Adb30030 Human PRO
65	657	100.0	123	6	ADA80558	Ada80558 Human PRO
66	657	100.0	123	6	ADA75800	Ada75800 Human PRO
67	657	100.0	123	6	ADA38558	Ada38558 Human sec
68	657	100.0	123	6	ADA47025	Ada47025 Human PRO
69	657	100.0	123	6	ADB25321	Adb25321 Human PRO
70	657	100.0	123	6	ADA93497	Ada93497 Human PRO
71	657	100.0	123	6	ADB26847	Adb26847 Human PRO
72	657	100.0	123	6	ADB31134	Adb31134 Human PRO
73	657	100.0	123	6	ADA92679	Ada92679 Human sec
74	657	100.0	123	6	ADA61062	Ada61062 Homo sapi
75	657	100.0	123	6	ADB24209	Adb24209 Human PRO
76	657	100.0	123	6	ADA96538	Ada96538 Human PRO
77	657	100.0	123	6	ADA81110	Ada81110 Human PRO
78	657	100.0	123	6	ADA95986	Ada95986 Human PRO
79	657	100.0	123	6	ADB26295	Adb26295 Human PRO
80	657	100.0	123	6	ADB21780	Adb21780 Novel hum
81	657	100.0	123	7	ADA77559	Ada77559 Human PRO
82	657	100.0	123	7	ADB18299	Adb18299 Human PRO
83	657	100.0	123	7	ADA86982	Ada86982 Novel hum
84	657	100.0	123	7	ADA88085	Ada88085 Novel hum
85	657	100.0	123	7	ADA46473	Ada46473 Novel hum
86	657	100.0	123	7	ADB28503	Adb28503 Human PRO
87	657	100.0	123	7	ADB29055	Adb29055 Human PRO
88	657	100.0	123	7	ABO53130	Abo53130 Human sec
89	657	100.0	123	7	ADA77007	Ada77007 Human PRO
90	657	100.0	123	7	ADA22240	Ada22240 Human sec
91	657	100.0	123	7	ADA88637	Ada88637 Novel hum
92	657	100.0	123	7	ADA97642	Ada97642 Human PRO
93	657	100.0	123	7	ADB27399	Adb27399 Human PRO
94	657	100.0	123	7	ADB22332	Adb22332 Novel hum
95	657	100.0	123	7	ABO22500	Abo22500 Human sec
96	657	100.0	123	7	ADA06406	Ada06406 Human sec
97	657	100.0	123	7	ADA39099	Ada39099 Human sec
98	657	100.0	123	7	ADA67023	Ada67023 Human PRO

99	657	100.0	123	7	ADB22884	Adb22884 Human PRO
100	657	100.0	123	7	ADB23657	Adb23657 Human PRO
101	657	100.0	123	7	ADA92379	Ada92379 Novel hum
102	657	100.0	123	7	ADB15442	Adb15442 Human PRO
103	657	100.0	123	7	ADB38694	Adb38694 Novel hum
104	657	100.0	123	7	ADB96125	Adb96125 Human PRO
105	657	100.0	123	7	ADB38142	Adb38142 Novel hum
106	657	100.0	123	7	ADB66614	Adb66614 Novel hum
107	657	100.0	123	7	ADB89694	Adb89694 Human PRO
108	657	100.0	123	7	ADB90426	Adb90426 Human PRO
109	657	100.0	123	7	ADB39527	Adb39527 Novel hum
110	657	100.0	123	7	ADB47150	Adb47150 Novel hum
111	657	100.0	123	7	ADB86757	Adb86757 Human PRO
112	657	100.0	123	7	ADB77362	Adb77362 Novel hum
113	657	100.0	123	7	ADB34519	Adb34519 Human PRO
114	657	100.0	123	7	ADB35623	Adb35623 Human PRO
115	657	100.0	123	7	ADB33967	Adb33967 Human PRO
116	657	100.0	123	7	ADB35071	Adb35071 Human PRO
117	657	100.0	123	7	ADB36175	Adb36175 Human PRO
118	657	100.0	123	7	ADB46570	Adb46570 Novel hum
119	657	100.0	123	7	ADC57597	Adc57597 Human PRO
120	657	100.0	123	7	ADC54961	Adc54961 Human PRO
121	657	100.0	123	7	ADC11828	Adc11828 Human sec
122	657	100.0	123	7	ADC56250	Adc56250 Human PRO
123	657	100.0	123	7	ADC07305	Adc07305 Human sec
124	657	100.0	123	7	ADC11295	Adc11295 Human sec
125	657	100.0	123	7	ADC50443	Adc50443 Novel hum
126	657	100.0	123	7	ADC71990	Adc71990 Novel hum
127	657	100.0	123	7	ADC59969	Adc59969 Novel hum
128	657	100.0	123	7	ADC52976	Adc52976 Novel hum
129	657	100.0	123	7	ADC57330	Adc57330 Novel hum
130	657	100.0	123	7	ADC60521	Adc60521 Novel hum
131	657	100.0	123	7	ADC50996	Adc50996 Novel hum
132	657	100.0	123	7	ADC65523	Adc65523 Human PRO
133	657	100.0	123	7	ADC54621	Adc54621 Novel hum
134	657	100.0	123	7	ADC53582	Adc53582 Novel hum
135	657	100.0	123	7	ADC59105	Adc59105 Novel hum
136	657	100.0	123	7	ADC55983	Adc55983 Novel hum
137	657	100.0	123	7	ADC58553	Adc58553 Novel hum
138	657	100.0	123	7	ADC14417	Adc14417 Novel hum
139	657	100.0	123	7	ADD07949	Add07949 Novel hum
140	657	100.0	123	7	ADD03227	Add03227 Novel hum
141	657	100.0	123	7	ADC90219	Adc90219 Novel hum
142	657	100.0	123	7	ADC81774	Adc81774 Human PRO
143	657	100.0	123	7	ADC69638	Adc69638 Human PRO
144	657	100.0	123	7	ADC48527	Adc48527 Human PRO
145	657	100.0	123	7	ADD10056	Add10056 Human PRO
146	657	100.0	123	7	ADD07416	Add07416 Novel hum
147	657	100.0	123	7	ADD04631	Add04631 Novel hum
148	657	100.0	123	7	ADC82307	Adc82307 Human PRO
149	657	100.0	123	7	ADC80587	Adc80587 Novel hum
150	657	100.0	123	7	ADD11094	Add11094 Human PRO
151	657	100.0	123	7	ADC47975	Adc47975 Human PRO
152	657	100.0	123	7	ADD08487	Add08487 Novel hum
153	657	100.0	123	7	ADC80035	Adc80035 Novel hum
154	657	100.0	123	7	ADD06736	Add06736 Novel hum
155	657	100.0	123	7	ADD09504	Add09504 Human PRO
156	657	100.0	123	7	ADC82983	Adc82983 Human PRO
157	657	100.0	123	7	ADD41217	Add41217 Novel hum
158	657	100.0	123	7	ADD52356	Add52356 Human PRO
159	657	100.0	123	7	ADD53096	Add53096 Human PRO
160	657	100.0	123	7	ADD53648	Add53648 Novel hum
161	657	100.0	123	7	ADD55090	Add55090 Human PRO
162	657	100.0	123	7	ADD56048	Add56048 Human PRO
163	657	100.0	123	7	ADD51804	Add51804 Human PRO
164	657	100.0	123	7	ADD02603	Add02603 Human PRO
165	657	100.0	123	7	ADD02037	Add02037 Human PRO
166	657	100.0	123	7	ADD54219	Add54219 Novel hum
167	657	100.0	123	7	ADD54486	Add54486 Human PRO
168	657	100.0	123	7	ADD92536	Add92536 Human PRO
169	657	100.0	123	7	ADD91432	Add91432 Human PRO
170	657	100.0	123	7	ADE04046	Ade04046 Human PRO
171	657	100.0	123	7	ADE26640	Ade26640 Novel hum
172	657	100.0	123	7	ADE32343	Ade32343 Novel hum
173	657	100.0	123	7	ADE22275	Ade22275 Human PRO
174	657	100.0	123	7	ADD79499	Add79499 Human PRO
175	657	100.0	123	7	ADE42035	Ade42035 Human PRO
176	657	100.0	123	7	ADE17852	Ade17852 Human PRO
177	657	100.0	123	7	ADD91984	Add91984 Human PRO
178	657	100.0	123	7	ADE33447	Ade33447 Novel hum
179	657	100.0	123	7	ADE33999	Ade33999 Novel hum
180	657	100.0	123	7	ADD80051	Add80051 Human PRO
181	657	100.0	123	7	ADD93088	Add93088 Human PRO
182	657	100.0	123	7	ADE19508	Ade19508 Human PRO
183	657	100.0	123	7	ADE18956	Ade18956 Human PRO
184	657	100.0	123	7	ADE43152	Ade43152 Human PRO
185	657	100.0	123	7	ADD95941	Add95941 Human PRO
186	657	100.0	123	7	ADE22827	Ade22827 Human PRO
187	657	100.0	123	7	ADD78945	Add78945 Human PRO
188	657	100.0	123	7	ADE26107	Ade26107 Novel hum
189	657	100.0	123	7	ADE32895	Ade32895 Novel hum
190	657	100.0	123	7	ADE42587	Ade42587 Human PRO
191	657	100.0	123	7	ADD80603	Add80603 Human PRO
192	657	100.0	123	7	ADD89631	Add89631 Human PRO
193	657	100.0	123	7	ADE40915	Ade40915 Human PRO
194	657	100.0	123	7	ADE04714	Ade04714 Human PRO
195	657	100.0	123	8	ADC81139	Adc81139 Novel hum
196	657	100.0	123	8	ADD76587	Add76587 Human PRO
197	657	100.0	123	8	ADD87951	Add87951 Human PRO
198	657	100.0	123	8	ADD86355	Add86355 Human PRO
199	657	100.0	123	8	ADE75803	Ade75803 Human PRO
200	657	100.0	123	8	ADE23379	Ade23379 Human PRO
201	657	100.0	123	8	ADE23931	Ade23931 Human PRO
202	657	100.0	123	8	ADE24574	Ade24574 Human PRO
203	657	100.0	123	8	ADD87399	Add87399 Human PRO
204	657	100.0	123	8	ADE89265	Ade89265 Human PRO
205	657	100.0	123	8	ADE18404	Ade18404 Human PRO
206	657	100.0	123	8	ADE88713	Ade88713 Human PRO

ALIGNMENTS

RESULT 1
AAW75123
ID AAW75123 standard; protein; 123 AA.
XX
AC AAW75123;
XX
DT 25-MAR-2003 (revised)
DT 28-JAN-1999 (first entry)
XX
DE Human secreted protein encoded by gene 67 clone HRGDF73.
XX
KW Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW developmental abnormality; foetal deficiency; blood; allergy; renal;
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS Homo sapiens.
XX
PN WO9839446-A2.
XX
PD 11-SEP-1998.
XX
PF 06-MAR-1998; 98WO-US004482.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040161P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.

PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048974P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057761P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Rosen CA, Fischer CL, Soppet DR, Carter KC;
PI Bednarik DP, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;
PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;
PI Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
DR WPI; 1998-609887/51.
DR N-PSDB; AAV34220.
XX
PT New isolated human genes and the secreted polypeptides they encode -
PT useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders.
XX
PS Claim 1; Page 320-321; 447pp; English.
XX
CC This sequence represents a secreted human protein encoded by the gene
CC clone detailed in the descriptor line. The gene can be used to generate
CC fusion proteins by linking to the gene to a human immunoglobulin Fc
CC portion (e.g. AAV34145) for increasing the stability of the fused protein
CC as compared to the human protein only. The invention relates to 70 novel
CC genes and their fragments (nucleic acid sequences: AAV34154-V34276; amino
CC acid sequences AAW75057-W75179) which are useful for preventing, treating
CC or ameliorating medical conditions e.g. by protein or gene therapy. Also,
CC pathological conditions can be diagnosed by determining the amount of the
CC new polypeptides in a sample or by determining the presence of mutations
CC in the new polynucleotides. Specific uses are described for each of the
CC 70 polynucleotides, based on which tissues they are most highly expressed
CC in (see AAV34154 for described uses). (Updated on 25-MAR-2003 to correct
CC PF field.) (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 2; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 2
AAY66655
ID AAY66655 standard; protein; 123 AA.
XX
AC AAY66655;
XX
DT 05-APR-2000 (first entry)

XX
DE Membrane-bound protein PRO619.
XX
KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
KW pharmaceutical; receptor immunoadhesin; gene mapping.
XX
OS Homo sapiens.
XX
PN WO9963088-A2.
XX
PD 09-DEC-1999.
XX
PF 02-JUN-1999; 99WO-US012252.
XX
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090538P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090691P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091358P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.

```
PR   26-AUG-1998;   98US-0098014P.
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   12-JAN-1999;   99US-0115565P.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker K,  Chen J,  Goddard A,  Gurney AL,  Smith V,  Watanabe CK;
PI   Wood WI,  Yuan J;
XX
DR   WPI; 2000-072883/06.
DR   N-PSDB; AAZ64983.
XX
PT   Membrane-bound proteins and related nucleotide sequences.
XX
PS   Claim 12; Fig 68; 822pp; English.
XX
CC   The invention provides membrane-bound PRO polypeptides and
CC   polynucleotides encoding them. The PRO sequences of the invention were
CC   identified based on extracellular domain homology screening. The PRO
CC   sequences have homology with proteins including LDL receptors, TIE
CC   ligands and various enzymes. The membrane-bound proteins and receptor
CC   molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC   immunoadhesins, for instance, can be used as therapeutic agents to block
CC   receptor-ligand interactions. The membrane-bound proteins can also be
CC   employed for screening of potential peptide or small molecule inhibitors
CC   of the relevant receptor/ligand interaction. The PRO encoding sequences
CC   are useful as hybridization probes, in chromosome and gene mapping and in
CC   the generation of antisense RNA and DNA. PRO nucleic acid sequences will
CC   also be useful for the preparation of PRO polypeptides, especially by
CC   recombinant techniques
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 3;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 3
AAB24061
ID   AAB24061 standard; protein; 123 AA.
XX
AC   AAB24061;
XX
DT   29-JAN-2001  (first entry)
XX
DE   Human PRO619 protein sequence SEQ ID NO:16.
XX
KW   Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
KW   proliferation; tumourigenesis; identification; cancer; cytostatic;
KW   nootropic; neuroprotective; antiinflammatory; immunosuppressive;
KW   immunostimulant; antiangiogenic; leukaemia; lymphoid malignancy;
KW   neuronal disorder; glial disorder; astrocytal disorder; angiogenic;
KW   hypothalamic disorder; glandular disorder; macrophagal disorder;
KW   epithelial disorder; stromal disorder; blastocoelic disorder;
KW   inflammatory disorder; immunologic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200053755-A2.
XX
PD   14-SEP-2000.
XX
PF   06-JAN-2000; 2000WO-US000376.
XX
PR   08-MAR-1999;   99WO-US005028.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   26-JUL-1999;   99US-0145698P.
PR   30-NOV-1999;   99WO-US028313.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Goddard A,  Gurney AL,  Hillan KJ,  Roy MA;
PI   Watanabe CK,  Wood WI;
XX
DR   WPI; 2000-572270/53.
DR   N-PSDB; AAC58371.
XX
PT   Thirty PRO polynucleotides encoding PRO polypeptides, useful in the
PT   treatment, diagnosis and prevention of cancer.
XX
PS   Claim 61; Fig 10; 286pp; English.
XX
CC   The present invention describes an isolated antibody that binds to one of
CC   the human PRO proteins designated PRO212, PRO290, PRO341, PRO535, PRO619,
CC   PRO717, PRO809, PRO830, PRO848, PRO943, PRO1005, PRO1009, PRO1025,
CC   PRO1030, PRO1097, PRO1107, PRO1111, PRO1153, PRO1182, PRO1184, PRO1187,
CC   PRO1281, PRO23, PRO39, PRO834, PRO1317, PRO1710, PRO2094, PRO2145 OR
CC   PRO2198. PRO antagonists can be used to inhibit tumour cell growth. The
CC   PRO polypeptides and nucleotides are useful in the treatment, diagnosis
CC   and prevention of cancer. The antibodies and other anti-tumour compounds
CC   maybe used to treat various conditions, including those characterised by
CC   overexpression and/or activation of the amplified PRO genes. Exemplary
CC   conditions or disorders to be treated with such antibodies and other
CC   compounds include benign or malignant tumours (e.g., renal, liver,
CC   kidney, bladder, breast, gastric, ovarian, colorectal, prostate,
CC   pancreatic, lung, vulva, thyroid, hepatic carcinomas, sarcomas,
CC   glioblastomas, and various head and neck tumours), leukaemias and
CC   lymphoid malignancies, other disorders such as neuronal, glial,
CC   astrocytal, hypothalamic and other glandular, macrophagal, epithelial,
CC   stromal and blastocoelic disorders, and inflammatory, angiogenic and
CC   immunologic disorders. AAC58242 to AAC58366 represent PCR primers and
CC   hybridisation probes used in the isolation of the human PRO sequences.
CC   AAC58367 to AAC58396 and AAB24057 to AAB24089 represent human PRO
CC   polynucleotide and protein sequences given in the exemplification of the
CC   present invention
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 3;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 4
AAU12372
ID   AAU12372 standard; protein; 123 AA.
```

XX
AC AAU12372;
XX
DT 24-OCT-2001 (first entry)
XX
DE Human PRO619 polypeptide sequence.
XX
KW Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;
KW prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage;
KW ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;
KW A-peptide; factor VIIA; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200140466-A2.
XX
PD 07-JUN-2001.
XX
PF 01-DEC-2000; 2000WO-US032678.
XX
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 09-DEC-1999; 99US-0170262P.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 03-MAR-2000; 2000US-0187202P.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 05-JUN-2000; 2000US-0209832P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2001-408281/43.
DR N-PSDB; AAS21444.
XX
PT Isolated , secretory and transmembrane PRO polypeptide used to detect
PT other PRO polypeptides, link bioactive molecules to cells expressing PRO
PT polypeptides, and detect the presence of mammalian tumors e.g. lung,
PT breast, prostate, cervical.
XX
PS Claim 12; Fig 402; 813pp; English.
XX
CC AAU12172-AAU12446 represent novel human secretory and transmembrane PRO
CC polypeptides. The PRO polypeptides are useful to detect other PRO
CC polypeptides, to link bioactive molecules to cells expressing PRO
CC polypeptides, to modulate biological activities of cells expressing PRO
CC polypeptides, and to detect the presence of mammalian lung, colon,
CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC polypeptide expression in a cell sample to that in a control sample. Some
CC of the 275 sequences are also useful to stimulate the release of tumour
CC necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or
CC differentiation of chondrocytes, the proliferation or gene expression in
CC pericyte cells, the release of proteoglycans from cartilage, the
CC proliferation of inner ear utricular supporting cells or of T-
CC lymphocytes, the release of a cytokine from peripheral blood monocytes
CC (PBMCs), or the proliferation of endothelial cells. Some of the PRO
CC polypeptides may modulate glucose or free fatty acid uptake by skeletal
CC muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
CC VIIA. The PRO polypeptides can be used in assays to identify molecules
CC involved in binding interactions. The polynucleotides encoding PRO
CC polypeptides can be used to generate probes, antisense RNA/DNA,
CC transgenic or knock out animals and can be used in gene therapy
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 4; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 5
AAB65178
ID AAB65178 standard; protein; 123 AA.
XX
AC AAB65178;
XX
DT 02-APR-2001 (first entry)
XX
DE Human PRO619 (UNQ355) protein sequence SEQ ID NO:117.
XX
KW Human; secreted and transmembrane protein; PRO; cytostatic; cell death;
KW cancer; chromosomal mapping; gene mapping; tissue typing;
KW diagnostic assay.
XX
OS Homo sapiens.
XX
PN WO200073454-A1.
XX
PD 07-DEC-2000.
XX
PF 30-MAR-2000; 2000WO-US008439.
XX
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.

```
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi CJ,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2001-032160/04.
DR   N-PSDB; AAF44129.
XX
PT   PRO polynucleotides used to produce polypeptides used to target bioactive
PT   molecules such as toxins, radiolabels or antibodies, to specific cells,
PT   to cause targeted cell death.
XX
PS   Claim 12; Fig 68; 935pp; English.
XX
CC   The present invention describes human secreted and transmembrane PRO
CC   proteins. The PRO proteins have cytostatic activity. The PRO proteins can
CC   be used for targeted delivery of bioactive molecules, such as toxins,
CC   radiolabels or antibodies, that cause cell death. PRO nucleotide
CC   sequences, and their fragments, can be used as hybridisation probes, in
CC   chromosomal and gene mapping, and in the generation of anti-sense RNA and
CC   DNA. They may also be used to produce transgenic animals which are used
CC   to develop and screen therapeutically useful reagents. The PRO nucleotide
CC   and protein sequence can be used for tissue typing and in treating
CC   cancer. Anti-PRO antibodies can be used in diagnostic assays. AAF44270 to
CC   AAF44470 represent PCR primers and hybridisation probes used in the
CC   isolation of human PRO sequences. AAF44087 to AAF44269 and AAB65154 to
CC   AAB65300 represent human PRO polynucleotide and protein sequences given
CC   in the exemplification of the present invention
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 4;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 6
ABU57993
ID   ABU57993 standard; protein; 123 AA.
XX
AC   ABU57993;
XX
DT   14-APR-2003  (first entry)
XX
DE   Human PRO polypeptide #25.
XX
KW   Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach; liver;
KW   horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT;
KW   antibody-dependent enzyme mediated prodrug therapy.
XX
OS   Homo sapiens.
XX
PN   US2003027163-A1.
XX
PD   06-FEB-2003.
XX
PF   15-NOV-2001; 2001US-00997666.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
```

PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 7
ABU59071
ID ABU59071 standard; protein; 123 AA.
XX

AC ABU59071;
XX
DT 28-APR-2003 (first entry)
XX
DE Novel human secreted or transmembrane protein PRO619.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2002132252-A1.
XX
PD 19-SEP-2002.
XX
PF 14-NOV-2001; 2001US-00990442.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-247083/24.
DR N-PSDB; ABX80196.
XX
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT are therapeutically useful for enhancing immune response and in cancer
PT treatments.
XX
PS Claim 12; Fig 68; 648pp; English.
XX
CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus

```
CC   useful for treating conditions or disorders where angiogenesis would be
CC   beneficial, e.g. wound healing and antagonist of this polypeptide are
CC   useful for treating cancerous tumours. PRO812 inhibits vascular
CC   endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC   cells and is thus useful for inhibiting endothelial cell growth in
CC   mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC   PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC   stimulated T-lymphocytes and are therapeutically useful for enhancing
CC   immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC   retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC   rod photoreceptor cells) and therefore are useful for treating retinal
CC   disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC   and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC   and therefore are useful for treating kidney disorders associated with
CC   decreased mesangial cell function such as Berger disease or other
CC   nephropathies associated with dermatitis, herpetiformis or Crohn's
CC   disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC   proliferation and/or redifferentiation of chondrocytes in culture and are
CC   thus useful for treating sports injuries, and arthritis. This is the
CC   amino acid sequence of a novel human PRO protein
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 8
ABU82583
ID   ABU82583 standard; protein; 123 AA.
XX
AC   ABU82583;
XX
DT   26-JUN-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO619.
XX
KW   Human; PRO; secreted protein; transmembrane protein;
KW   cardiac insufficiency disorders; angiogenesis; wound healing;
KW   cancerous tumour; immune response; retinal disorder; sight loss;
KW   retinitis pigmentosum; age-related macular degeneration; AMD;
KW   kidney disorder; Berger disease; nephropathy; dermatitis; herpetiformis;
KW   Crohn's disease; sports injury; arthritis.
XX
OS   Homo sapiens.
XX
PN   US2003032023-A1.
XX
PD   13-FEB-2003.
XX
PF   14-NOV-2001; 2001US-00990711.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
```

PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 9
ABO17816
ID ABO17816 standard; protein; 123 AA.
XX
AC ABO17816;
XX
DT 26-AUG-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bioreactor; tissue typing.
XX
OS Homo sapiens.
XX
PN US2003032156-A1.
XX
PD 13-FEB-2003.
XX
PF 06-MAY-2002; 2002US-00140474.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-341980/32.
DR N-PSDB; ACD24053.
XX
PT New secreted and transmembrane PRO nucleic acids, for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, axquired immunodeficiency
PT syndrome (AIDS), or cancer.
XX
PS Claim 12; Fig 402; 660pp; English.
XX
CC The invention describes an isolated nucleic acid (I) comprising, or which
CC has 80 % sequence identity to, or the full-length coding sequence of, one
CC of 275 nucleotide sequences, and which encodes a corresponding
CC polypeptide selected from 275 amino acid sequences, where all sequences
CC are given in the specification. The polypeptide encoded by (I) is used to
CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulate a biological activity of a cell, stimulate the
CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate
CC the uptake of glucose or free fatty acid by cells, stimulate or inhibit
CC the proliferation or differentiation of cells or gene expression,
CC stimulate the release of proteoglycans, stimulate the release of cytokine
CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide
CC to factor VIIA, or detect the presence of tumour in a mammal. The nucleic
CC acid and polypeptide encoded by it, are useful for treating inflammatory
CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,
CC birth defects, premature aging, acquired immunodeficiency syndrome
CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
CC hybridisation probes, in chromosome and gene mapping, and in generating
CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
CC This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

```
Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 10
ABU60502
ID   ABU60502 standard; protein; 123 AA.
XX
AC   ABU60502;
XX
DT   01-MAY-2003  (first entry)
XX
DE   Human secreted/transmembrane protein, #43.
XX
KW   Human; PRO; secreted; transmembrane; signal peptide; pharmaceutical;
KW   diagnostic; therapeutic; gene therapy.
XX
OS   Homo sapiens.
XX
PN   US2002160384-A1.
XX
PD   31-OCT-2002.
XX
PF   14-NOV-2001; 2001US-00992598.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   02-JUN-1999;   99WO-US012252.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-JUN-2001; 2001WO-US017800.
PR   20-JUN-2001; 2001WO-US019692.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   28-AUG-2001; 2001US-00941992.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi JC,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2003-288106/28.
DR   N-PSDB; ABX90174.
XX
PT   New transmembrane polypeptides and nucleic acids encoding the
PT   polypeptides, useful in gene therapy, in chromosome identification, as
PT   chromosome markers, or in generating probes.
XX
PS   Claim 12; Fig 68; 650pp; English.
XX
CC   The invention discloses isolated PRO secreted/transmembrane polypeptides
CC   comprising a sequence without signal peptide and the nucleic acid
CC   encoding them. The polypeptides can be used to raise antibodies that
CC   specifically bind to the PRO polypeptide, for linking a bioactive
CC   molecule to a cell expressing a PRO protein and for modulating at least
```

```
CC   one biological activity of a cell. The PRO polypeptides or
CC   polynucleotides are also useful in gene therapy, in chromosome
CC   identification, as chromosome markers, or in generating probes. The PRO
CC   polypeptides are useful as molecular markers for protein electrophoresis,
CC   and the isolated nucleic acids may be used for recombinantly expressing
CC   those markers. The PRO polypeptides and nucleic acids may also be used in
CC   tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
CC   PRO, and in affinity purification of PRO from recombinant cell culture or
CC   natural sources. The sequences presented in ABU60478-ABU60624 are the PRO
CC   polynucleotides of the invention. Note: The sequence data for this patent
CC   is also available in electronic format from USPTO at
CC   seqdata.uspto.gov/sequence.html
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 11
ABU13884
ID   ABU13884 standard; protein; 123 AA.
XX
AC   ABU13884;
XX
DT   26-FEB-2003  (first entry)
XX
DE   Human PRO619 polypeptide.
XX
KW   Human; PRO polypeptide; secreted protein; transmembrane protein;
KW   genetic disorder; antibacterial; immunosuppressive.
XX
OS   Homo sapiens.
XX
PN   US2002103125-A1.
XX
PD   01-AUG-2002.
XX
PF   20-NOV-2001; 2001US-00989731.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   02-JUN-1999;   99WO-US012252.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   06-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-JUN-2001; 2001WO-US017800.
PR   20-JUN-2001; 2001WO-US019692.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   28-AUG-2001; 2001US-00941992.
```

XX
PA (GETH) GENENTECH LTD.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-102117/09.
DR N-PSDB; ABX64020.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
PS Claim 12; Fig 68; 649pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for for
CC identifying agonists or antagonists. The polynucleotide sequences
CC encoding PRO polypeptides are useful as hybridisation probes, in
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
CC in the preparation of PRO polypeptides, for generating transgenic animals
CC or knockout animals, to construct hybridisation probes for mapping the
CC gene which encodes the PRO polypeptide, and for the genetic analysis of
CC individuals with genetic disorders, in gene therapy, for chromosome
CC identification, as chromosome markers, and for generating probes for PCR,
CC Northern analysis, Southern analysis and Western analysis. ABU13860-
CC ABU14006 represent the human PRO polypeptides of the invention. Note: The
CC sequence data for this patent was obtained in electronic format directly
CC from the USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 12
ABU81070
ID ABU81070 standard; protein; 123 AA.
XX
AC ABU81070;
XX
DT 23-JUN-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW anti-PRO antibody; diagnostic assay; gene expression; diabetes;
KW bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
KW sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
KW hearing loss; coagulation disorder; stroke; heart attack; cardiant;
KW antidiabetic; anorectic; vulnerary; antiarthritic; osteopathic;
KW antirheumatic; auditory; cerebroprotective; angiogenic.
XX
OS Homo sapiens.
XX
PN US2003004311-A1.
XX
PD 02-JAN-2003.
XX
PF 19-DEC-2001; 2001US-00028072.
XX
PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.

```
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-352836/33.
DR   N-PSDB; ACA67194.
XX
PT   New isolated PRO polypeptide useful for treating diabetes, rheumatoid
PT   arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
PT   heart attack.
XX
PS   Claim 12; Fig 402; 643pp; English.
XX
CC   The present invention relates to the isolation of novel human PRO
CC   polypeptides, and the polynucleotide sequences encoding them. The PRO
CC   polypeptides are secreted and transmembrane proteins. The PRO
CC   polypeptides and polynucleotides are useful for preparing a medicament
CC   useful in the treatment of diabetes, bone and/or cartilage disorders
CC   (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
CC   hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
CC   (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
CC   assays for PRO, by detecting its expression in specific cells, tissues or
CC   serum, and for affinity purification of PRO from recombinant cell culture
CC   or natural sources. ABU80870-ABU81144 represent the human PRO
CC   polypeptides of the invention. Note: The sequence data for this patent
CC   was obtained in electronic format directly from the USPTO web site at
CC   seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 13
ABU72469
ID   ABU72469 standard; protein; 123 AA.
XX
AC   ABU72469;
XX
DT   17-JUN-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; cytostatic; anti-HIV;
KW   virucide; hepatotropic; antiinflammatory; neuroprotective; gene therapy;
KW   PRO; pharmaceutical; diagnostic; biosensor; bioreactor; malignancy;
KW   cancer; ovarian cancer; colorectal cancer; Kaposi's sarcoma; leukaemia;
KW   lymphoma; hepatitis B; multiple sclerosis; Crohn's disease;
KW   drug screening.
XX
OS   Homo sapiens.
XX
PN   US2003003531-A1.
XX
PD   02-JAN-2003.
XX
PF   19-NOV-2001; 2001US-00989734.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
```

PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-352829/33.
DR N-PSDB; ACA64242.
XX
PT New genes and secreted and transmembrane polypeptides (e.g. PRO183 or
PT PRO184), useful for treating or diagnosing e.g. ovarian cancer, Kaposi's
PT sarcoma, leukemia, lymphoma, hepatitis B, multiple sclerosis or Crohn's
PT disease.
XX
PS Claim 12; Fig 68; 663pp; English.
XX
CC The invention describes a new isolated nucleic acid molecule comprising
CC the full length coding sequence of the DNA deposited with the American
CC Type Culture Collection (e.g. ATCC Deposit No. 209621, 552-PTA, 819-PTA,
CC 209439, 203135, etc); or a sequence with at least 80% identity to a DNA
CC encoding a PRO polypeptide. The PRO polypeptides or polynucleotides are
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These
CC are particularly useful for detecting or treating e.g. malignancies or
CC cancers (e.g. ovarian cancer, colorectal cancer, Kaposi's sarcoma,
CC leukaemia or lymphoma), hepatitis B, multiple sclerosis, or Crohn's
CC disease in mammals. The PRO polypeptides are useful in drug screening,
CC particularly as targets for therapeutic intervention in these diseases,
CC and in the diagnostic determination of the presence of these diseases.
CC The PRO polypeptides are also useful as molecular weight markers, or for
CC chromosome identification. The PRO genes are useful as hybridisation
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
CC The PRO genes may also be used in gene therapy, particularly for
CC replacing a defective gene. This is the amino acid sequence of a novel
CC human secreted and transmembrane PRO polypeptide
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 14
ABU66770
ID ABU66770 standard; protein; 123 AA.
XX
AC ABU66770;
XX
DT 23-MAY-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
KW differentiation; chondrocyte; tumour; genetic disorder; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003036180-A1.
XX
PD 20-FEB-2003.
XX
PF 09-MAY-2002; 2002US-00143114.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-332040/31.
DR N-PSDB; ACA03803.
XX
PT New secreted and transmembrane PRO nucleic acids, useful for gene
PT therapy, in chromosome and gene mapping, as chromosome markers, in tissue
PT typing, and in chromosome identification.
XX
PS Claim 12; Fig 402; 660pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for for
CC identifying agonists or antagonists. The PRO polypeptides are useful for
CC for stimulating the release of tumour necrosis factor (TNF)-alpha from
CC human blood, for stimulating the proliferation or differentiation of
CC chondrocytes, and detecting the presence of tumours. The polynucleotide
CC sequences encoding PRO polypeptides are useful as hybridisation probes,
CC in chromosome and gene mapping, in the generation of antisense RNA and
CC DNA, in the preparation of PRO polypeptides, for generating transgenic
CC animals or knockout animals, for the genetic analysis of individuals with
CC genetic disorders, and in gene therapy. ABU66570-ABU66844 represent the
CC human PRO polypeptides of the invention. Note: The sequence data for this
CC patent was obtained in electronic format directly from the USPTO web site
CC at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 15
ABU59851

ID ABU59851 standard; protein; 123 AA.
XX
AC ABU59851;
XX
DT 13-MAY-2003 (first entry)
XX
DE Novel secreted and transmembrane protein PRO619.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2003017563-A1.
XX
PD 23-JAN-2003.
XX
PF 07-MAY-2002; 2002US-00140808.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-148238/14.
DR N-PSDB; ABX89341.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; Fig 402; 659pp; English.
XX
CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO

CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpetiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and are
CC thus useful for treating sports injuries, and arthritis. This is the
CC amino acid sequence of a novel human PRO protein
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 16
ABU59218
ID ABU59218 standard; protein; 123 AA.
XX
AC ABU59218;
XX
DT 22-APR-2003 (first entry)
XX
DE Human secreted/transmembrane protein, #43.
XX
KW Human; PRO; secreted; transmembrane; pharmaceutical; diagnostic;
KW biosensor; bioreactor; tumour; therapeutic; gene therapy;
KW tumour-associated antigenic target; TAT; ADEPT;
KW antibody-dependent enzyme mediated prodrug therapy; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003027162-A1.
XX
PD 06-FEB-2003.
XX
PF 15-NOV-2001; 2001US-00997428.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.

PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 17
ABO25915
ID ABO25915 standard; protein; 123 AA.
XX
AC ABO25915;
XX
DT 10-SEP-2003 (first entry)
XX
DE Human PRO619 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW genetic disorder; antibacterial; immunosuppressive.
XX
OS Homo sapiens.
XX
PN US2002127576-A1.
XX
PD 12-SEP-2002.
XX
PF 14-NOV-2001; 2001US-00991073.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-340824/32.
DR N-PSDB; ACD44210.
XX
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT and are therapeutically useful for enhancing immune responses.
XX
PS Claim 12; Fig 68; 661pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for for
CC identifying agonists or antagonists. The polynucleotide sequences
CC encoding PRO polypeptides are useful as hybridisation probes, in
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
CC in the preparation of PRO polypeptides, for generating transgenic animals
CC or knockout animals, to construct hybridisation probes for mapping the
CC gene which encodes the PRO polypeptide, and for the genetic analysis of
CC individuals with genetic disorders, in gene therapy, for chromosome
CC identification, as chromosome markers, and for generating probes for PCR,
CC Northern analysis, Southern analysis and Western analysis. ABO25891-
CC ABO26037 represent the human PRO polypeptides of the invention. Note: The
CC sequence data for this patent was obtained in electronic format directly
CC from the USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 18
ABO25041
ID ABO25041 standard; protein; 123 AA.

XX
AC ABO25041;
XX
DT 05-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) #201.
XX
KW Human; PRO; secreted protein; transmembrane protein; tumour; cytostatic;
KW gene therapy; tumour necrosis factor-alpha; TNF-alpha; blood;
KW proteoglycan; cartilage; cytokine; peripheral blood mononuclear cell;
KW PBMC; glucose uptake; FFA; skeletal muscle cell; adipocyte cell;
KW chondrocyte cell proliferation; chondrocyte cell differentiation;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell; A-peptide; factor VIIA.
XX
OS Homo sapiens.
XX
PN US2003036179-A1.
XX
PD 20-FEB-2003.
XX
PF 10-MAY-2002; 2002US-00142431.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-466355/44.
DR N-PSDB; ACD41995.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 402; 659pp; English.
XX
CC The invention relates to an isolated nucleic acid comprising at least 80%
CC sequence identity to a PRO (secreted and transmembrane protein) cDNA
CC comprising a nucleic acid (a) encoding a PRO polypeptide, or its
CC extracellular domain (with or without its associated signal peptide),
CC which comprises any of the 275 120-850 residue amino acid sequences,
CC given in the specification; (b) comprising any of the 275 300-3500
CC nucleotide sequences, given in the specification; or (c) comprising the
CC full-length coding sequence of the nucleotide sequences given in the

```
CC   specification, or of the DNA deposited under any of the American Type
CC   Culture Collection (ATCC) Accession Numbers listed in the specification.
CC   Also included are a vector comprising the novel nucleic acid, a host cell
CC   comprising the vector, producing a PRO polypeptide, the isolated PRO
CC   polypeptides detailed above, a chimaeric molecule comprising the PRO
CC   polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
CC   antibody, detecting a PRO polypeptide in a sample suspected of containing
CC   the PRO polypeptide, linking a bioactive molecule to a cell expressing a
CC   PRO polypeptide, modulating at least one biological activity of a cell
CC   expressing a PRO polypeptide, stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
CC   cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
CC   modulating the uptake of glucose or FFA by skeletal muscle cells or
CC   adipocyte cells, stimulating the proliferation or differentiation of
CC   chondrocyte cells (or proliferation of or gene expression in pericyte
CC   cells), stimulating the proliferation of inner ear utricular supporting
CC   cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
CC   binding of A-peptide to factor VIIA, or differentiation of adipocyte
CC   cells, detecting the presence of a tumour in a mammal and an
CC   oligonucleotide probe derived from any of the nucleotide sequences given
CC   in the specification. The polynucleotide is useful in molecular biology,
CC   including uses as hybridisation probes, in chromosome and gene mapping,
CC   in generating antisense RNA and DNA, and in gene therapy. The
CC   polynucleotide may also be used in preparing PRO polypeptides by
CC   recombinant techniques, and in generating either transgenic animals or
CC   knock-out animals which, in turn, are useful in the development and
CC   screening of therapeutically useful reagents. The PRO polypeptide or the
CC   antibody is used in preparing a medicament for treating a condition
CC   responsive to the polypeptide or antibody, such as tumours, and in
CC   various diagnostic assays. The present sequence rperesents a PRO
CC   polypeptide
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 19
ABO01999
ID   ABO01999 standard; protein; 123 AA.
XX
AC   ABO01999;
XX
DT   12-AUG-2003  (first entry)
XX
DE   Novel human secreted protein #67.
XX
KW   Human; immunoglobulin G; IgG; fragment of crystallisation; Fc;
KW   immune system disorder; haematopoietic cell disorder;
KW   immunologic deficiency disorder; ataxia telangiectasia; HIV infection;
KW   Wiskott-Aldrich disorder; thrombocytopenia; haemoglobinuria;
KW   blood coagulation disorder; blood platelet disorder; autoimmune disorder;
KW   Addison's disease; haemolytic anaemia; rheumatoid arthritis; dermatitis;
KW   glomerulonephritis; Grave's disease; allergic reaction;
KW   graft-versus-host disease; hyperproliferative disorder; neoplasm;
KW   infectious disease; nervous system disease; spinal cord disorder;
KW   head trauma; stroke; tissue regeneration; congenital defect; trauma;
KW   wound; burn; incision; ulcer; age disease; osteoporosis;
KW   periodontal disease; liver failure; catabolism; anabolism; metabolism;
KW   food additive; preservative; secreted protein.
XX
OS   Homo sapiens.
XX
PN   US2003027132-A1.
XX
PD   06-FEB-2003.
XX
PF   04-SEP-1998;   98US-00148545.
XX
PR   07-MAR-1997;   97US-0038621P.
PR   07-MAR-1997;   97US-0040161P.
PR   07-MAR-1997;   97US-0040162P.
PR   07-MAR-1997;   97US-0040163P.
PR   07-MAR-1997;   97US-0040333P.
PR   07-MAR-1997;   97US-0040334P.
PR   07-MAR-1997;   97US-0040336P.
PR   07-MAR-1997;   97US-0040626P.
PR   11-APR-1997;   97US-0043311P.
PR   11-APR-1997;   97US-0043312P.
PR   11-APR-1997;   97US-0043313P.
PR   11-APR-1997;   97US-0043314P.
PR   11-APR-1997;   97US-0043315P.
PR   11-APR-1997;   97US-0043568P.
PR   11-APR-1997;   97US-0043569P.
PR   11-APR-1997;   97US-0043576P.
PR   11-APR-1997;   97US-0043578P.
PR   11-APR-1997;   97US-0043580P.
PR   11-APR-1997;   97US-0043669P.
PR   11-APR-1997;   97US-0043670P.
PR   11-APR-1997;   97US-0043671P.
PR   11-APR-1997;   97US-0043672P.
PR   11-APR-1997;   97US-0043674P.
PR   23-MAY-1997;   97US-0047492P.
PR   23-MAY-1997;   97US-0047500P.
PR   23-MAY-1997;   97US-0047501P.
PR   23-MAY-1997;   97US-0047502P.
PR   23-MAY-1997;   97US-0047503P.
PR   23-MAY-1997;   97US-0047581P.
PR   23-MAY-1997;   97US-0047582P.
PR   23-MAY-1997;   97US-0047583P.
PR   23-MAY-1997;   97US-0047584P.
PR   23-MAY-1997;   97US-0047585P.
PR   23-MAY-1997;   97US-0047586P.
PR   23-MAY-1997;   97US-0047587P.
PR   23-MAY-1997;   97US-0047588P.
PR   23-MAY-1997;   97US-0047589P.
PR   23-MAY-1997;   97US-0047590P.
PR   23-MAY-1997;   97US-0047592P.
PR   23-MAY-1997;   97US-0047593P.
PR   23-MAY-1997;   97US-0047594P.
PR   23-MAY-1997;   97US-0047595P.
PR   23-MAY-1997;   97US-0047596P.
PR   23-MAY-1997;   97US-0047597P.
PR   23-MAY-1997;   97US-0047598P.
PR   23-MAY-1997;   97US-0047599P.
PR   23-MAY-1997;   97US-0047600P.
PR   23-MAY-1997;   97US-0047601P.
PR   23-MAY-1997;   97US-0047612P.
PR   23-MAY-1997;   97US-0047613P.
PR   23-MAY-1997;   97US-0047614P.
PR   23-MAY-1997;   97US-0047615P.
PR   23-MAY-1997;   97US-0047617P.
PR   23-MAY-1997;   97US-0047618P.
PR   23-MAY-1997;   97US-0047632P.
PR   23-MAY-1997;   97US-0047633P.
PR   06-JUN-1997;   97US-0048964P.
PR   06-JUN-1997;   97US-0048974P.
PR   22-AUG-1997;   97US-0056630P.
PR   22-AUG-1997;   97US-0056631P.
PR   22-AUG-1997;   97US-0056632P.
PR   22-AUG-1997;   97US-0056636P.
PR   22-AUG-1997;   97US-0056637P.
```

PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057761P.
PR 06-MAR-1998; 98WO-US004482.
XX
PA (RUBE/) RUBEN S M.
PA (ROSE/) ROSEN C A.
PA (FISC/) FISCHER C L.
PA (SOPP/) SOPPET D R.
PA (CART/) CARTER K C.
PA (BEDN/) BEDNARIK D R.
PA (ENDR/) ENDRESS G A.
PA (YUGG/) YU G.
PA (NIJJ/) NI J.
PA (FENG/) FENG P.
PA (YOUN/) YOUNG P E.
PA (GREE/) GREENE J M.
PA (FERR/) FERRIE A M.
PA (DUAN/) DUAN R.
PA (HUJJ/) HU J.
PA (FLOR/) FLORENCE K A.
PA (OLSE/) OLSEN H S.
PA (EBNE/) EBNER R.
PA (BREW/) BREWER L A.
PA (SHIY/) SHI Y.
XX
PI Ruben SM, Rosen CA, Fischer CL, Soppet DR, Carter KC;
PI Bednarik DR, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;
PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;
PI Shi Y;
XX
DR WPI; 2003-466138/44.
DR N-PSDB; ACD08091.
XX
PT Novel isolated human secreted HODAZ50 polypeptide useful for diagnosing
PT or treating deficiencies or disorders of the immune system, autoimmune
PT disorders, hyperproliferative disorders, and infectious diseases.
XX
PS Claim 11; Page 205; 243pp; English.
XX
CC The invention describes an isolated human secreted HODAZ50 polypeptide
CC (I) comprising a sequence at least 95% identical to a sequence selected
CC from polypeptide fragment of any one of the 123 polypeptide sequences
CC (PS) fully defined in the specification and having biological activity,
CC polypeptide domain or epitope of PS, secreted form of PS, full-length
CC protein of PS, or variant, allelic variant or species homologue of PS.
CC (I) or a polynucleotide (II) encoding (I) is useful for preventing,
CC treating, or ameliorating a medical condition in a mammalian subject. (I)
CC or (II) is also useful for diagnosing a pathological condition or a
CC susceptibility to a pathological condition in a subject. (I) is useful
CC for identifying a binding partner which involves contacting the
CC polypeptide with the binding partner and determining whether the binding
CC partner affects the activity of the polypeptide. (I) or (II) is useful
CC for diagnosing or treating deficiencies or disorders of the immune
CC system, deficiencies or disorders of haematopoietic cells, to treat
CC immunologic deficiency disorders, ataxia telangiectasia, HIV infection,
CC Wiskott-Aldrich disorders, thrombocytopenia or haemoglobinuria, blood
CC coagulation disorders, blood platelet disorders, autoimmune disorders
CC (e.g., Addison's disease, haemolytic anaemia, rheumatoid arthritis,
CC dermatitis, glomerulonephritis, Grave's disease), allergic reactions,
CC graft-versus-host disease, hyperproliferative disorders (e.g., neoplasms
CC located in the abdomen, bone, breast, digestive system, liver, pancreas,
CC peritoneum, endocrine glands), infectious diseases (e.g., viral,
CC bacterial, fungal or parasitic infection), central and peripheral nervous
CC system diseases (e.g., spinal cord disorders, head trauma or stroke), to
CC differentiate, proliferate and attract cells leading to the regeneration
CC of tissues to repair, replace or protect tissue damaged by congenital
CC defects, trauma (wounds, burns, incisions, or ulcers) age disease (e.g.,
CC osteoporosis, periodontal disease, liver failure) or surgery. (I) or (IV)
CC is useful to modulate mammalian characteristics, to modulate mammalian
CC metabolism affecting catabolism, anabolism, processing, utilisation, and
CC storage of energy, to change a mammal's mental state or physical state,
CC or as a food additive or preservative, such as to increase or decrease
CC storage capabilities, fat content, lipid, protein, carbohydrate,
CC vitamins, minerals, cofactors or other nutritional components. This is
CC the amino acid sequence of a novel human secreted protein
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 20
ABU58924
ID ABU58924 standard; protein; 123 AA.
XX
AC ABU58924;
XX
DT 16-APR-2003 (first entry)
XX
DE Human sectreted/transmembrane protein, #43.
XX
KW Human; PRO; secreted; transmembrane; signal peptide; pharmaceutical;
KW diagnostic; biosensor; bioreactor; tumour; therapeutic; colon cancer;
KW lung cancer; breast cancer; cancer; gene therapy.
XX
OS Homo sapiens.
XX
PN US2002142961-A1.
XX
PD 03-OCT-2002.
XX
PF 19-NOV-2001; 2001US-00989721.
XX
PR 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-155950/15.
XX
PT New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
PT PRO361 or PRO846) useful as targets for therapeutic intervention in
PT cancers (e.g. lung or breast cancers), or for diagnosing these cancers.
XX
PS Claim 12; Fig 68; 647pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful as pharmaceuticals, diagnostics,
CC biosensors or bioreactors, for detecting or treating e.g. tumours in
CC mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats or
CC rabbits as targets for therapeutic intervention in certain cancers (e.g.
CC colon, lung or breast cancers) and diagnostic determination of the
CC presence of these cancers. The PRO polypeptides are also useful as
CC molecular weight markers or for chromosome identification. The PRO genes
CC are useful as hybridisation probes or for screening libraries of human
CC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
CC therapy, particularly for replacing a defective gene. The sequences
CC presented in ABU58900-ABU59046 are the PRO polypeptides of the invention
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

```
RESULT 21
ABU92302
ID   ABU92302 standard; protein; 123 AA.
XX
AC   ABU92302;
XX
DT   16-JUL-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO; PRO183; PRO184; PRO185;
KW   PRO943; PRO1133; PRO331; PRO1387; PRO363; PRO5723; PRO1114; PRO3301;
KW   PRO9940; PRO1181; PRO7170; PRO361; PRO846; bioactive molecule; toxin;
KW   radiolabel; antibody; cell death; tissue typing; gene therapy;
KW   cytostatic; chromosome mapping; gene mapping; transgenic animal;
KW   knockout animal; immunohistochemical staining.
XX
OS   Homo sapiens.
XX
PN   US2003022187-A1.
XX
PD   30-JAN-2003.
XX
PF   14-NOV-2001; 2001US-00993667.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   22-JUN-1998;   98US-0090282P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
PR   10-AUG-1998;   98US-0095929P.
PR   10-AUG-1998;   98US-0096012P.
PR   11-AUG-1998;   98US-0096143P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   17-AUG-1998;   98US-0096757P.
PR   17-AUG-1998;   98US-0096766P.
PR   17-AUG-1998;   98US-0096768P.
PR   17-AUG-1998;   98US-0096773P.
PR   17-AUG-1998;   98US-0096791P.
PR   17-AUG-1998;   98US-0096867P.
PR   17-AUG-1998;   98US-0096891P.
PR   17-AUG-1998;   98US-0096894P.
PR   17-AUG-1998;   98US-0096895P.
PR   17-AUG-1998;   98US-0096897P.
PR   18-AUG-1998;   98US-0096949P.
PR   18-AUG-1998;   98US-0096950P.
PR   18-AUG-1998;   98US-0096959P.
PR   18-AUG-1998;   98US-0096960P.
PR   18-AUG-1998;   98US-0097022P.
PR   19-AUG-1998;   98US-0097141P.
PR   20-AUG-1998;   98US-0097218P.
```

PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 20-FEB-1999; 99WO-US030911.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 22
ABU59367
ID ABU59367 standard; protein; 123 AA.
XX
AC ABU59367;
XX
DT 22-APR-2003 (first entry)
XX
DE Novel human secreted or transmembrane protein PRO943.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2003027985-A1.
XX
PD 06-FEB-2003.
XX
PF 14-NOV-2001; 2001US-00990562.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 23
ABU67046
ID ABU67046 standard; protein; 123 AA.
XX
AC ABU67046;
XX
DT 27-MAY-2003 (first entry)
XX
DE Human secreted/transmembrane, PRO, protein SEQ ID 402.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW infertility; birth defects; premature aging; AIDS; biosensor;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW bioreactor; tumour.
XX
OS Homo sapiens.
XX
PN US2003032155-A1.
XX
PD 13-FEB-2003.
XX
PF 03-MAY-2002; 2002US-00137865.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-331925/31.
DR N-PSDB; ACA04224.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 12; Fig 402; 659pp; English.
XX
CC The invention relates to an isolated nucleic acid comprising, or which is
CC at least 80% identical to, or the full-length coding sequence of, any of
CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
CC (one of 275 secreted or transmembrane proteins). The nucleic acid further

CC comprises the full-length coding sequence of the DNA deposited under
CC American Type Culture Collection (ATCC) accession number in a list given
CC in the specification. Also included are vectors and host cells for
CC producing PRO proteins, PRO fusion proteins, anti-PRO antibodies, PRO
CC extracellular domains and mature sequences, methods of detecting PRO
CC proteins, methods for stimulating the release of TNF-alpha (tumour
CC necrosis factor alpha) from human blood, (and the proliferation of
CC differentiation of chondrocyte cells, the proliferation of, or gene
CC expression in pericyte cells, the release or proteoglycans from
CC cartilage, proliferation of inner ear urticular supporting cells, the
CC proliferation of T-lymphocyte cells, the release of a cytokine from
CC peripheral blood mononuclear cells (PBMC), or the proliferation of
CC endothelial cells), a method for modulating the uptake of glucose or free
CC fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the
CC binding of A-peptide to factor VIIA, or the differentiation of adipocyte
CC cells, a method for detecting the presence of a tumour in a mammal and an
CC oligonucleotide probe derived from any of the nucleotide sequences cited
CC above. The nucleic acids and polypeptides are useful for treating
CC inflammatory diseases, organ failure, atherosclerosis, cardiac injury,
CC infertility, birth defects, premature aging, AIDS (acquired
CC immunodeficiency syndrome), cancer, or diabetic complications. The
CC nucleic acids are useful as hybridisation probes, in chromosome and gene
CC mapping, and in generating antisense RNA or DNA. The polypeptides are
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. Both
CC are useful in tissue typing. The present sequence represents a PRO
CC protein of the invention
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 24
ABU92133
ID ABU92133 standard; protein; 123 AA.
XX
AC ABU92133;
XX
DT 16-JUL-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO; nootropic;
KW neuroprotective; antiparkinsonian; cytostatic; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.
XX
OS Homo sapiens.
XX
PN US2003017476-A1.
XX
PD 23-JAN-2003.
XX
PF 20-NOV-2001; 2001US-00989724.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.

PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 25
ABU10839
ID ABU10839 standard; protein; 123 AA.
XX
AC ABU10839;
XX
DT 04-FEB-2003 (first entry)
XX
DE Human PRO polypeptide #25.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide; toxin;
KW radiolabel; cell death; gene mapping; chromosome mapping;
KW protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
KW antibacterial.
XX
OS Homo sapiens.
XX
PN US2002123463-A1.
XX
PD 05-SEP-2002.
XX
PF 19-NOV-2001; 2001US-00989732.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-066810/06.
DR N-PSDB; ABX16984.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
PS Claim 12; Fig 68; 655pp; English.
XX
CC The invention relates to a secreted and transmembrane polypeptide, termed
CC PRO polypeptide, and the polynucleotide encoding it. The polypeptide is
CC useful for detecting PRO polypeptides and for linking a bioactive
CC molecule to a cell expressing the above polypeptides, where the bioactive
CC molecule is a toxin, radiolabel or an antibody. The bioactive material
CC causes the death of the cell. The polypeptide is useful for identifying
CC agonists or antagonists of the PRO polypeptide, for preparing variants of
CC PRO, as a molecular weight marker for protein electrophoresis purposes
CC and the PRO polynucleotide is useful for recombinantly expressing those
CC markers. The polynucleotide is also useful as a hybridisation probe, in
CC chromosome and gene mapping, in generation of antisense RNA and DNA, in
CC the preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, to construct hybridisation
CC probes for mapping the gene which encodes PRO and for the genetic
CC analysis of individuals with genetic disorders, in gene therapy, for
CC chromosome identification, as a chromosome marker and for generating
CC probes for PCR, Northern analysis, Southern analysis and Western
CC analysis. This sequence represents a human PRO polypeptide of the
CC invention
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 26
ABU81591
ID ABU81591 standard; protein; 123 AA.
XX
AC ABU81591;
XX
DT 24-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; gene therapy; PRO; PRO943;
KW PRO183; PRO184; PRO185; PRO331; PRO1133; PRO363; PRO5723; PRO1387;
KW PRO1114; PRO3301; PRO9940; PRO1181; PRO7170; PRO361; PRO846;
KW bioactive molecule; toxin; radiolabel; antibody; cell death; cancer;
KW autoimmune disease; chromosome mapping; gene mapping; transgenic animal;
KW knockout animal; septic shock.
XX
OS Homo sapiens.
XX
PN US2002177164-A1.
XX
PD 28-NOV-2002.
XX
PF 20-NOV-2001; 2001US-00989293.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-328481/31.
DR N-PSDB; ACA67839.
XX
PT New secreted and transmembrane polypeptide, useful for modulating
PT biological activity of cell expressing the polypeptide, for identifying
PT agonists or antagonists of polypeptide, and as molecular weight markers.
XX
PS Claim 12; Fig 68; 654pp; English.
XX
CC The invention describes an isolated, secreted and transmembrane
CC polypeptide (I), termed PRO polypeptide. (I) is useful for detecting
CC PRO943, PRO183, PRO184, PRO185, PRO331, PRO1133, PRO363, PRO5723,
CC PRO1387, PRO1114, PRO3301, PRO9940, PRO1181, PRO7170, PRO361 or PRO846
CC polypeptide comprising contacting the sample with the polypeptide and
CC determining formation of a polypeptide conjugate. (I) is also useful for
CC linking a bioactive molecule e.g. toxin, radiolabel or antibody, to a
CC cell expressing the above polypeptides to cause cell death. (I) is also

CC useful as a therapeutic agent e.g. for treating cancer and autoimmune
CC disease. PRO is useful in assays to identify other proteins or molecules
CC involved in binding interactions. The polynucleotide (II) encoding (I) is
CC useful in chromosome and gene mapping, for generating transgenic animals
CC or knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, for the genetic analysis of
CC individuals with genetic disorders, in gene therapy, for chromosome
CC identification, and as a chromosome marker. An anti-(I)-antibody is
CC useful in diagnostic assays for PRO, e.g. detecting its expression in
CC specific cells, tissues or serum, for affinity purification of PRO, and
CC for treating septic shock. This is the amino acid sequence of a novel
CC human secreted and transmembrane PRO polypeptide
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 27
ABU88530
ID ABU88530 standard; protein; 123 AA.
XX
AC ABU88530;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human secreted and transmembrane polypeptide PRO619.
XX
KW Human; gene therapy; cancer; retinal disorder; wound healing;
KW kidney disorder.
XX
OS Homo sapiens.
XX
PN US2002197615-A1.
XX
PD 26-DEC-2002.
XX
PF 16-NOV-2001; 2001US-00991181.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.

```
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi JC,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2003-370792/35.
DR   N-PSDB; ACA88288.
XX
PT   New secreted and transmembrane nucleic acids and polypeptides, designated
PT   as PRO, useful for the preparation of a medicament for treating a
PT   condition that is responsive to the PRO polypeptide. e.g., cancer.
XX
PS   Claim 12; Fig 68; 647pp; English.
XX
CC   The invention relates to an isolated nucleic acid encoding a PRO
CC   polypeptide. The polypeptide, agonist, antagonist and antibody are useful
CC   for the preparation of a medicament for treating a condition that is
CC   responsive to the PRO polypeptide. The nucleotide sequence is useful in
CC   molecular biology including being used as hybridisation probes, in
CC   chromosome and gene mapping and in the generation of anti-sense RNA and
CC   DNA. The PRO polypeptides can also be used in the treatment of e.g.
CC   cancer, retinal disorders, wound healing and kidney disorders. The
CC   present sequence represents the amino acid sequence of a human secreted
CC   and transmembrane PRO polypeptide of the present invention. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification but was obtained in electronic format directly from USPTO
CC   at seqdata.uspto.gov/sequence.html?DocID=20020197615
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 28
ABO34044
ID   ABO34044 standard; protein; 123 AA.
XX
AC   ABO34044;
XX
DT   19-SEP-2003  (first entry)
XX
DE   Human PRO619 polypeptide.
XX
KW   Human; PRO polypeptide; secreted protein; transmembrane protein;
KW   biosensor; bioreactor; tumour; cancer; diabetes; ALS; ulcer;
KW   rheumatoid arthritis; amyotrophic lateral sclerosis; cytostatic;
KW   antidiabetic; antiarthritic; antirheumatic; antiulcer.
XX
OS   Homo sapiens.
XX
PN   US2003017981-A1.
XX
PD   23-JAN-2003.
XX
PF   20-NOV-2001; 2001US-00989728.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
```

PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091633P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 29
ADA45921
ID ADA45921 standard; protein; 123 AA.
XX
AC ADA45921;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX

PN US2003022328-A1.
XX
PD 30-JAN-2003.
XX
PF 16-APR-2002; 2002US-00123904.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-584997/55.
DR N-PSDB; ADA45920.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
PS Claim 12; Fig 402; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for

```
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 30
ADA76352
ID   ADA76352 standard; protein; 123 AA.
XX
AC   ADA76352;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #201.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003073212-A1.
XX
PD   17-APR-2003.
XX
PF   16-APR-2002; 2002US-00123903.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
```

PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-687639/65.
DR N-PSDB; ADA76351.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and
PT gene mapping, in generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 402; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 31
ADA19002
ID ADA19002 standard; protein; 123 AA.
XX
AC ADA19002;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW factor VIIA; endothelial cell.
XX
OS Homo sapiens.
XX
PN US2003054517-A1.
XX
PD 20-MAR-2003.
XX
PF 08-MAY-2002; 2002US-00141755.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-521854/49.
DR N-PSDB; ADA19001.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumors.
XX
PS Claim 12; Fig 402; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. lung, colon, breast,
CC prostate, rectal, cervical and liver tumours). The polynucleotides are
CC useful in molecular biology, including uses as hybridisation probes, in
CC chromosome and gene mapping, in generating antisense RNA and DNA and in
CC gene therapy. The polynucleotides may also be used in preparing PRO
CC polypeptides by recombinant techniques and in generating either
CC transgenic animals or knock-out animals which are useful in the
CC development and screening of therapeutically useful reagents. The PRO
CC polypeptides or antibodies are used in preparing a medicament for
CC treating a condition responsive to the polypeptides or antibodies, such
CC as tumours, for modulating the uptake of glucose or FFA by adipocyte
CC cells, for stimulating the proliferation of or gene expression in
CC pericyte cells, for stimulating the release of proteoglycans from
CC cartilage, for stimulating the proliferation of inner ear utricular
CC supporting cells, for stimulating the release of cytokines from PBMC
CC cells, for inhibiting the binding of A-peptide to factor VIIA, for
CC inhibiting the differentiation of adipocyte cells and for stimulating the
CC proliferation of endothelial cells. This sequence represents a human PRO
CC polypeptide of the invention. Note: The sequence data for this patent is
CC also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 32
ADA61625
ID ADA61625 standard; protein; 123 AA.
XX
AC ADA61625;
XX
DT 20-NOV-2003 (first entry)
XX
DE Homo sapiens.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Novel.
OS human.
OS secreted.
OS and.
OS transmembrane.
OS protein.
OS PRO619.
XX
PN US2003049816-A1.
XX
PD 13-MAR-2003.
XX

PF 15-APR-2002; 2002US-00123262.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695892/66.
DR N-PSDB; ADA61624.
XX
PT New PRO nucleic acid and encode polypeptides, are useful for
PT manufacturing a medicament for diagnosing or treating cancer.
XX
PS Claim 12; Fig 402; 660pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX

```
SQ   Sequence 123 AA;

  Query Match           100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 33
ADB19410
ID   ADB19410 standard; protein; 123 AA.
XX
AC   ADB19410;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine releas.
XX
OS   Homo sapiens.
XX
PN   US2003068796-A1.
XX
PD   10-APR-2003.
XX
PF   15-APR-2002; 2002US-00123261.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
```

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695927/66.
DR N-PSDB; ADB19409.
XX
PT Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha and detecting the presence of
PT a tumor in a mammal.
XX
PS Claim 12; Fig 402; 660pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyt
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 34
ADB27951
ID ADB27951 standard; protein; 123 AA.
XX
AC ADB27951;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082704-A1.
XX
PD 01-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131819.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-765415/72.
DR N-PSDB; ADB27950.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 35
ADA86430
ID ADA86430 standard; protein; 123 AA.
XX
AC ADA86430;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX

KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082711-A1.
XX
PD 01-MAY-2003.
XX
PF 16-MAY-2002; 2002US-00147508.
XX
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUN-1999; 99WO-US012252.
PR 07-JUL-1999; 99US-0143048P.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786914/74.
DR N-PSDB; ADA86429.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;

Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 36
ADB15994
ID ADB15994 standard; protein; 123 AA.
XX
AC ADB15994;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087350-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127821.
XX
PR 04-AUG-1998; 98US-0095301P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786941/74.
DR N-PSDB; ADB15993.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

```
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 37
ADA37628
ID   ADA37628 standard; protein; 123 AA.
XX
AC   ADA37628;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO619.
XX
KW   PRO; secreted protein; transmembrane protein;
KW   hypertrophy of neonatal heart; angiogenesis;
KW   vascular endothelial growth factor; VEGF-stimulated proliferation;
KW   endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW   c-fos induction; adipocyte cell; chondrocyte differentiation;
KW   pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW   cancer; human; colon cancer; lung cancer; breast cancer;
KW   rod photoreceptor cell.
XX
OS   Homo sapiens.
XX
PN   US2003008297-A1.
XX
PD   09-JAN-2003.
XX
PF   15-NOV-2001; 2001US-00997653.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   02-JUN-1999;   99WO-US012252.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
```

PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-531419/50.
DR N-PSDB; ADA37627.
XX
PT New isolated PRO183, PRO184, PRO361 or PRO846 nucleic acid and secreted
PT transmembrane polypeptides, useful as targets for the diagnosis and
PT treatment of cancers, such as lung and breast cancers.
XX
PS Claim 12; Fig 68; 660pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule comprising the
CC full-length coding sequence of the DNA ATCC Accession Numbers given in
CC the specification, or comprising a sequence with at least 80% identity
CC to: (a) a nucleotide encoding any of 147 PRO polypeptides, or an
CC extracellular domain of the polypeptide; or (b) any of 147 nucleotide
CC sequences fully defined in the specification. Also included are the PRO
CC proteins (or their extracellular domains with or without their associated
CC extracellular domains), expression vectors, host cells, PRO chimaeric
CC proteins, anti-PRO antibodies, methods of detecting polypeptide in a
CC sample, methods of linking a bioactive molecule to a cell expressing a
CC polypeptide and methods of modulating at least one biological activity of
CC a cell expressing the polypeptide. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocyte
CC cells, inducing proliferation and/or re-differentiation of chondrocytes,
CC or inducing pancreatic beta-cell precursor differentiation. In
CC particular, these are useful for detecting or treating tumours and
CC certain cancers (colon, lung or breast cancers) in mammals, e.g. humans,
CC dogs, cats, cattle, horses, sheep, pigs, goats, or rabbits. The PRO genes
CC may also be used in gene therapy, particularly for replacing a defective
CC gene. The present sequence represents a PRO protein.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 38
ADA47780
ID ADA47780 standard; protein; 123 AA.
XX
AC ADA47780;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073215-A1.
XX
PD 17-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140925.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-644801/61.
DR N-PSDB; ADA47779.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 12; Fig 402; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 39
ADA21314
ID ADA21314 standard; protein; 123 AA.
XX
AC ADA21314;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane polypeptide PRO619.
XX
KW human; tumour; cancer; colorectal cancer; gene therapy;

KW chondrocyte differentiation; VEGF inhibition;
KW vascular endothelial growth factor; Alzheimer's disease;
KW Parkinson's disease; atherosclerosis; cystic fibrosis;
KW multiple sclerosis; ovarian cancer; tissue typing.
XX
OS Homo sapiens.
XX
PN US2003054404-A1.
XX
PD 20-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997601.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.

```
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.

  Query Match           100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 40
ADA10101
ID   ADA10101 standard; protein; 123 AA.
XX
AC   ADA10101;
XX
DT   06-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane protein, PRO619.
XX
KW   PRO; secreted protein; transmembrane protein; human; septic shock;
KW   immunogen.
XX
OS   Homo sapiens.
XX
PN   US2003059831-A1.
XX
PD   27-MAR-2003.
XX
PF   19-NOV-2001; 2001US-00989729.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
```

PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 41
ADA67575
ID ADA67575 standard; protein; 123 AA.
XX
AC ADA67575;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.

XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068795-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123236.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695926/66.
DR N-PSDB; ADA67574.
XX
PT Novel isolated PRO secreted and transmembrane polypeptides useful for
PT stimulating the release of tumor necrosis factor-alpha from human blood
PT and detecting the presence of a tumor in a mammal.
XX
PS Claim 12; Fig 402; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 42
ADB30582
ID ADB30582 standard; protein; 123 AA.
XX
AC ADB30582;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068794-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123155.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.

PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-708391/67.
DR N-PSDB; ADB30581.
XX
PT New isolated PRO polypeptides e.g. PRO1801 and PRO1114, useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Claim 12; Fig 402; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 43
ADA85878
ID ADA85878 standard; protein; 123 AA.
XX
AC ADA85878;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082693-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127843.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786907/74.
DR N-PSDB; ADA85877.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,

CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 44
ADA17645
ID ADA17645 standard; protein; 123 AA.
XX
AC ADA17645;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO619 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW transgenic; tumour; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003054987-A1.
XX
PD 20-MAR-2003.
XX
PF 14-NOV-2001; 2001US-00990443.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.

PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 45
ADA97090
ID ADA97090 standard; protein; 123 AA.
XX
AC ADA97090;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082705-A1.
XX
PD 01-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131829.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755112/71.
DR N-PSDB; ADA97089.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 46
ADA79394
ID ADA79394 standard; protein; 123 AA.
XX
AC ADA79394;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082763-A1.
XX
PD 01-MAY-2003.
XX
PF 17-APR-2002; 2002US-00124818.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755116/71.
DR N-PSDB; ADA79393.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in detection and treatment of cancer and in modulating the uptake of
PT glucose or free fatty acid by skeletal muscle cells or adipocyte cells.
XX
PS Claim 12; Fig 402; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 47
ADA87533
ID ADA87533 standard; protein; 123 AA.
XX
AC ADA87533;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087345-A1.
XX
PD 08-MAY-2003.
XX
PF 16-APR-2002; 2002US-00123907.

XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786937/74.
DR N-PSDB; ADA87532.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 12; Fig 402; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 123 AA;

```
  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 48
ADB16735
ID   ADB16735 standard; protein; 123 AA.
XX
AC   ADB16735;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #201.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003087349-A1.
XX
PD   08-MAY-2003.
XX
PF   19-APR-2002; 2002US-00125928.
XX
PR   19-JUN-1998;   98US-0089947P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   02-MAR-2000; 2000WO-US005841.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-786940/74.
DR   N-PSDB; ADB16734.
XX
PT   New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT   and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 49
ADA27753
ID   ADA27753 standard; protein; 123 AA.
XX
AC   ADA27753;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO619.
XX
KW   PRO; secreted protein; transmembrane protein;
KW   hypertrophy of neonatal heart; angiogenesis;
KW   vascular endothelial growth factor; VEGF-stimulated proliferation;
KW   endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW   rod photoreceptor cell; c-fos induction; adipocyte cell;
KW   chondrocyte differentiation;
KW   pancreatic beta-cell precursor differentiation;
KW   cardiac insufficiency disorder; wound; cancerous tumour;
KW   retinal disorders; loss of sight; retinitis pigmentosum; kidney disorder;
KW   obesity; diabetes; hyperinsulinaemia; hypoinsulinaemia; bone disorder;
KW   cartilage disorder; sports injury; arthritis; cancer; human.
XX
OS   Homo sapiens.
XX
PN   US2003054359-A1.
```

XX
PD 20-MAR-2003.
XX
PF 14-NOV-2001; 2001US-00990726.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.

```
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.

  Query Match           100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 50
ADA91827
ID   ADA91827 standard; protein; 123 AA.
XX
AC   ADA91827;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082694-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127845.
XX
PR   03-MAR-2000; 2000US-0187202P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786908/74.
DR   N-PSDB; ADA91826.
XX
PT   New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT   or a composition for treating e.g., tumor or for tissue typing.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 123 AA;

  Query Match           100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 51
ADB14890
ID   ADB14890 standard; protein; 123 AA.
```

XX
AC ADB14890;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087351-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127822.
XX
PR 17-JUN-1998; 98US-0089532P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786942/74.
DR N-PSDB; ADB14889.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 52
ADB18851
ID ADB18851 standard; protein; 123 AA.
XX
AC ADB18851;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine releas.
XX
OS Homo sapiens.
XX
PN US2003073211-A1.
XX
PD 17-APR-2003.
XX
PF 15-APR-2002; 2002US-00123292.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695954/66.
DR N-PSDB; ADB18850.
XX
PT New isolated nucleic acid and encoded PRO polypeptide, are useful in the
PT diagnosis and treatment of cancer.
XX
PS Claim 12; Fig 402; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyt
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 53
ADA94066
ID ADA94066 standard; protein; 123 AA.
XX
AC ADA94066;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077722-A1.
XX
PD 24-APR-2003.
XX
PF 03-MAY-2002; 2002US-00137872.
XX
PR 03-MAR-2000; 2000US-0187202P.

PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755077/71.
DR N-PSDB; ADA94065.
XX
PT New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and/or liver tumors.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 54
ADB19962

ID ADB19962 standard; protein; 123 AA.
XX
AC ADB19962;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082691-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127838.
XX
PR 17-NOV-1998; 98US-0108802P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755108/71.
DR N-PSDB; ADB19961.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for

```
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 55
ADB13274
ID   ADB13274 standard; protein; 123 AA.
XX
AC   ADB13274;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #201.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082710-A1.
XX
PD   01-MAY-2003.
XX
PF   16-MAY-2002; 2002US-00147484.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-786913/74.
DR   N-PSDB; ADB13273.
XX
PT   New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT   preparing a composition for treating e.g., tumor, or for tissue typing.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 56
ABO43349
ID   ABO43349 standard; protein; 123 AA.
XX
AC   ABO43349;
XX
DT   26-SEP-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO; gene therapy;
KW   chromosome identification; tissue typing.
XX
OS   Homo sapiens.
XX
PN   US2003044945-A1.
XX
PD   06-MAR-2003.
XX
PF   10-MAY-2002; 2002US-00142419.
XX
PR   31-MAR-1997;   97WO-US005230.
```

PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-492275/46.
DR N-PSDB; ACD98624.
XX
PT New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX
PS Claim 12; Fig 402; 660pp; English.
XX
CC The invention describes an isolated nucleic acid encoding a PRO (secreted
CC and transmembrane) polypeptide. Nucleic acids which encode PRO can be
CC used to generate either transgenic animals or knock-out animals useful in
CC developing and screening of therapeutically useful reagents. The nucleic
CC acids may also be used in gene therapy, in chromosome identification, as
CC chromosome markers, or in generating probes. The PRO polypeptides are
CC useful as molecular markers for protein electrophoresis, and the isolated
CC nucleic acids may be used for recombinantly expressing those markers. The
CC PRO polypeptides and nucleic acids may also be used in tissue typing.
CC Anti-PRO antibodies are useful in diagnostic assays for PRO, and in
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 57
ADA94333
ID ADA94333 standard; protein; 123 AA.
XX
AC ADA94333;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO619.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003059832-A1.
XX
PD 27-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997349.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.

PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 58
ADA74528
ID ADA74528 standard; protein; 123 AA.
XX
AC ADA74528;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068798-A1.
XX
PD 10-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140928.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-625490/59.
DR N-PSDB; ADA74527.
XX
PT Novel secreted and transmembrane PRO polypeptides and polynucleotides
PT encoding them, useful for treating bone disorders, arthritis, heart
PT attack, injuries, tumors, and stimulating release of Tumor Necrosis
PT Factor-alpha from human blood.
XX
PS Claim 12; Fig 402; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 59
ADB24761
ID ADB24761 standard; protein; 123 AA.
XX
AC ADB24761;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 402.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077713-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127839.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755068/71.
DR N-PSDB; ADB24760.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 60
ADA82285
ID ADA82285 standard; protein; 123 AA.
XX
AC ADA82285;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082701-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128686.
XX
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 02-JUN-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755110/71.
DR N-PSDB; ADA82284.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 61
ADA75248
ID ADA75248 standard; protein; 123 AA.
XX
AC ADA75248;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073216-A1.
XX
PD 17-APR-2003.
XX
PF 30-MAY-2002; 2002US-00160498.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.

```
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-765392/72.
DR   N-PSDB; ADA75247.
XX
PT   New secreted and transmembrane PRO polypeptides useful for stimulating
PT   the release of tumor necrosis factor alpha in human blood and detecting
PT   the presence of tumor in a mammal.
XX
PS   Claim 12; Fig 402; 638pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 62
ADA85326
ID   ADA85326 standard; protein; 123 AA.
XX
AC   ADA85326;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082695-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127846.
XX
PR   03-MAR-2000; 2000US-0187202P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786909/74.
DR   N-PSDB; ADA85325.
XX
PT   New nucleic acid encoding a PRO polypeptide, useful for preparing a
PT   composition for treating e.g. tumor by gene therapy, or for tissue
PT   typing.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
```

```
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 63
ADA84774
ID   ADA84774 standard; protein; 123 AA.
XX
AC   ADA84774;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082708-A1.
XX
PD   01-MAY-2003.
XX
PF   15-MAY-2002; 2002US-00146729.
XX
PR   05-JUN-2000; 2000US-0209832P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786911/74.
DR   N-PSDB; ADA84773.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g. tumor or for tissue typing.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 64
ADB30030
ID   ADB30030 standard; protein; 123 AA.
XX
AC   ADB30030;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #201.
XX
```

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073214-A1.
XX
PD 17-APR-2003.
XX
PF 17-APR-2002; 2002US-00124822.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-720081/68.
DR N-PSDB; ADB30029.
XX
PT Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha and detecting the presence of
PT a tumor in a mammal.
XX
PS Claim 12; Fig 402; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in

```
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 65
ADA80558
ID   ADA80558 standard; protein; 123 AA.
XX
AC   ADA80558;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #201.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082761-A1.
XX
PD   01-MAY-2003.
XX
PF   12-APR-2002; 2002US-00121061.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
```

PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755115/71.
DR N-PSDB; ADA80557.
XX
PT New PRO polypeptides useful for treating diabetes, hyper- or hypo-
PT insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,
PT various coagulation disorders and tumors.
XX
PS Claim 12; Fig 402; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 66
ADA75800
ID ADA75800 standard; protein; 123 AA.
XX
AC ADA75800;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082703-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128691.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zharg Z;
XX
DR WPI; 2003-765414/72.
DR N-PSDB; ADA75799.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

```
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 67
ADA38558
ID   ADA38558 standard; protein; 123 AA.
XX
AC   ADA38558;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO619.
XX
KW   PRO; secreted protein; transmembrane protein; gene therapy; tumour;
KW   cancer; human; colon cancer; lung cancer; breast cancer.
XX
OS   Homo sapiens.
XX
PN   US2003059780-A1.
XX
PD   27-MAR-2003.
XX
PF   14-NOV-2001; 2001US-00991854.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
```

PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 68
ADA47025
ID ADA47025 standard; protein; 123 AA.
XX
AC ADA47025;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073210-A1.
XX
PD 17-APR-2003.

XX
PF 11-APR-2002; 2002US-00121045.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-644800/61.
DR N-PSDB; ADA47024.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 402; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 69
ADB25321
ID ADB25321 standard; protein; 123 AA.
XX
AC ADB25321;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 402.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077715-A1.
XX
PD 24-APR-2003.
XX
PF 23-APR-2002; 2002US-00128693.
XX
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 02-JUN-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755070/71.
DR N-PSDB; ADB25320.
XX
PT New isolated, secreted and transmembrane PRO nucleic acids, useful for
PT the diagnosis, prevention and/or treatment of tumors, such as lung,
PT colon, breast, prostate, rectal, cervical and/or liver tumors.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 70
ADA93497
ID ADA93497 standard; protein; 123 AA.
XX
AC ADA93497;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077721-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131837.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755076/71.
DR N-PSDB; ADA93496.
XX
PT New PRO nucleic acid, useful for recombinantly producing a PRO
PT polypeptide and for manufacturing a medicament for diagnosing or treating
PT tumor.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 71
ADB26847
ID ADB26847 standard; protein; 123 AA.
XX
AC ADB26847;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003092147-A1.
XX
PD 15-MAY-2003.
XX
PF 11-APR-2002; 2002US-00121051.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-777249/73.
DR N-PSDB; ADB26846.
XX
PT Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX
PS Claim 12; Fig 402; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 72
ADB31134
ID ADB31134 standard; protein; 123 AA.
XX
AC ADB31134;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.

XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003096386-A1.
XX
PD 22-MAY-2003.
XX
PF 11-APR-2002; 2002US-00121042.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786990/74.
DR N-PSDB; ADB31133.
XX
PT Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX
PS Claim 12; Fig 402; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 PSP 123
              |||
Db        121 PSP 123
```

RESULT 73
ADA92679
ID ADA92679 standard; protein; 123 AA.
XX
AC ADA92679;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO619.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003060407-A1.
XX
PD 27-MAR-2003.
XX
PF 14-NOV-2001; 2001US-00990440.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.

PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 74
ADA61062
ID ADA61062 standard; protein; 123 AA.
XX
AC ADA61062;
XX
DT 20-NOV-2003 (first entry)
XX
DE Homo sapiens.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Novel.
OS human.
OS secreted.
OS and.
OS transmembrane.
OS protein.
OS PRO619.
XX
PN US2003049817-A1.
XX
PD 13-MAR-2003.

XX
PF 10-MAY-2002; 2002US-00142423.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PR 10-MAR-2009; 2000WO-US006319.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695893/66.
DR N-PSDB; ADA61061.
XX
PT New secreted and transmembrane PRO polypeptide and nucleic acid, useful
PT for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 12; Fig 402; 658pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.

```
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 75
ADB24209
ID   ADB24209 standard; protein; 123 AA.
XX
AC   ADB24209;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide SEQ ID NO 402.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003077714-A1.
XX
PD   24-APR-2003.
XX
PF   22-APR-2002; 2002US-00127901.
XX
PR   17-JUN-1998;   98US-0089599P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   30-NOV-1999;   99WO-US028313.
PR   30-MAR-2000; 2000WO-US008439.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755069/71.
DR   N-PSDB; ADB24208.
XX
PT   New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT   acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT   such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT   tumors.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 76
ADA96538
ID   ADA96538 standard; protein; 123 AA.
XX
AC   ADA96538;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #201.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
```

```
XX
OS   Homo sapiens.
XX
PN   US2003082690-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127837.
XX
PR   01-SEP-1998;   98US-0098750P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-755107/71.
DR   N-PSDB; ADA96537.
XX
PT   PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT   tumor or for tissue typing.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||

Db        121 FSP 123


RESULT 77
ADA81110
ID   ADA81110 standard; protein; 123 AA.
XX
AC   ADA81110;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #201.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082702-A1.
XX
PD   01-MAY-2003.
XX
PF   23-APR-2002; 2002US-00128690.
XX
PR   02-MAR-2000; 2000WO-US005841.
PR   30-MAY-2000; 2000WO-US014941.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-755111/71.
DR   N-PSDB; ADA81109.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor or for tissue typing.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
```

CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 78
ADA95986
ID ADA95986 standard; protein; 123 AA.
XX
AC ADA95986;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082759-A1.
XX
PD 01-MAY-2003.
XX
PF 11-APR-2002; 2002US-00121040.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.

PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755114/71.
DR N-PSDB; ADA95985.
XX
PT New isolated PRO polypeptides, useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders and tumors.
XX
PS Claim 12; Fig 402; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 79
ADB26295
ID ADB26295 standard; protein; 123 AA.
XX
AC ADB26295;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082760-A1.
XX
PD 01-MAY-2003.
XX
PF 12-APR-2002; 2002US-00121056.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX

PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-777204/73.
DR N-PSDB; ADB26294.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 12; Fig 402; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 123 AA;

```
  Query Match           100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 80
ADB21780
ID ADB21780 standard; protein; 123 AA.
XX

AC ADB21780;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082765-A1.
XX
PD 01-MAY-2003.
XX
PF 17-MAY-2002; 2002US-00147492.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786920/74.
DR N-PSDB; ADB21779.
XX
PT New secreted and transmembrane PRO polypeptide useful for detecting the
PT presence of tumor in a mammal, or modulating the uptake of glucose or
PT free fatty acid by skeletal muscle cells or adipocyte cells.
XX
PS Claim 12; Fig 402; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,

```
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 6;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 81
ADA77559
ID   ADA77559 standard; protein; 123 AA.
XX
AC   ADA77559;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #201.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003068797-A1.
XX
PD   10-APR-2003.
XX
PF   07-MAY-2002; 2002US-00140921.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
```

PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-625489/59.
DR N-PSDB; ADA77558.
XX
PT Novel isolated, secreted and transmembrane PRO polypeptides e.g. PRO1801
PT and PRO1114, useful in the preparation of a medicament for treating a
PT condition responsive to PRO polypeptide, and as therapeutic agents e.g.
PT vaccines.
XX
PS Claim 12; Fig 402; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 82
ADB18299
ID ADB18299 standard; protein; 123 AA.
XX
AC ADB18299;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077710-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127825.
XX
PR 22-OCT-1998; 98US-0105169P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755065/71.
DR N-PSDB; ADB18298.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
PT in tissue typing, and in identifying chromosomes.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 83
ADA86982
ID ADA86982 standard; protein; 123 AA.
XX
AC ADA86982;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082709-A1.
XX
PD 01-MAY-2003.
XX
PF 15-MAY-2002; 2002US-00146791.
XX
PR 17-AUG-1998; 98US-0096895P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786912/74.
DR N-PSDB; ADA86981.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT for preparing a composition for treating e.g., tumor, or for tissue
PT typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
```

```
              |||
Db        121 FSP 123


RESULT 84
ADA88085
ID   ADA88085 standard; protein; 123 AA.
XX
AC   ADA88085;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082700-A1.
XX
PD   01-MAY-2003.
XX
PF   23-APR-2002; 2002US-00128684.
XX
PR   05-JUN-2000; 2000US-0209832P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao-W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786910/74.
DR   N-PSDB; ADA88084.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor or for tissue typing.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 85
ADA46473
ID   ADA46473 standard; protein; 123 AA.
XX
AC   ADA46473;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003054516-A1.
XX
PD   20-MAR-2003.
XX
PF   12-APR-2002; 2002US-00121050.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
```

PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-521853/49.
DR N-PSDB; ADA46472.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor.
XX
PS Claim 12; Fig 402; 200pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 86
ADB28503
ID ADB28503 standard; protein; 123 AA.
XX

AC ADB28503;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082699-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127851.
XX
PR 17-JUN-1998; 98US-0089599P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-777202/73.
DR N-PSDB; ADB28502.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 87
ADB29055
ID ADB29055 standard; protein; 123 AA.
XX
AC ADB29055;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082706-A1.
XX
PD 01-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131836.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforgre L, Desnoyers L, Filvaroff E;
PI Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-777203/73.
DR N-PSDB; ADB29054.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX

PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 88
ABO53130
ID ABO53130 standard; protein; 123 AA.
XX
AC ABO53130;
XX
DT 14-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO619.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW adrenal cortical capillary endothelial cell; angiogenesis; wound healing;
KW diabetes; obesity; hyper-insulinaemia; hypo-insulinaemia;
KW chondrocyte redifferentiation; bone disorder; cartilage disorder;
KW sports injury; arthritis; kidney mesangial cell proliferation;
KW kidney disorder; Berger disease; neuropathy; coeliac disease;
KW dermatitis herpetiformis; Crohn's disease; tumour; cancer.
XX
OS Homo sapiens.
XX
PN US2003044806-A1.
XX
PD 06-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00998156.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.

PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 89
ADA77007
ID ADA77007 standard; protein; 123 AA.
XX
AC ADA77007;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003059909-A1.
XX
PD 27-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00143032.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-540684/51.
DR N-PSDB; ADA77006.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 12; Fig 402; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of

```
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 90
ADA22240
ID   ADA22240 standard; protein; 123 AA.
XX
AC   ADA22240;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane polypeptide PRO619.
XX
KW   human; tumour; cancer; colorectal cancer; gene therapy;
KW   chondrocyte differentiation; VEGF inhibition;
KW   vascular endothelial growth factor; Alzheimer's disease;
KW   Parkinson's disease; atherosclerosis; cystic fibrosis;
KW   multiple sclerosis; ovarian cancer; tissue typing.
XX
OS   Homo sapiens.
XX
PN   US2003040473-A1.
XX
PD   27-FEB-2003.
XX
PF   19-NOV-2001; 2001US-00989726.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
```

PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 91
ADA88637
ID ADA88637 standard; protein; 123 AA.
XX
AC ADA88637;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003073213-A1.
XX
PD 17-APR-2003.
XX
PF 17-APR-2002; 2002US-00124819.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-743816/70.
DR N-PSDB; ADA88636.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 12; Fig 402; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

```
Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 92
ADA97642
ID   ADA97642 standard; protein; 123 AA.
XX
AC   ADA97642;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #201.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082686-A1.
XX
PD   01-MAY-2003.
XX
PF   19-APR-2002; 2002US-00125926.
XX
PR   05-JUN-2000; 2000US-0209832P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-755106/71.
DR   N-PSDB; ADA97641.
XX
PT   Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT   PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT   generating antisense RNA and DNA, and in gene therapy.
XX
PS   Claim 12; Fig 402; 666pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 93
ADB27399
ID   ADB27399 standard; protein; 123 AA.
XX
AC   ADB27399;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #201.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003022239-A1.
XX
PD   30-JAN-2003.
XX
PF   12-APR-2002; 2002US-00121049.
XX
PR   18-JUN-1997;   97US-0049911P.
PR   26-AUG-1997;   97US-0056974P.
PR   17-SEP-1997;   97US-0059113P.
PR   17-SEP-1997;   97US-0059115P.
PR   17-SEP-1997;   97US-0059117P.
PR   17-SEP-1997;   97US-0059122P.
PR   17-SEP-1997;   97US-0059184P.
```

PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.

```
PR   16-DEC-1998;   98US-0112850P.
PR   22-DEC-1998;   98US-0113296P.
PR   22-DEC-1998;   98US-0113299P.
PR   22-DEC-1998;   98US-0113300P.
PR   22-DEC-1998;   98US-0113313P.
PR   22-DEC-1998;   98US-0113314P.
PR   22-DEC-1998;   98US-0113315P.
PR   22-DEC-1998;   98US-0113510P.
PR   22-DEC-1998;   98US-0113511P.
PR   23-DEC-1998;   98US-0113605P.
PR   23-DEC-1998;   98US-0113621P.
PR   05-JAN-1999;   99WO-US000106.
PR   12-JAN-1999;   99US-0115549P.
PR   12-JAN-1999;   99US-0115557P.
PR   12-JAN-1999;   99US-0115560P.
PR   12-JAN-1999;   99US-0115562P.
PR   12-JAN-1999;   99US-0115564P.
PR   12-JAN-1999;   99US-0115630P.
PR   12-JAN-1999;   99US-0115705P.
PR   12-JAN-1999;   99US-0115733P.

  Query Match           100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 94
ADB22332
ID   ADB22332 standard; protein; 123 AA.
XX
AC   ADB22332;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003087344-A1.
XX
PD   08-MAY-2003.
XX
PF   16-APR-2002; 2002US-00123905.
XX
PR   18-JUN-1997;   97US-0049911P.
PR   26-AUG-1997;   97US-0056974P.
PR   17-SEP-1997;   97US-0059113P.
PR   17-SEP-1997;   97US-0059115P.
PR   17-SEP-1997;   97US-0059117P.
PR   17-SEP-1997;   97US-0059122P.
PR   17-SEP-1997;   97US-0059184P.
PR   18-SEP-1997;   97US-0059263P
PR   19-SEP-1997;   97US-0059352P.
PR   19-SEP-1997;   97US-0059588P.
PR   24-SEP-1997;   97US-0059836P.
PR   17-OCT-1997;   97US-0062250P.
PR   17-OCT-1997;   97US-0062285P.
PR   17-OCT-1997;   97US-0062287P.
PR   17-OCT-1997;   97US-0063755P.
PR   24-OCT-1997;   97US-0062814P.
PR   24-OCT-1997;   97US-0062816P.
PR   24-OCT-1997;   97US-0063045P.
PR   24-OCT-1997;   97US-0063082P.
PR   24-OCT-1997;   97US-0063127P.
PR   27-OCT-1997;   97US-0063327P.
PR   27-OCT-1997;   97US-0063329P.
PR   28-OCT-1997;   97US-0063550P.
PR   28-OCT-1997;   97US-0063561P.
PR   29-OCT-1997;   97US-0063704P.
PR   29-OCT-1997;   97US-0063733P.
PR   29-OCT-1997;   97US-0063735P.
PR   29-OCT-1997;   97US-0063738P.
PR   03-NOV-1997;   97US-0064248P.
PR   07-NOV-1997;   97US-0064809P.
PR   12-NOV-1997;   97US-0065186P.
PR   17-NOV-1997;   97US-0065846P.
PR   21-NOV-1997;   97US-0066364P.
PR   24-NOV-1997;   97US-0066453P.
PR   24-NOV-1997;   97US-0066511P.
PR   24-NOV-1997;   97US-0066770P.
PR   11-DEC-1997;   97US-0069212P.
PR   11-DEC-1997;   97US-0069278P.
PR   11-DEC-1997;   97US-0069334P.
PR   16-DEC-1997;   97US-0069694P.
PR   23-JAN-1998;   98US-0072320P.
PR   04-FEB-1998;   98US-0073612P.
PR   09-FEB-1998;   98US-0074086P.
PR   09-FEB-1998;   98US-0074092P.
PR   12-MAR-1998;   98US-0077791P.
PR   20-MAR-1998;   98US-0078910P.
PR   25-MAR-1998;   98US-0079294P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079728P.
PR   31-MAR-1998;   98US-0080165P.
PR   09-APR-1998;   98US-0081229P.
PR   14-APR-1998;   98US-0081695P.
PR   15-APR-1998;   98US-0081817P.
PR   15-APR-1998;   98US-0081818P.
PR   24-APR-1998;   98US-0082999P.
PR   28-APR-1998;   98US-0083322P.
PR   29-APR-1998;   98US-0083545P.
PR   07-MAY-1998;   98US-0084600P.
PR   07-MAY-1998;   98US-0084627P.
PR   07-MAY-1998;   98US-0084637P.
PR   12-MAY-1998;   98US-0085149P.
PR   13-MAY-1998;   98US-0085323P.
PR   13-MAY-1998;   98US-0085338P.
PR   13-MAY-1998;   98US-0085339P.
PR   15-MAY-1998;   98US-0085579P.
PR   15-MAY-1998;   98US-0085697P.
PR   15-MAY-1998;   98US-0085704P.
PR   22-MAY-1998;   98US-0086414P.
PR   22-MAY-1998;   98US-0086430P.
PR   28-MAY-1998;   98US-0087106P.
PR   04-JUN-1998;   98US-0088026P.
PR   10-JUN-1998;   98US-0088730P.
PR   10-JUN-1998;   98US-0088741P.
PR   10-JUN-1998;   98US-0088810P.
PR   11-JUN-1998;   98US-0088858P.
PR   12-JUN-1998;   98WO-US012456.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089599P.
PR   18-JUN-1998;   98US-0089907P.
PR   19-JUN-1998;   98US-0089947P.
PR   23-JUN-1998;   98US-0090349P.
```

PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-JAN-1999; 99US-0115549P.
PR 12-JAN-1999; 99US-0115557P.
PR 12-JAN-1999; 99US-0115560P.
PR 12-JAN-1999; 99US-0115562P.
PR 12-JAN-1999; 99US-0115564P.
PR 12-JAN-1999; 99US-0115630P.
PR 12-JAN-1999; 99US-0115705P.
PR 12-JAN-1999; 99US-0115733P.
PR 20-JAN-1999; 99US-0116533P.
PR 01-FEB-1999; 99US-0118210P.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 95
ABO22500
ID ABO22500 standard; protein; 123 AA.
XX
AC ABO22500;
XX
DT 04-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO619.
XX
KW Human; PRO; secreted protein; transmembrane protein; antidiabetic;
KW cytostatic; antirheumatic; antiarthritic; antiulcer; neuroprotective;
KW antiinflammatory; antibacterial; immunosuppressive; gene therapy;
KW diabetes; cancer; rheumatoid arthritis; ulcers;
KW amyotrophic lateral sclerosis; inflammatory condition; septic shock.
XX
OS Homo sapiens.
XX
PN US2003017982-A1.
XX
PD 23-JAN-2003.
XX
PF 16-NOV-2001; 2001US-00990441.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 96
ADA06406
ID ADA06406 standard; protein; 123 AA.
XX
AC ADA06406;
XX
DT 29-JAN-2004 (revised)
DT 06-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane PRO polypeptide #25.
XX
KW human; tissue typing; cardiac insufficiency disorder; angiogenesis;
KW wound healing; tumour; immune response; retinal disorder; retinal injury;
KW sight loss; age-related macular degeneration; AMD; kidney disorder;
KW mesangial cell function; Berger disease; nephropathy; dermatitis;
KW herpetiform; Crohn's disease; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2003049638-A1.
XX
PD 13-MAR-2003.
XX
PF 16-NOV-2001; 2001US-00991157.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.

PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 97
ADA39099
ID ADA39099 standard; protein; 123 AA.
XX
AC ADA39099;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO619.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003059782-A1.
XX
PD 27-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997628.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.

PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 98
ADA67023
ID ADA67023 standard; protein; 123 AA.
XX
AC ADA67023;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068793-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123108.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.

PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695925/66.
DR N-PSDB; ADA67022.
XX
PT Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT release of tumor necrosis factor-alpha from human blood and detecting the
PT presence of a tumor in a mammal.
XX
PS Claim 12; Fig 402; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 99
ADB22884
ID ADB22884 standard; protein; 123 AA.
XX
AC ADB22884;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077711-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127829.
XX
PR 22-OCT-1998; 98US-0105169P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755066/71.
DR N-PSDB; ADB22883.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, as diagnostic markers for the presence of a disease
PT condition, or as therapeutic targets for treating tumors, diabetes,
PT obesity or arthritis.
XX
PS Claim 12; Fig 402; 637pp; English.
XX

CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 100
ADB23657
ID ADB23657 standard; protein; 123 AA.
XX
AC ADB23657;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 402.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077712-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127835.
XX
PR 20-OCT-1998; 98US-0104987P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755067/71.
DR N-PSDB; ADB23656.
XX
PT New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and/or liver tumors.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

```
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 101
ADA92379
ID ADA92379 standard; protein; 123 AA.
XX
AC ADA92379;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082712-A1.
XX
PD 01-MAY-2003.
XX
PF 16-MAY-2002; 2002US-00147512.
XX
PR 15-MAY-1998; 98US-0085697P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00380138.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786915/74.
DR N-PSDB; ADA92378.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 123 AA;

```
  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 102
ADB15442
ID ADB15442 standard; protein; 123 AA.
XX
AC ADB15442;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087352-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127824.
XX
PR 17-AUG-1998; 98US-0096891P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX

```
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-786943/74.
DR   N-PSDB; ADB15441.
XX
PT   New PRO nucleic acid, useful for producing a recombiannt PRO polypeptide
PT   and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 103
ADB38694
ID   ADB38694 standard; protein; 123 AA.
XX
AC   ADB38694;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082766-A1.
XX
PD   01-MAY-2003.
XX
PF   30-MAY-2002; 2002US-00158782.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
```

PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786921/74.
DR N-PSDB; ADB38693.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 12; Fig 402; 660pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 104
ADB96125
ID ADB96125 standard; protein; 123 AA.
XX
AC ADB96125;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #25.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003054403-A1.
XX
PD 20-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997559.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.

```
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 105
ADB38142
ID   ADB38142 standard; protein; 123 AA.
XX
AC   ADB38142;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003087347-A1.
XX
PD   08-MAY-2003.
XX
PF   19-APR-2002; 2002US-00125921.
XX
PR   17-AUG-1998;   98US-0096791P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   30-MAR-2000; 2000WO-US008439.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786938/74.
DR   N-PSDB; ADB38141.
XX
PT   New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT   and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 106
ADB66614
ID   ADB66614 standard; protein; 123 AA.
XX
AC   ADB66614;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
```

KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082689-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127831.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786905/74.
DR N-PSDB; ADB66613.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g. tumor or for tissue typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or

```
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 123 AA;

  Query Match           100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 107
ADB89694
ID   ADB89694 standard; protein; 123 AA.
XX
AC   ADB89694;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Human PRO polypeptide #201.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082698-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127850.
XX
PR   20-AUG-1998;   98US-0097218P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   02-MAR-2000; 2000WO-US005841.
PR   30-MAR-2000; 2000WO-US008439.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-743896/70.
DR   N-PSDB; ADB89693.
XX
PT   New PRO nucleic acids and encoded polypeptides, useful in the treatment
PT   of cancer.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match           100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 108
ADB90426
ID   ADB90426 standard; protein; 123 AA.
XX
AC   ADB90426;
XX
DT   04-DEC-2003  (first entry)
XX
```

DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082762-A1.
XX
PD 01-MAY-2003.
XX
PF 15-APR-2002; 2002US-00123235.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-743899/70.
DR N-PSDB; ADB90425.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, and in the detection and treatment of tumor in a mammal.
XX
PS Claim 12; Fig 402; 649pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

```
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 109
ADB39527
ID   ADB39527 standard; protein; 123 AA.
XX
AC   ADB39527;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082764-A1.
XX
PD   01-MAY-2003.
XX
PF   03-MAY-2002; 2002US-00137868.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
```

PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786919/74..
DR N-PSDB; ADB39526.
XX
PT New secreted and transmembrane PRO polypeptide useful for detecting the
PT presence of tumor in a mammal, or modulating the uptake of glucose or
PT free fatty acid by skeletal muscle cells or adipocyte cells.
XX
PS Claim 12; Fig 402; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 110
ADB47150
ID ADB47150 standard; protein; 123 AA.
XX
AC ADB47150;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082687-A1.
XX
PD 01-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125930.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786904/74.
DR N-PSDB; ADB47149.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 402; 627pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,

```
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 111
ADB86757
ID   ADB86757 standard; protein; 123 AA.
XX
AC   ADB86757;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Human PRO polypeptide #201.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082697-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127849.
XX
PR   20-OCT-1998;   98US-0104987P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-743895/70.
DR   N-PSDB; ADB86756.
XX
PT   New secreted and transmembrane PRO polypeptides, useful in the diagnosis
PT   and treatment of cancer.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 112
ADB77362
ID   ADB77362 standard; protein; 123 AA.
XX
AC   ADB77362;
XX
DT   04-DEC-2003  (first entry)
```

XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082696-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127848.
XX
PR 03-NOV-1998; 98US-0106934P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755109/71.
DR N-PSDB; ADB77361.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX

SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 113
ADB34519
ID ADB34519 standard; protein; 123 AA.
XX
AC ADB34519;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 402.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077717-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131818.
XX
PR 07-OCT-1998; 98US-0103328P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755072/71.
DR N-PSDB; ADB34518.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

```
  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 114
ADB35623
ID ADB35623 standard; protein; 123 AA.
XX
AC ADB35623;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 402.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077719-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131824.
XX
PR 09-FEB-1999; 99US-0119341P.
PR 01-DEC-1999; 99WO-US028634.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755074/71.
DR N-PSDB; ADB35622.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

```
  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
```

```
Qy          61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy         121 FSP 123
               |||
Db         121 FSP 123
```

RESULT 115
ADB33967
ID ADB33967 standard; protein; 123 AA.
XX
AC ADB33967;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 402.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077716-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131813.
XX
PR 07-OCT-1998; 98US-0103315P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755071/71.
DR N-PSDB; ADB33966.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
PT in tissue typing, and in identifying chromosomes.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynuclectides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

```
  Query Match           100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy          61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy         121 FSP 123
               |||
Db         121 FSP 123
```

RESULT 116
ADB35071
ID ADB35071 standard; protein; 123 AA.
XX
AC ADB35071;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 402.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077718-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131823.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755073/71.
DR N-PSDB; ADB35070.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 402; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 117
ADB36175
ID ADB36175 standard; protein; 123 AA.
XX
AC ADB36175;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 402.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077720-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131830.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755075/71.
DR N-PSDB; ADB36174.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 118
ADB46570
ID ADB46570 standard; protein; 123 AA.
XX
AC ADB46570;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082692-A1.
XX
PD 01-MAY-2003.

XX
PF 22-APR-2002; 2002US-00127842.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786906/74.
DR N-PSDB; ADB46569.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 119
ADC57597
ID ADC57597 standard; protein; 123 AA.
XX
AC ADC57597;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #25.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003027754-A1.
XX
PD 06-FEB-2003.
XX
PF 14-NOV-2001; 2001US-00990438.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.

PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 120
ADC54961

ID ADC54961 standard; protein; 123 AA.
XX
AC ADC54961;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #25.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003045463-A1.
XX
PD 06-MAR-2003.
XX
PF 16-NOV-2001; 2001US-00990437.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.

PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 121

ADC11828
ID ADC11828 standard; protein; 123 AA.
XX
AC ADC11828;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO619.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003049681-A1.
XX
PD 13-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997514.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.

PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 122
ADC56250
ID ADC56250 standard; protein; 123 AA.
XX
AC ADC56250;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #25.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003064375-A1.
XX
PD 03-APR-2003.
XX
PF 15-NOV-2001; 2001US-00997857.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.

PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 123
ADC07305
ID ADC07305 standard; protein; 123 AA.
XX
AC ADC07305;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO619.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003068647-A1.
XX
PD 10-APR-2003.
XX
PF 15-NOV-2001; 2001US-00997542.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.

PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

```
RESULT 124
ADC11295
ID   ADC11295 standard; protein; 123 AA.
XX
AC   ADC11295;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO619.
XX
KW   PRO; secreted protein; transmembrane protein;
KW   hypertrophy of neonatal heart; angiogenesis;
KW   vascular endothelial growth factor; VEGF-stimulated proliferation;
KW   endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW   c-fos induction; adipocyte cell; chondrocyte differentiation;
KW   pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW   cancer; human; colon cancer; lung cancer; breast cancer;
KW   rod photoreceptor cell.
XX
OS   Homo sapiens.
XX
PN   US2003069403-A1.
XX
PD   10-APR-2003.
XX
PF   14-NOV-2001; 2001US-00993748.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
PR   10-AUG-1998;   98US-0095929P.
PR   10-AUG-1998;   98US-0096012P.
PR   11-AUG-1998;   98US-0096143P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   17-AUG-1998;   98US-0096757P.
PR   17-AUG-1998;   98US-0096766P.
PR   17-AUG-1998;   98US-0096768P.
PR   17-AUG-1998;   98US-0096773P.
PR   17-AUG-1998;   98US-0096791P.
PR   17-AUG-1998;   98US-0096867P.
PR   17-AUG-1998;   98US-0096891P.
PR   17-AUG-1998;   98US-0096894P.
PR   17-AUG-1998;   98US-0096895P.
PR   17-AUG-1998;   98US-0096897P.
PR   18-AUG-1998;   98US-0096949P.
PR   18-AUG-1998;   98US-0096950P.
PR   18-AUG-1998;   98US-0096959P.
```

```
PR   18-AUG-1998;   98US-0096960P.
PR   18-AUG-1998;   98US-0097022P.
PR   19-AUG-1998;   98US-0097141P.
PR   20-AUG-1998;   98US-0097218P.
PR   24-AUG-1998;   98US-0097661P.
PR   26-AUG-1998;   98US-0097952P.
PR   26-AUG-1998;   98US-0097954P.
PR   26-AUG-1998;   98US-0097955P.
PR   26-AUG-1998;   98US-0097971P.
PR   26-AUG-1998;   98US-0097974P.
PR   26-AUG-1998;   98US-0097978P.
PR   26-AUG-1998;   98US-0097979P.
PR   26-AUG-1998;   98US-0097986P.
PR   26-AUG-1998;   98US-0098014P.
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.

  Query Match           100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
```

```
Db        121 FSP 123


RESULT 125
ADC50443
ID   ADC50443 standard; protein; 123 AA.
XX
AC   ADC50443;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW   transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW   chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW   rectum; kidney; cervix; liver; microvascular endothelial cell;
KW   glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW   cell differentiation; skeletal muscle cell; adipocyte cell;
KW   pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW   immune system cell infiltration; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003092106-A1.
XX
PD   15-MAY-2003.
XX
PF   24-APR-2002; 2002US-00131822.
XX
PR   19-AUG-1998;   98US-0097141P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   30-MAR-2000; 2000WO-US008439.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801171/75.
DR   N-PSDB; ADC50442.
XX
PT   New secreted and transmembrane nucleic acid useful for treating
PT   inflammation, organ failure, atherosclerosis, cardiac injury,
PT   infertility, birth defects, premature aging, acquired immunodeficiency
PT   syndrome or cancer.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
```

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 126
ADC71990
ID ADC71990 standard; protein; 123 AA.
XX
AC ADC71990;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003092107-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131828.
XX
PR 07-OCT-1998; 98US-0103315P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801172/75.
DR N-PSDB; ADC71989.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 127

```
ADC59969
ID   ADC59969 standard; protein; 123 AA.
XX
AC   ADC59969;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW   transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW   chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW   rectum; kidney; cervix; liver; microvascular endothelial cell;
KW   glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW   cell differentiation; skeletal muscle cell; adipocyte cell;
KW   pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW   immune system cell infiltration; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003092105-A1.
XX
PD   15-MAY-2003.
XX
PF   24-APR-2002; 2002US-00131821.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801170/75.
DR   N-PSDB; ADC59968.
XX
PT   New secreted and transmembrane nucleic acids and polypeptides, designated
PT   as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT   cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT   cancer.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC   cells, for stimulating differentiation of adipocyte cells, for
CC   stimulating proliferation of or gene expression in pericyte cells, for
CC   stimulating the proliferation of inner ear utricular supporting cells or
CC   T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC   treating various bone and/or cartilage disorders such as sports injuries
CC   and arthritis. PRO polypeptides which stimulate the release of
CC   proteoglycans from cartilage are useful for treating sports-related joint
CC   problems, articular cartilage defects, osteoarthritis and rheumatoid
CC   arthritis. PRO polypeptides are also useful for treating various
CC   mammalian haemoglobin-associated disorders such as various thalassaemias
CC   and conditions which may benefit from enhanced local immune system cell
CC   infiltration. This sequence represents a human PRO polypeptide of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 128
ADC52976
ID   ADC52976 standard; protein; 123 AA.
XX
AC   ADC52976;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein Seq ID402.
XX
KW   human; PRO; membrane bound protein; membrane bound receptor;
KW   cell proliferation; cell migration; cell differentiation;
KW   mitogenic factor; survival factor; cytotoxic factor;
KW   differentiation factor; neuropeptide; hormone; cell receptor;
KW   receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS   Homo sapiens.
XX
PN   US2003087365-A1.
XX
PD   08-MAY-2003.
XX
PF   23-APR-2002; 2002US-00128689.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   10-MAR-1999; 2000WO-US006319.
```

PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godwoski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801150/75.
DR N-PSDB; ADC52975.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 1; SEQ ID NO 402; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is the amino acid sequence of a human PRO protein of the
CC invention.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 129
ADC57330
ID ADC57330 standard; protein; 123 AA.
XX
AC ADC57330;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein Seq ID402.
XX

KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS Homo sapiens.
XX
PN US2003087366-A1.
XX
PD 08-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128694.
XX
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801151/75.
DR N-PSDB; ADC57329.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 1; SEQ ID NO 402; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is the amino acid sequence of a human PRO protein of the
CC invention.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 130
ADC60521
ID ADC60521 standard; protein; 123 AA.
XX
AC ADC60521;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087367-A1.
XX
PD 08-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131825.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801152/75.
DR N-PSDB; ADC60520.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 12; Fig 402; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 131
ADC50996
ID ADC50996 standard; protein; 123 AA.
XX
AC ADC50996;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;

KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087361-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127841.
XX
PR 09-SEP-1998; 98US-0099536P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801146/75.
DR N-PSDB; ADC50995.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 132
ADC65523
ID ADC65523 standard; protein; 123 AA.
XX
AC ADC65523;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087362-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127844.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801147/75.
DR N-PSDB; ADC65522.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 133
ADC54621
ID ADC54621 standard; protein; 123 AA.
XX
AC ADC54621;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein Seq ID402.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS Homo sapiens.
XX
PN US2003087363-A1.
XX
PD 08-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128687.
XX
PR 10-SEP-1998; 98US-0099816P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801148/75.
DR N-PSDB; ADC54620.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 1; SEQ ID NO 402; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is the amino acid sequence of a human PRO protein of the
CC invention.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 134
ADC53582
ID ADC53582 standard; protein; 123 AA.
XX
AC ADC53582;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein Seq ID402.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS Homo sapiens.
XX
PN US2003087364-A1.
XX
PD 08-MAY-2003.

```
XX
PF   23-APR-2002; 2002US-00128688.
XX
PR   09-FEB-1999;   99US-0119341P.
PR   01-DEC-1999;   99WO-US028634.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-801149/75.
DR   N-PSDB; ADC53581.
XX
PT   New PRO nucleic acid, useful for manufacturing a medicament for
PT   diagnosing or treating tumor.
XX
PS   Claim 1; SEQ ID NO 402; 637pp; English.
XX
CC   This invention relates to novel nucleic acids encoding human PRO secreted
CC   and transmembrane proteins. Extracellular proteins play important roles
CC   in the formation, differentiation and maintenance of multicellular
CC   organisms. The fate of many individual cells (for example proliferation,
CC   migration or differentiation) is typically governed by information
CC   received from other cells and the immediate environment. The information
CC   is often transmitted by secreted polypeptides (for example mitogenic
CC   factors, survival factors, cytotoxic factors, differentiation factors,
CC   neuropeptides and hormones) which are received and interpreted by diverse
CC   cell receptors or membrane bound proteins. These membrane bound proteins
CC   and receptors may be of use as pharmaceutical and diagnostic agents, such
CC   as in the blocking of receptor-ligand interactions. The current invention
CC   provides the amino acid sequences of novel human membrane bound receptors
CC   and proteins, along with the cDNA sequences encoding them. The novel
CC   proteins of the invention may have cytostatic activities through the
CC   stimulation of chondrocytes. The nucleic acids of the invention may be
CC   useful for the manufacture of a medicament for diagnosing or treating a
CC   tumour in a mammal. In addition, they may be useful for measuring or
CC   detecting the expression of a tumour associated gene. The present
CC   sequence is the amino acid sequence of a human PRO protein of the
CC   invention.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 135
ADC59105
ID   ADC59105 standard; protein; 123 AA.
XX
AC   ADC59105;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein Seq ID402.
XX
KW   human; PRO; membrane bound protein; membrane bound receptor;
KW   cell proliferation; cell migration; cell differentiation;
KW   mitogenic factor; survival factor; cytotoxic factor;
KW   differentiation factor; neuropeptide; hormone; cell receptor;
KW   receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS   Homo sapiens.
XX
PN   US2003087359-A1.
XX
PD   08-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127834.
XX
PR   17-SEP-1998;   98US-0100710P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-801144/75.
DR   N-PSDB; ADC59104.
XX
PT   New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT   and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS   Claim 1; SEQ ID NO 402; 637pp; English.
XX
CC   This invention relates to novel nucleic acids encoding human PRO secreted
CC   and transmembrane proteins. Extracellular proteins play important roles
CC   in the formation, differentiation and maintenance of multicellular
CC   organisms. The fate of many individual cells (for example proliferation,
CC   migration or differentiation) is typically governed by information
CC   received from other cells and the immediate environment. The information
CC   is often transmitted by secreted polypeptides (for example mitogenic
CC   factors, survival factors, cytotoxic factors, differentiation factors,
CC   neuropeptides and hormones) which are received and interpreted by diverse
CC   cell receptors or membrane bound proteins. These membrane bound proteins
CC   and receptors may be of use as pharmaceutical and diagnostic agents, such
CC   as in the blocking of receptor-ligand interactions. The current invention
CC   provides the amino acid sequences of novel human membrane bound receptors
CC   and proteins, along with the cDNA sequences encoding them. The novel
CC   proteins of the invention may have cytostatic activities through the
CC   stimulation of chondrocytes. The nucleic acids of the invention may be
CC   useful for the manufacture of a medicament for diagnosing or treating a
CC   tumour in a mammal. In addition, they may be useful for measuring or
CC   detecting the expression of a tumour associated gene. The present
CC   sequence is the amino acid sequence of a human PRO protein of the
CC   invention.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
```

```
Db        121 FSP 123


RESULT 136
ADC55983
ID   ADC55983 standard; protein; 123 AA.
XX
AC   ADC55983;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein Seq ID402.
XX
KW   human; PRO; membrane bound protein; membrane bound receptor;
KW   cell proliferation; cell migration; cell differentiation;
KW   mitogenic factor; survival factor; cytotoxic factor;
KW   differentiation factor; neuropeptide; hormone; cell receptor;
KW   receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS   Homo sapiens.
XX
PN   US2003087360-A1.
XX
PD   08-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127836.
XX
PR   17-NOV-1998;   98US-0108802P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-AUG-2000; 2000WO-US023522.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801145/75.
DR   N-PSDB; ADC55982.
XX
PT   New PRO nucleic acid, useful for manufacturing a medicament for
PT   diagnosing or treating tumor.
XX
PS   Claim 1; SEQ ID NO 402; 637pp; English.
XX
CC   This invention relates to novel nucleic acids encoding human PRO secreted
CC   and transmembrane proteins. Extracellular proteins play important roles
CC   in the formation, differentiation and maintenance of multicellular
CC   organisms. The fate of many individual cells (for example proliferation,
CC   migration or differentiation) is typically governed by information
CC   received from other cells and the immediate environment. The information
CC   is often transmitted by secreted polypeptides (for example mitogenic
CC   factors, survival factors, cytotoxic factors, differentiation factors,
CC   neuropeptides and hormones) which are received and interpreted by diverse
CC   cell receptors or membrane bound proteins. These membrane bound proteins
CC   and receptors may be of use as pharmaceutical and diagnostic agents, such
CC   as in the blocking of receptor-ligand interactions. The current invention
CC   provides the amino acid sequences of novel human membrane bound receptors
CC   and proteins, along with the cDNA sequences encoding them. The novel
CC   proteins of the invention may have cytostatic activities through the
CC   stimulation of chondrocytes. The nucleic acids of the invention may be
CC   useful for the manufacture of a medicament for diagnosing or treating a
CC   tumour in a mammal. In addition, they may be useful for measuring or
CC   detecting the expression of a tumour associated gene. The present
CC   sequence is the amino acid sequence of a human PRO protein of the
CC   invention.
XX
SQ   Sequence 123 AA;

  Query Match           100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 137
ADC58553
ID   ADC58553 standard; protein; 123 AA.
XX
AC   ADC58553;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein Seq ID402.
XX
KW   human; PRO; membrane bound protein; membrane bound receptor;
KW   cell proliferation; cell migration; cell differentiation;
KW   mitogenic factor; survival factor; cytotoxic factor;
KW   differentiation factor; neuropeptide; hormone; cell receptor;
KW   receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS   Homo sapiens.
XX
PN   US2003087346-A1.
XX
PD   08-MAY-2003.
XX
PF   17-APR-2002; 2002US-00124815.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801137/75.
DR   N-PSDB; ADC58552.
XX
PT   Isolated nucleic acid for use in industrial applications has at least 80
PT   percent nucleic acid sequence identity to nucleotide sequence that
PT   encodes amino acid sequence selected from amino acid sequence group.
XX
PS   Claim 1; SEQ ID NO 402; 637pp; English.
XX
CC   This invention relates to novel nucleic acids encoding human PRO secreted
CC   and transmembrane proteins. Extracellular proteins play important roles
CC   in the formation, differentiation and maintenance of multicellular
CC   organisms. The fate of many individual cells (for example proliferation,
CC   migration or differentiation) is typically governed by information
CC   received from other cells and the immediate environment. The information
CC   is often transmitted by secreted polypeptides (for example mitogenic
CC   factors, survival factors, cytotoxic factors, differentiation factors,
CC   neuropeptides and hormones) which are received and interpreted by diverse
CC   cell receptors or membrane bound proteins. These membrane bound proteins
CC   and receptors may be of use as pharmaceutical and diagnostic agents, such
CC   as in the blocking of receptor-ligand interactions. The current invention
```

CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is the amino acid sequence of a human PRO protein of the
CC invention.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 138
ADC14417
ID ADC14417 standard; protein; 123 AA.
XX
AC ADC14417;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW human; secreted and transmembrane protein; PRO; nootropic;
KW neuroprotective; antiparkinsonian; cytostatic; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.
XX
OS Homo sapiens.
XX
PN US2003082546-A1.
XX
PD 01-MAY-2003.
XX
PF 28-AUG-2001; 2001US-00941992.
XX
PR 06-NOV-1996; 96US-00743698.
PR 16-JUN-1997; 97US-0049787P.
PR 16-JUN-1997; 97US-00876698.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97US-00965056.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.

PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 20-FEB-1999; 99WO-US030911.
PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 09-MAR-1999; 99US-00254460.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 12-APR-1999; 99US-00284291.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 18-OCT-1999; 99US-00403296.
PR 12-NOV-1999; 99US-00423844.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 139
ADD07949
ID ADD07949 standard; protein; 123 AA.
XX
AC ADD07949;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW neonatal heart hypertrophy; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW rod photoreceptor cell; c-fos induction; adipocyte;
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW Parkinson's disease; Alzheimer's disease; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW antidiabetic; antianaemic; cytostatic; nootropic; neuroprotective;
KW antiparkinsonian.
XX
OS Homo sapiens.
XX
PN US2003068623-A1.
XX
PD 10-APR-2003.
XX
PF 14-NOV-2001; 2001US-00993469.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 140
ADD03227
ID ADD03227 standard; protein; 123 AA.
XX
AC ADD03227;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003092104-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131817.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801169/75.
DR N-PSDB; ADD03226.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 402; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 141
ADC90219
ID ADC90219 standard; protein; 123 AA.
XX
AC ADC90219;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087348-A1.
XX
PD 08-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125923.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786939/74.
DR N-PSDB; ADC90218.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 12; SEQ ID NO 402; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding

```
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 142
ADC81774
ID   ADC81774 standard; protein; 123 AA.
XX
AC   ADC81774;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #25.
XX
KW   Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW   insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW   thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW   polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW   cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS   Homo sapiens.
XX
PN   US2003083461-A1.
XX
PD   01-MAY-2003.
XX
PF   14-NOV-2001; 2001US-00992521.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
```

PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 143
ADC69638
ID ADC69638 standard; protein; 123 AA.
XX
AC ADC69638;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194770-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152375.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI; 2003-844453/78.
DR N-PSDB; ADC69637.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 144
ADC48527
ID ADC48527 standard; protein; 123 AA.
XX
AC ADC48527;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #201.
XX

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194773-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152391.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-844455/78.
DR N-PSDB; ADC48526.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of tumor necrosis factor
PT alpha and stimulating the proliferation of endothelial cells.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 145
ADD10056
ID ADD10056 standard; protein; 123 AA.
XX
AC ADD10056;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194776-A1.
XX
PD 16-OCT-2003.
XX
PF 29-MAY-2002; 2002US-00157785.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852596/79.
DR N-PSDB; ADD10055.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of proteoglycans from
PT cartilage and inhibiting the differentiation of adipocyte cells.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 146
ADD07416
ID ADD07416 standard; protein; 123 AA.
XX
AC ADD07416;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW neonatal heart hypertrophy; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW rod photoreceptor cell; c-fos induction; adipocyte;
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW Parkinson's disease; Alzheimer's disease; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW antidiabetic; antianaemic; cytostatic; nootropic; neuroprotective;
KW antiparkinsonian.
XX
OS Homo sapiens.

XX
PN US2002193299-A1.
XX
PD 19-DEC-2002.
XX
PF 19-NOV-2001; 2001US-00989735.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-657230/62.
DR N-PSDB; ADD07415.
XX
PT Isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346 and
PT PRO1375, which stimulate proliferation of stimulated T-lymphocytes and
PT are thus therapeutically useful e.g. for enhancing immune response.
XX
PS Claim 12; SEQ ID NO 117; 659pp; English.
XX
CC The invention relates to human secreted and transmembrane PRO
CC polypeptides and the polynucleotides encoding them. The PRO polypeptides
CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors
CC or bioreactors. They are useful for stimulating hypertrophy of neonatal
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocytes,
CC inducing proliferation and/or re-differentiation of chondrocytes, or
CC inducing pancreatic beta-cell precursor differentiation into mature
CC pancreatic beta-cells. They may therefore be useful in the treatment of
CC various insulin deficient states in mammals, including diabetes mellitus,
CC and in treating undesired endothelial cell growth, e.g., inhibiting
CC tumour growth. The sequences are also useful for treating mammalian
CC haemoglobin-associated disorders (e.g., various thalassaemias), cystic
CC renal dysplasia, polycystic kidney disease, renal tumours, and other
CC cancers such as those of the colon, lung and breast. PRO polypeptides or
CC antibodies to PRO polypeptides may be used to detect a PRO polypeptide in
CC a sample; to link a bioactive molecule to a cell; to modulate a
CC biological activity of a cell; as molecular weight markers for protein
CC electrophoresis purposes; for tissue typing; to prepare a medicament for
CC treating a condition responsive to the polypeptide or antibody, such as
CC neurodegenerative disorders (e.g., Parkinson's disease or Alzheimer's
CC disease); and in various diagnostic assays. The PRO polynucleotides can
CC be used as hybridisation probes, in chromosome and gene mapping, in
CC generating antisense RNA and DNA, and in gene therapy. The polynucleotide
CC may also be used in preparing PRO polypeptides by recombinant techniques,

```
CC   and in generating either transgenic animals or knock-out animals which,
CC   in turn, are useful in the development and screening of therapeutically
CC   useful reagents. This sequence represents a human PRO polypeptide of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 147
ADD04631
ID   ADD04631 standard; protein; 123 AA.
XX
AC   ADD04631;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW   transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW   chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW   rectum; kidney; cervix; liver; microvascular endothelial cell;
KW   glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW   cell differentiation; skeletal muscle cell; adipocyte cell;
KW   pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW   immune system cell infiltration; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003087354-A1.
XX
PD   08-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127827.
XX
PR   17-AUG-1998;   98US-0096891P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   30-MAR-2000; 2000WO-US008439.
PR   30-MAY-2000; 2000WO-US014941.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801139/75.
DR   N-PSDB; ADD04630.
XX
PT   New PRO nucleic acid, useful for manufacturing a medicament for
PT   diagnosing or treating tumor.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC   cells, for stimulating differentiation of adipocyte cells, for
CC   stimulating proliferation of or gene expression in pericyte cells, for
CC   stimulating the proliferation of inner ear utricular supporting cells or
CC   T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC   treating various bone and/or cartilage disorders such as sports injuries
CC   and arthritis. PRO polypeptides which stimulate the release of
CC   proteoglycans from cartilage are useful for treating sports-related joint
CC   problems, articular cartilage defects, osteoarthritis and rheumatoid
CC   arthritis. PRO polypeptides are also useful for treating various
CC   mammalian haemoglobin-associated disorders such as various thalassaemias
CC   and conditions which may benefit from enhanced local immune system cell
CC   infiltration. This sequence represents a human PRO polypeptide of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 148
ADC82307
ID   ADC82307 standard; protein; 123 AA.
XX
AC   ADC82307;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #25.
XX
KW   Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW   insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW   thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW   polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW   cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
```

XX
OS Homo sapiens.
XX
PN US2003059833-A1.
XX
PD 27-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997440.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.

```
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   20-FEB-1999;   99WO-US030911.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.

  Query Match           100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 149
ADC80587
ID   ADC80587 standard; protein; 123 AA.
XX
AC   ADC80587;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW   transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW   chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW   rectum; kidney; cervix; liver; microvascular endothelial cell;
KW   glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW   cell differentiation; skeletal muscle cell; adipocyte cell;
KW   pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW   immune system cell infiltration; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003092103-A1.
XX
PD   15-MAY-2003.
XX
PF   24-APR-2002; 2002US-00131815.
XX
PR   22-DEC-1998;   98US-0113511P.
PR   01-DEC-1999;   99WO-US028634.
PR   22-FEB-2000; 2000WO-US004414.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801168/75.
DR   N-PSDB; ADC80586.
XX
PT   New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT   PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT   generating antisense RNA and DNA, and in gene therapy.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC   cells, for stimulating differentiation of adipocyte cells, for
CC   stimulating proliferation of or gene expression in pericyte cells, for
CC   stimulating the proliferation of inner ear utricular supporting cells or
CC   T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC   treating various bone and/or cartilage disorders such as sports injuries
CC   and arthritis. PRO polypeptides which stimulate the release of
CC   proteoglycans from cartilage are useful for treating sports-related joint
CC   problems, articular cartilage defects, osteoarthritis and rheumatoid
CC   arthritis. PRO polypeptides are also useful for treating various
CC   mammalian haemoglobin-associated disorders such as various thalassaemias
CC   and conditions which may benefit from enhanced local immune system cell
CC   infiltration. This sequence represents a human PRO polypeptide of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;
```

```
  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 150
ADD11094
ID ADD11094 standard; protein; 123 AA.
XX
AC ADD11094;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194774-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152399.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852594/79.
DR N-PSDB; ADD11093.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the proliferation or differentiation
PT of chondrocyte cells and stimulating the release of tumor necrosis factor
PT alpha.
XX
PS Claim 12; SEQ ID NO 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

```
  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 151
ADC47975
ID ADC47975 standard; protein; 123 AA.
XX
AC ADC47975;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194771-A1.
XX
PD 16-OCT-2003.

XX
PF 21-MAY-2002; 2002US-00152377.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Gurney SL, Smith V;
PI Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-844454/78.
DR N-PSDB; ADC47974.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids useful
PT for detecting a tumor, stimulating the release of proteoglycans from
PT cartilage and stimulating the proliferation of endothelial cells.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

```
  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 152
ADD08487
ID ADD08487 standard; protein; 123 AA.
XX
AC ADD08487;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW neonatal heart hypertrophy; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW rod photoreceptor cell; c-fos induction; adipocyte;
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW Parkinson's disease; Alzheimer's disease; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW antidiabetic; antianaemic; cytostatic; nootropic; neuroprotective;
KW antiparkinsonian.
XX
OS Homo sapiens.
XX
PN US2003073090-A1.
XX
PD 17-APR-2003.
XX
PF 16-NOV-2001; 2001US-00990439.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
                 |||
```

```
Db        121 FSP 123


RESULT 153
ADC80035
ID   ADC80035 standard; protein; 123 AA.
XX
AC   ADC80035;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW   transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW   chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW   rectum; kidney; cervix; liver; microvascular endothelial cell;
KW   glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW   cell differentiation; skeletal muscle cell; adipocyte cell;
KW   pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW   immune system cell infiltration; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003087358-A1.
XX
PD   08-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127833.
XX
PR   01-SEP-1998;   98US-0098750P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-801143/75.
DR   N-PSDB; ADC80034.
XX
PT   New PRO nucleic acid, useful for manufacturing a medicament for
PT   diagnosing or treating tumor.
XX
PS   Claim 12; Fig 402; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC   cells, for stimulating differentiation of adipocyte cells, for
CC   stimulating proliferation of or gene expression in pericyte cells, for
CC   stimulating the proliferation of inner ear utricular supporting cells or
CC   T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC   treating various bone and/or cartilage disorders such as sports injuries
CC   and arthritis. PRO polypeptides which stimulate the release of
CC   proteoglycans from cartilage are useful for treating sports-related joint
CC   problems, articular cartilage defects, osteoarthritis and rheumatoid
CC   arthritis. PRO polypeptides are also useful for treating various
CC   mammalian haemoglobin-associated disorders such as various thalassaemias
CC   and conditions which may benefit from enhanced local immune system cell
CC   infiltration. This sequence represents a human PRO polypeptide of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 123 AA;

  Query Match           100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity  100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123


RESULT 154
ADD06736
ID   ADD06736 standard; protein; 123 AA.
XX
AC   ADD06736;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO619.
XX
KW   Human; secreted protein; transmembrane protein; PRO;
KW   neonatal heart hypertrophy; angiogenesis;
KW   vascular endothelial growth factor; VEGF-stimulated proliferation;
KW   endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW   rod photoreceptor cell; c-fos induction; adipocyte;
KW   chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW   breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW   insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW   thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW   polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW   Parkinson's disease; Alzheimer's disease; gene therapy;
KW   chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW   antidiabetic; antianaemic; cytostatic; nootropic; neuroprotective;
KW   antiparkinsonian.
XX
OS   Homo sapiens.
XX
PN   US2002193300-A1.
XX
PD   19-DEC-2002.
XX
PF   14-NOV-2001; 2001US-00990444.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
```

PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-657231/62.
DR N-PSDB; ADD06735.
XX
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT and are thus therapeutically useful for enhancing immune response.
XX
PS Claim 12; SEQ ID NO 117; 653pp; English.
XX
CC The invention relates to human secreted and transmembrane PRO
CC polypeptides and the polynucleotides encoding them. The PRO polypeptides
CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors
CC or bioreactors. They are useful for stimulating hypertrophy of neonatal
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocytes,
CC inducing proliferation and/or re-differentiation of chondrocytes, or
CC inducing pancreatic beta-cell precursor differentiation into mature
CC pancreatic beta-cells. They may therefore be useful in the treatment of
CC various insulin deficient states in mammals, including diabetes mellitus,
CC and in treating undesired endothelial cell growth, e.g., inhibiting
CC tumour growth. The sequences are also useful for treating mammalian
CC haemoglobin-associated disorders (e.g., various thalassaemias), cystic
CC renal dysplasia, polycystic kidney disease, renal tumours, and other
CC cancers such as those of the colon, lung and breast. PRO polypeptides or
CC antibodies to PRO polypeptides may be used to detect a PRO polypeptide in
CC a sample; to link a bioactive molecule to a cell; to modulate a
CC biological activity of a cell; as molecular weight markers for protein
CC electrophoresis purposes; for tissue typing; to prepare a medicament for
CC treating a condition responsive to the polypeptide or antibody, such as
CC neurodegenerative disorders (e.g., Parkinson's disease or Alzheimer's
CC disease); and in various diagnostic assays. The PRO polynucleotides can
CC be used as hybridisation probes, in chromosome and gene mapping, in
CC generating antisense RNA and DNA, and in gene therapy. The polynucleotide
CC may also be used in preparing PRO polypeptides by recombinant techniques,
CC and in generating either transgenic animals or knock-out animals which,
CC in turn, are useful in the development and screening of therapeutically
CC useful reagents. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 155
ADD09504
ID ADD09504 standard; protein; 123 AA.
XX
AC ADD09504;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #201.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194775-A1.
XX
PD 16-OCT-2003.
XX
PF 28-MAY-2002; 2002US-00156848.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852595/79.
DR N-PSDB; ADD09503.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of tumor necrosis factor
PT alpha from blood and stimulating the release of proteoglycans from
PT cartilage.
XX
PS Claim 12; Fig 402; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 123 AA;

```
  Query Match             100.0%;  Score 657;  DB 7;  Length 123;
  Best Local Similarity   100.0%;  Pred. No. 4.3e-62;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy        121 FSP 123
              |||
Db        121 FSP 123
```

RESULT 156
ADC82983
ID ADC82983 standard; protein; 123 AA.
XX
AC ADC82983;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #25.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003059783-A1.
XX
PD 27-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997683.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.

PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 157
ADD41217
ID ADD41217 standard; protein; 123 AA.
XX
AC ADD41217;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO619.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003203438-A1.
XX
PD 30-OCT-2003.
XX
PF 15-MAY-2002; 2002US-00146786.
XX
PR 24-NOV-1997; 97US-0066511P.
PR 16-SEP-1998; 98WO-US019330.
PR 25-AUG-1999; 99US-00380139.
PR 22-FEB-2000; 2000WO-US004414.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875645/81.
DR N-PSDB; ADD41216.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; SEQ ID NO 402; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 657; DB 7; Length 123;
Best Local Similarity 100.0%; Pred. No. 4.3e-62;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60
Db 1 MACRCLSFLLMGTFLSVSQTVLAQLDALLVFPGQVAQLSCTLSPQHVTIRDYGVSWYQQR 60

Qy 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120
Db 61 AGSAPRYLLYYRSEEDHHRPADIPDRFSAAKDEAHNACVLTISPVQPEDDADYYCSVGYG 120

Qy 121 FSP 123
Db 121 FSP 123

RESULT 158
ADD52356
ID ADD52356 standard; protein; 123 AA.
XX